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The worldwide incidence of Alzheimer’s disease (AD) is rapidly increasing.  Current 
diagnosis requires the observation of symptoms before a verdict can be reached; 
however, recent thinking indicates disease pathology potentially begins up to 20 years 
earlier.  In addition, a shift is beginning to occur in pharmaceutical research, shifting 
towards a disease modification approach, aiming to prevent and alter disease 
progression from an early pre-symptomatic stage.  Therefore, there is a requirement 
for biomarkers capable of the accurate diagnosis of the disease, before the 
development of symptoms.   
The discovery of biomarker molecules can also provide markers to monitor response 
to treatment, and disease progression.  This ability is of use in a clinical environment 
as surrogate endpoints in trials. 
Current lead candidates consist of imaging, genetics and proteins, each of which has 
drawbacks preventing its routine use in the clinic.  An alternative is the employment of 
circulating small molecules (<1500 Daltons) such as lipids, carbohydrates and amino 
acids. 
Small molecule markers were investigated using experiments which employed Liquid 
Chromatography-Mass Spectrometry (LC-MS).  Initially a hypothesis driven 
experiment was designed to investigate total fatty acids (FATOTAL) in human plasma 
(n=30).  Results revealed significant decreases in eicosapentaenoic acid (EPA) 
(p=0.023) and a significant increase in the ratio of arachidonic acid (AA) to EPA 
(p=0.05). 
As the project evolved, a non-targeted discovery investigation employed LC-MS in the 
analysis of plasma (n=35).  .  Following multivariate data analysis a number of lipid 
groups were uncovered, and were progressed for further investigation.  In order to 
achieve this, a comprehensive lipid specific LC-MS method was designed.  Key 
developments in the method enabled the reduction in analytical variation, whilst 
enabling the increase in molecular coverage. 
The developed method was applied to an increased sample cohort (n=141).  Results 
revealed three phosphatidylcholine (PC) species as significantly reduced in AD: 
PC16:0/20:5 (p=<0.001), PC; PC16:0/22:6 (p=<0.05); PC18:0/22:6 (p=<0.005).  The 
data underwent a receiver operated characteristic analysis (ROC) resulting in an area 
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1.1 – Introduction to Alzheimer’s disease 
Alzheimer’s disease (AD) was first described in academic print in 1907 by Alois 
Alzheimer [1] (an English translation can be found at [2]).  The paper describes the 
initial observations made regarding a 51 year old woman based at a psychiatric 
facility in Frankfurt, Germany.  Reports describe disorientation, confusion and 
memory loss, with symptoms described as “sometimes stronger, sometimes 
weaker”, with the eventual patient death occurring four and a half years later.  
What followed was the first reported brain autopsy of the disease, with 
observations of abnormal deposits of neurofibrils that form tangle structures in 
the cells.  In addition there was a further deposit of a substance that can be 
observed in the cortex region of the brain.  These observations laid the foundation 
to studies into dementia and in particular AD. 
Knowledge of the disease has progressed from this first report, and it is now 
considered a major global health burden.  Current estimates suggest that the 
worldwide incidence of Alzheimer’s disease is 25 to 30 million people, with future 
predictions suggesting the number of cases will triple by the year 2040 [3] (Figure 
1.1).  A 2013 study has suggested cases in the United States will dramatically 
increase from 4.7million to 13.8million cases[4].  It is also predicted that particular 
expansion will occur in developing countries, including India and China as medical 
research becomes more proficient at treating infectious and acute disease, 
increasing average lifespan and expanding an already aging population.  It is 
currently accepted that one of the major risk factors for the disease is age, with the 




Figure 1.1: Predicted future worldwide incidence of Alzheimer’s disease 
The above plot signifies the predicted increase of AD over the next few decades.  Incidence 
is expected to increase 100% in developed counties, but the major impact is predicted to 
occur in nations such as India and China, where an increase of up to 300% is forecast. 




































1.1.1 – Familial and Sporadic Alzheimer’s Disease 
It is now widely accepted that there are two main forms of AD: 
• Familial AD (FAD) 
• Sporadic AD (SAD) 
1.1.2 – Familial Alzheimer’s Disease  
Familial AD is a genetic condition and is caused by a mutation in single genes 
which are inherited in an autosomal-dominant fashion.  It is thought that this form 
of AD accounts for approximately 5% of all cases.  It can often be referred to as 
early onset AD (EOAD) due to the reduced age of pathological progression, 
compared with sporadic AD.  There are three major genes which are currently 
regarded as being responsible for the onset of familial AD, with over 150 
polymorphisms reported.: 
• Amyloid Precursor Protein (APP) 
• Presenilin-1 (PSEN-1) 
• Presenilin-2 (PSEN-2) 
These genes are important when considering the current consensus on the 
mechanism of AD pathology.  Termed the Amyloid Cascade Model (ACM), the 
theory hypothesises that the build-up of Aβ is an early mechanistic stage in the 
disease, and leads to neuro-degeneration [6].  To summarise, APP is a trans-
membrane protein.  The two main enzymes thought to degrade the protein are α-
secretase and β-secretase.  When APP is cleaved along the β-secretase pathway 
(often termed the amyloidogenic pathway), it leaves an Aβ fragment still bound to 
the cell membrane.  Alternatively, breakdown via the α-secretase pathway (non-
amyloidogenic pathway) cleaves inside the Aβ section, therefore only leaving a p3 
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peptide remaining bound to the membrane.  The final extracellular fragment is 
then spliced via the protease complex γ-secretase, resulting in the release of the Aβ 
protein.  This process is summarised in Figure 1.2.   
Both the amyloidogenic and the non-amyloidogenic pathways exist in normal 
physiology, however, evidence suggests that it is an increase in activity of the β-
secretase enzyme complex which leads to the increase in Aβ in AD [7, 8]. 
Additionally, genetic polymorphisms associated with familial AD are closely linked 
to this pathway.  To date, the γ-secretase complex, has been shown to contain at 
least four individual proteins: presenilin, nicastrin, anterior pharynx-defective 1, 
and presenilin enhancer 2 [9].  Presenilin, is the catalytic subunit; and it is here 
where polymorphisms in the presenilin gene have been reported in familial AD. 
γ-secretase demonstrates some unusual characteristics for a protease complex, 
and there is a certain amount of variation in the cleavage site at the C-terminal in 
amyloid beta proteolysis.  For example, γ-secretase is known to be able to cleave 
APP at multiple different sites to generate a peptide fragment isoforms that range 
from 39 to 42 amino acids in length.  The most common of these isoforms is Aβ40, 
whilst Aβ42 is the most susceptible to the aggregation process which eventually 
leads to amyloid fibrillogenesis and plaque formation in AD.  The previously 
discussed polymorphisms in the genes coding for APP and both types of presenilin 
have been reported in association with increased Aβ42 production in familial 
Alzheimer's disease [10].  
The mechanism of this link to Aβ42 in familial AD is not fully known however there 
is evidence to suggest that different forms of the γ-secretase complex are 
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differentially responsible for generating the different Aβ isoforms, suggesting 
specificity of the enzyme complex may play a role in Aβ aggregation [11]. 
Polymorphisms in the gene coding for APP have been shown to greatly increase 
the production of Aβ isoforms [12].  Further to this, the proteins PSEN1 and PSEN2 
are known to be involved in the γ-secretase enzyme complex and again have been 
shown to influence the ratio of Aβ isomers, with Aβ42 known to be the most prone 




































































































































































































































































































































































































































































































































































1.1.2.1 – Sporadic Alzheimer’s Disease 
Sporadic Alzheimer’s disease (SAD)(also termed late onset Alzheimer’s disease 
(LOAD)) is the most common form of the disease.  The diagnosis of SAD is far more 
challenging that FAD, as there can often be no obvious family history, or apparent 
cause, hence it can also be frequently referred to as sporadic AD. 
Currently, the largest risk factor associated with SAD is age, with the incidence of 
the disease doubling every 5 years after 65 [14].  As with FAD, the disease is 
characterised with the formation of Aβ plaques as well as the formation of deposits 
of the protein tau in the brain.  Although a number of genetic polymorphisms have 
been identified as risk factors, the full mechanism is still not fully understood. 
For example, patients who are carriers of the apolipoprotein ε4 allele coding for the 
E4 isoform of apolipoprotein E (ApoE), have been shown to be at increased risk of 
developing AD [15].  In comparison, research suggests that carriers of the 
apolipoprotein ε2 allele coding for the E2 ApoE isoform have a reduced risk of 
developing AD.  It is thought that ApoE modulates the previously discussed γ-
secretase activity, and therefore affects the ratio of Aβ isomers [16].  It has also been 
reported that an increase in the β-secretase activity is associated with ApoE ε4 
genotype increasing the production of Aβ [17]. 
Further evidence exists in the literature linking sporadic AD to genetic risk factors 
which may predispose individuals to the disease.  Recent large scale genome wide 
association studies have reported APOE, CLU, PICALM, CR1, BIN1, ABCA7, MS4A6A, 
CD33, CD2AP, and EPHA1 as significant risk factors to AD [18, 19]. 
Outside of genetic mutations, some environmental risk factors have been mooted 
in the literature, including previous traumatic brain injury [20], previous diagnosis 
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of depression [21, 22], history of gum disease [23], and those patients with a low level 
of education or with a low level of mental capability [24].  Additionally, family 
history has been shown to be a risk factor of AD, without an obvious genetic link.  
Currently the link to family history and sporadic AD is poorly understood, however 
evidence suggests that family history may modulate the effect of APOE4 [25]. 
Again, there is no definitive risk factor which is currently employed for the 
diagnosis of SAD.  It is in part for these reasons why the recent discussion group 
from the National Institute of Aging in collaboration with the Alzheimer’s 
Association (NIA-AA) (discussed in more detail in Section 1.1.3) have targeted the 
development of an improvement in biomarker research, to enable the earlier 
detection of the disease, ideally before typical symptoms emerge.  Again, because 
of the difficulties and the many unknowns associated with SAD, the majority of 
biomarker research in the literature is focused upon SAD.  This is also true of the 
contents of the thesis presented herein and from this point forward references to 
AD refer to SAD, unless stated otherwise. 
1.1.3 – National Institute of Aging and Alzheimer’s Association 
Discussion Group  
As technological advances have been made over time, the original description 
made in 1907 has been constantly refined, with the latest diagnostic guidelines 
being released in 2011 by the National Institute of Aging in collaboration with the 
Alzheimer’s Association (NIA-AA) [26].  The guidelines were released as part of an 
international collaborative project which began in 2009 with the aim of updating 




Diagnosis and classification using the 1984 guidelines is based solely around 
traditional approaches relying on the clinical assessment by a doctor, taking into 
account patient history, cognitive testing, for example by use of the 30 question 
mini-mental state examination (MMSE) [28] and general neurological assessment.   
However, the new recommendations and targets set out to improve this in two 
main ways: 
• Identify three stages of AD 
• To incorporate biomarker research in AD diagnosis 
These aims are now discussed in more detail below:  
The guidelines presented by the NIA-AA aim to implement three main stages of the 
disease into clinical research.  Previously, when using the 1984 criteria, in order 
for AD to be diagnosed, memory loss and reduction in cognition was required.  
However focus is shifting to an earlier diagnosis, with recent publications 
suggesting that the first pathological instances of AD might occur up to 20 years 
prior to the presentation of symptoms [29, 30].  This finding may lead to the earlier 
detection and therefore earlier treatment of the disease, ideally improving the long 
term quality of life of the patient. 
Stage one of the new guidelines is classed as preclinical AD, and is defined as 
patients who have measurable changes in markers in the brain (including 
imaging), cerebrospinal fluid (CSF) or blood plasma or serum, however exhibit 
none of the traditional symptoms such as memory loss.  The guidelines as yet have 
no definitive biomarker approved for this role, therefore implying a significant 
need for progression in AD biomarker research. 
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Stage two is defined as mild cognitive impairment (MCI) as a result of AD.  MCI is a 
condition of reduced mental and cognitive impairment; however the individual is 
still able to live a relatively normal life and is able to complete day to day tasks.  
Current estimates suggest up to 20% of >65 year olds suffer from a form of MCI [31].  
MCI is viewed as a significant risk factor for AD; however, conversion rates are 
unclear depending on the study.  Mitchell and Shiri-Feshki recently published a 
systematic review of the literature and found progression to AD to be 
approximately 29% in population studies [32].  Currently it is unclear as to why 
some patients progress to more severe forms of dementia and why some remain 
stable.  It is a frequent debate, with some research teams believing MCI is simply a 
pre-stage of a particular dementia, with others believing MCI is a separate 
condition altogether and simply acts as a risk factor for further cognitive decline.  
As part of the recent recommendations, it is advised that further research goes into 
biomarker discovery, with the aim of identifying more underlying mechanisms of 
the progression from MCI to AD. 
The final stage of the clinical categories recommended in the NIA-AA guidelines is 
described as dementia due to AD.  In this instance symptoms such as disorientation 
and memory loss are clearly apparent and are caused by AD related pathology.  For 
this stage to be reached the symptoms are suggested to be severe to the extent that 
an individual’s daily life is detrimentally affected.  
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1.2 – Biomarker Research and the Clinical Diagnosis of 
Alzheimer’s Disease 
As well as recommending the implementation of three major clinical stages of AD, 
the recent report by the NIA-AA also reported that reliable biomarkers for the 
disease are required, and therefore research in this area should expand. 
This requirement for diagnostic markers is perhaps not surprising, with current 
diagnostic procedures being relatively subjective, relying on a clinical specialist, to 
observe a combination of mental cognition, patient history, family history and 
general physical health.   
1.2.1 – Definition of a Biomarker 
A biomarker of AD is defined as a parameter (physiological, biochemical, anatomic) 
that can be measured in vivo and that reflects specific features of disease related 
pathophysiological processes.  Previous use of the term has often been used to 
describe fluid analytes, however in the case of AD, it can also be used to term any 
observations via imaging techniques [26].   
A biomarker is required to be able to accurately classify those patients with the 
disease, this is termed sensitivity.  Additionally, a biomarker should be able to 
classify controls and other disease variations as non-disease category, and this is 
termed specificity.  To be suitable for clinical use a biomarker is required to have 
both a high sensitivity and specificity. 
Many biomarker molecules are routinely used in other diseases, a classic example 
is the monitoring of circulating plasma glucose, and more recently the circulating 
level of glycosylated haemoglobin (HbA1c) levels to diagnose and monitor patients 
suffering from diabetes mellitus [33]. 
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1.2.2 – Current Methods of the Diagnosis of Alzheimer’s Disease 
Current diagnostic approaches are structured around both a clinical examination 
and a neuropsychological assessment of the patient.  Whilst work on the 
implementation strategy of the NIA-AA recommendations continues [26, 34], much of 
immediate diagnosis still relates to the classic set of criteria presented by the 
National Institute of Neurological and Communicative Disorders and Stroke-
Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA).[27].  
However, it should also be noted that other sets of criteria are also in circulation, 
for example those published by the World Health Organisation (International 
Classification of Disease) [35] and American Psychiatric Association [36].  In each 
case the main clinical symptom is the presence of cognitive impairment, with a 
gradual progression, whilst no secondary cause of the dementia exists, for example 
signs of vascular dementia, intracranial mass such as a tumour, normal pressure 
hydrocephalus (the abnormal accumulation of CSF within brain regions) and 
further neuropsychiatric disorders. 
Following the elimination of secondary causes the clinician can assess the patient’s 
history and recent symptoms.  Such history and details can be determined from 
family members, or friends, and their accounts are often used in the diagnosis.  The 
cognitive status of patients is also a vital consideration and there are a number of 
ways in which this is examined. 
Cognitive impairment is typically assessed using a battery of cognitive tests.  A 
widely used example of this is the MMSE [28].  The MMSE is made up of 30 
questions divided up into six sections.  A typical MMSE obtained from the Guy’s 
and St Thomas’ trust can be observed in Figure 1.3.  It tests the individual on a 




Figure 1.3: Example Mini-Mental State Examination 
A typical Mini-Mental State Examination (MMSE), routinely used in the assessment of the 
cognitive condition of both patients and suspect patients of Alzheimer’s disease (AD).  
Healthy controls with non cognitive impairment are expected to score 30, with the greater 
the impairment the lower the expected outcome score from the examination. 
MMSE obtained online from the Guy’s and St. Thomas’ Trust [37]. 
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greater than or equal to 25 indicates normal cognition.  A score of 21-24 indicates 
mild cognitive impairment, 10-20 moderate impairment and a score of less than or 
equal to 9 indicated severe impairment.  The score, however, only acts as an 
indication of cognition as an aid for diagnosis, and it is possible for a patient 
suffering from dementia to score 30.  Other examples of cognition scales are also 
employed, for example the Alzheimer’s Disease Assessment Scale-Cognitive 
subscale (ADAS-Cog) [38] and the Neuropsychological Battery for the Consortium to 
Establish a Registry for Alzheimer’s Disease (CERAD) [39].  Further scales can also 
be employed such as the Global Deterioration Scale [40] and the Clinical Dementia 
Rating [41] which attempt to combine mental cognition, functional symptoms and 
neuropsychiatric elements in a single approach. 
In addition, a number of various other scales and tests are completed to examine 
for signs of patient depression [42, 43], memory impairments such as delayed recall 
and poor recognition [44-46], spatial memory [47] and patient levels of apraxia [48]. 
There are many other scales discussed in the literature, with debates in constant 
evolution in attempts to define a clear methodology for AD diagnosis.  However 
using the common techniques described here, for example, those stipulated by the 
NINCDS-ADRDA, the relative diagnostic accuracy varies depending on the study 
with values of 65-96% reported [49-54].   
More problematic is the diagnosis specificity between patients with AD and those 
with other types of dementia, with reports suggesting diagnosis accuracy varies 
between as low as 23-88% [51-53]. 
From these figures there is clearly a pressing need to improve diagnosis accuracy, 
and it is here where recent proposals have suggested improved laboratory tests, 
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combined with structural imaging data to provide a greater reliability in the 
diagnosis procedure.  
1.2.3 – The Advantages of Biomarkers in the Diagnosis of Alzheimer’s 
Disease 
The use of a standardised, recognised biomarker which is easily monitored in a 
laboratory test would be of great value.  Firstly, if any biomarker candidate is 
successfully implemented in a clinical environment it would improve the diagnosis 
rates of AD.  However, perhaps the most value would be obtained in any ability to 
diagnose the disease at an earlier time point, preferably prior to the surfacing of 
the major symptoms associated with the disease.   
As research into the treatment of AD progresses, many novel avenues are 
investigating what are termed “disease modifying” treatments.  These approaches 
are focused upon the changing of pathological processes, for example preventing 
the accumulation of the two major proteins β-amyloid (Aβ) and tau.  The 
hypothesis is that this prevention would lead to a slowing of the progression of the 
disease, and is more likely to be more effective than attempting to manage the 
condition once the full pathological mechanisms have set in [55].  Therefore there is 
a pressing requirement to diagnose AD as early as possible, in order to give disease 
modifying treatments the best possible chance of success. 
In addition, if a biomarker screen is able to diagnose AD, it might also be used to 
track both the progression and the response to treatment of the disease.  This 
could lead to the development of personalised treatments, designed for individuals 
at different time points of the pathology [56]. 
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Finally, the identification of a novel biomarker, be it a protein, gene or small 
molecule, has the potential for identifying novel mechanistic pathways of the 
disease.  These can act as new targets for therapeutic research, and may lead to 
new approaches to pharmaceutical design.  This is of particular importance as 
there is an on-going discussion as to whether current pharmaceutical treatments 
targeting the amyloid cascade pathways (Figure 1.2) are providing successful 
results [57].  Therefore the identification of novel biomarkers may open new 




1.3 – Current Lead Biomarkers in Alzheimer’s Disease 
There are a number of biomarker candidates that have been frequently reported 
and tested in the literature, those which have shown the most promise to date are 
discussed below. 
1.3.1 – Brain Imaging 
As discussed above in Section 1.2, as part of the NIA-AA recommendation on the 
discovery of a biomarker, the term can be applied to describe any observations 
obtained via the use of imaging techniques [26].   
Imaging approaches have been investigated in the literature, particularly with 
regard to observations of brain volume and specific brain region volume.  Studies 
have employed magnetic resonance imaging (MRI) to estimate the volumes of 
individual brain regions.  Estimation of size is achieved following a patient MRI 
scan either manually [58], or more recently, via semi-automated computerised brain 
mapping techniques [59].  These work by using a marked reference image, and using 
this as a template to trace the test brain region.  Algorithms for this procedure are 
commercially available and are widely accepted and routinely used in imaging 
studies [59].  
Results have demonstrated that the hippocampus region of the brain is prone to 
reduce in size compared with controls, by as much as 12% in mild AD [60], 
increasing to findings of up to 37% in moderate AD [61].  Further studies have also 
demonstrated a significant difference in the rate of hippocampal volume reduction, 
with an average change of 2-6% per year in patients with AD compared with <2% 
in controls [62].  Hippocampal volume has been used to diagnose AD with a 
sensitivity and specificity of 85% and 82% respectively [61].  This was shown to 
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perform even better using an approach which also takes into account general aging 
with sensitivity and specificity figures of 90% and 91% after the age adjustment 
[61]. 
The sensitivity and specificity has also been improved by combining information 
on hippocampal volumes with data from magnetic resonance spectroscopy (MRS) 
which allows the quantification of metabolites.  The diagnostic performance is 
particularly observed when combined with MRS data used to quantify level of the 
metabolite N-acetyl-aspartate (NAA) (with a reduction identified in AD patients) 
[63].   
Despite this, challenges exist with the use of MRI in a clinical environment, mainly 
due to the high cost of imaging technologies.  In addition, data currently has to be 
processed by a specialist trained at interpreting the data, adding further cost and 
time.  Further complications are added as the undertaking of a brain scan can be an 
uncomfortable experience, especially for those disorientated by the symptoms of 
dementia.  In addition, diagnostic challenges also present themselves as both a 
decrease in hippocampal volume and levels of NAA have been shown to decrease 
in MCI [64, 65], impacting the requirements of the NIA-AA guidelines. 
An alternative imaging approach is termed positron emission tomography (PET).  
The technique works by detecting a labelled radionuclide molecule termed a 
tracer.  The tracer is introduced into the body bound to a biological molecule of 
interest.  Three-dimensional images of tracer concentration within the body are 
then constructed by computer analysis.  With regard to Alzheimer’s disease PET is 
useful for the quantification of metabolites in vivo in the brain.  A particular 
advantage of the technique is that is allows imaging of Aβ load in living patients 
using the tracer Pittsburgh compound B (PiB), that binds to Aβ. 
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Studies have reported a marked retention in PiB in AD patients, compared with 
controls.  PiB retention has been reported at increased levels most prominently in 
frontal cortex (p = 0.0001), whilst increases also were observed in parietal (p = 
0.0002), temporal (p = 0.002), and occipital (p= 0.002) as well as the cortex and 
striatum (p = 0.0001).  In the brain regions known to be relatively unaffected by 
amyloid deposition in AD (such as subcortical white matter, pons, and cerebellum), 
PiB retention has been shown to be at similar levels in both AD and control cases 
[66].   
PET imaging has also been applied to monitoring glucose metabolism in AD using a 
fluoro-2-deoxy-D-glucose (FDG) tracer.  Results have revealed reductions in 
glucose metabolism in the parieto-temporal, frontal and posterior regions of AD 
brain.  The results have been used for prediction of future AD cases as well as in 
distinguishing AD from other neurodegenerative diseases.  FDG-PET has 
demonstrated a 90% sensitivity in identifying AD cases, however, specificity in 
differentiating AD from other dementias is reported as low as 53% [67].  Further 
disadvantages include the relatively high cost of PET scan, as well as 
considerations with regard to radiolabelled tracers, with limits on the number of 
repeat scans achievable with individual patients, so as not to over expose them to 
the radioactive isotopes. 





Figure 1.4: Example Positron Emission Tomography 
The upper section demonstrates Pittsburgh Compound B (PiB) PET imaging of Aβ in 
control and AD brain.  Increased Aβ retention can clearly be seen in AD. 
The lower image is an example of fluoro-2-deoxy-D-glucose (FDG) PET imaging of glucose 
metabolism.  Control demonstrates normal FDG uptake, whilst the AD image shows a 
typical pattern of FDG hypometabolism (arrows - bottom right) along with preserved 




1.3.2– Genotyping in Alzheimer’s Disease 
1.3.2.1 – Apolipoprotein E4 
A current biomarker benchmark of the disease is the genotyping for at least one ε4 
allele which codes for the E4 isoform of the protein apolipoprotein E (ApoE).  The 
ApoE protein is coded by an allele pair, which can be made up of any combination 
of ɛ2, ɛ3 or ɛ4.  Results have shown that individuals who carry at least one ɛ4 allele 
in the pair are at increased risk of developing AD. 
In one study investigating the diagnosis of AD in a patient cohort of 2188, 
consisting of both AD patients and those suffering from other forms of dementia, it 
was found that 65% of those who were pathologically diagnosed with AD at 
autopsy held one of the alleles.  Results concluded that the genotyping the alleles 
on their own currently does not hold the required diagnostic power (sensitivity 
and specificity against controls of 65% and 68% respectively), however when used 
in combination with traditional clinical diagnosis such as the NINCDS-ADRDA 
criteria, it can improve diagnosis specificity, particularly against other dementias 
from 55% to 85% [68].   
Further research presented and discussed in a review by Ashford [15], shows the 
increased relative risk of the diagnosis of AD in those carrying the ε4 allele.  The 
review presented data from two population studies and reported a large relative 
risk of AD when one or two ε4 alleles are inherited.  Data that was presented in the 
review, taken from a publication by Saunders et al [69] described a relative risk of 
2.07 for an allele pair combination of ε3+ε4 and 7.50 for presence of allele pair 
ε4+ε4.  This compares with a relative risk of ε3+ε3 (0.58), ε3+ε2 (0.31) and ε2+ε2 
(0.00). Similarly data presented by Farrer et al. [70] suggested a relative risk of 
ε3+ε4 of 1.92 and for ε4+ε4 of 8.22.  Again the comparative risk of other allele 
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combinations ε3+ε3 (0.6), ε3+ε2 (0.38) and ε2+ε2 (0.25) was reduced.  
Interestingly, results show that when an individual carries the ɛ2 and ɛ4 in 
combination (ɛ2ɛ4), the overall effect is a reduced risk of AD incidence.  For 
example, the relative risk for ε2+ε4 was 1.00 and 0.52 in the two data sets 
discussed above [69, 70].  It is currently thought that the presence of ε2 has a 
protective effect on AD development, although the exact mechanism is not clear. 
A full understanding of ApoE with regard to the increased risk of AD has not yet 
been fully elucidated, however current research has shown that the ApoE protein 
is linked to the regulation of Aβ, with research showing that ApoE protein 
promotes its degradation [71]. Further results in the study suggested that the ApoE 
protein from the ε4 allele is less efficient at catalysing the reaction than other 
variations of the lipoprotein and, therefore, presence of the allele may be in part 
responsible for the build-up of Aβ [71].  Further evidence in the literature suggests 
that ApoE is involved in the regulation of the γ-secretase cascade and, therefore, it 
may influence the ratio of Aβ isomer ratios [16]. 
However, despite the research on ApoE genotyping it is still not common place in 
AD diagnosis and instead is more utilised in the research environment.  This is 
mainly because of its limitations when it comes to disease prediction, but also 
because of psychological effects that results have on patients, particularly those 
who are asymptomatic, and the resulting effect on their treatment 
management [72]. 
1.3.3 – Lead Protein Markers in Alzheimer’s Disease 
The proteins Aβ and tau, which are considered to be a cause of much of the AD 
pathology, have also been mooted in the literature as potential biomarker 
candidates.  Although it is well documented that accumulation of the proteins in 
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the brain is a common result of the disease pathology, it is clearly currently 
unfeasible to take a biopsy of brain for diagnostic testing purposes.  It is for this 
reason that definitive diagnosis can currently only be achieved post mortem.  
Therefore, for a protein biomarker such as tau and Aβ to be useful in a clinical 
environment it must be shown to be present and detectable in a periphery 
biofluids which can be obtained via a relatively non-invasive procedure such as 
urine or plasma (although CSF has also been the source of research). 
 
Figure 1.5: Protein Deposits in Alzheimer’s Disease 
Histopathology imaging of an example brain from a patient suffering from Alzheimer’s 
disease (AD).  Following immunohistological staining of post mortem brain tissue, the 
major protein deposits in the brain can be observed as brown lesions demonstrating (A) 
Amyloid β (Aβ) senile plaques and (B) phosphorylated tau (p-tau) tangles. 
Figure adapted from reference [5] 
1.3.3.1 – Amyloid β 
Aβ is one of the major proteins associated with AD, as it is known to form the 
protein plaque deposits in the brain that are traditionally associated with the 
disease (Figure 1.5).  The full mechanism of Aβ toxicity is unknown, however it has 
been suggested that once released from APP the protein undergoes conformational 
changes, which result in the shift from a soluble form to large fibril clusters which 
eventually develop into the plaques [73].  Braak and Braak first described the 
pathology and progression of amyloid deposition in AD.  They observed initial 
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deposits of Aβ accumulating in the basal regions of the cortex, with subsequently 
spreading in a gradual pattern to the most associative neocortical areas with the 
sensory and motor areas being significantly affected in late stage AD [74].  As well as 
accumulation of Aβ in brain tissue, observations have also been made reporting Aβ 
deposits in blood vessels in the brain, which are termed cerebral amyloid 
angiopathy [75]. 
Aβ isomers range from Aβ39-42 and differ in their tendency to form plaques, with 
Aβ42 identified as the least soluble and therefore considered the most prone to 
plaque initiation in brain tissue [76, 77].  However, interestingly, it has been reported 
that Aβ40 is the isomer form that is most prone to aggregation in cerebral amyloid 
angiopathy [78].  The Aβ plaques have been reported to be neurotoxic causing 
neuronal death in the brain [79, 80], hence the gradual decline in cognition associated 
with the disease. 
As Aβ I plays such a pathological role in AD isomers of the protein have been 
investigated as biomarkers for the disease.  To date, analysis of Aβ levels in plasma 
and urine have been inconsistently reported in the literature [81, 82], with the most 
promising findings obtained from analysis of CSF [56, 83-85].  Although CSF is not a 
perfect biofluid due to the difficulties and discomfort experienced by patients 
during collection, it is the closest biofluid to the brain and therefore, is likely to 
better reflect brain pathology than more peripheral fluids. 
Interestingly, studies have reported a decrease in CSF Aβ42 in those patients with 
AD when compared with controls [83-85].  This reduction is thought to be because of 
the plaque formation of Aβ42 in AD patient brain, and therefore is not available for 
circulation in the CSF [83].  The use of Aβ42 levels has been reported to provide 
sensitivity and specificity values of up to 85%. However, its use in a diagnostic 
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environment has been hampered due to the fact that a reduction in values has also 
been observed in other variants of dementia, for example Lewy body dementia [86], 
vascular dementia [87] and frontotemporal dementia [84]. 
1.3.3.2 – Tau 
The protein tau is also known to form deposits in the brains of AD patients when it 
becomes abnormally phosphorylated.  These are described as neurofibrillary 
tangles, as they take on a more fibril structure (Figure 1.5).  Tau deposits are found 
inside neuronal cells, again highlighting why complete diagnosis can only occur 
post mortem.  Links between tau and Aβ are unclear but it has been suggested that 
abnormal ionic homeostasis and an increase in oxidative stress following Aβ 
plaque formation alters the balance of those enzymes responsible for the 
regulation of tau [5, 88].  This has been shown to lead to tangle formation followed 
by synaptic dysfunction and axonal loss [89].  It is therefore no surprise that tau and 
phosphorylated tau (p-tau) have been investigated as a biomarker for AD and is 
currently regarded as a lead candidate. 
Again CSF has demonstrated the most promising results, with a number of 
publications reporting increases in both tau [83, 87, 90, 91] and p-tau [87, 91-94] in the CSF 
of patients suffering from AD, with sensitivity and specificity shown to reach levels 
of up to 90% and 80% respectively when compared with controls and other forms 
of dementia [93].  However, the literature raises concerns about the use of tau in a 
diagnostic capacity as it has been identified at significantly increased levels in 
patient CSF in other conditions including variations of dementia [87, 90], stroke [95], 
multiple sclerosis [96] and those patients with brain tumour [97]. 
To overcome the previously discussed disadvantages encountered when using Aβ 
and tau as individual biomarkers, analytical results of the two proteins has often 
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been combined in an attempt to improve the diagnostic sensitivity and specificity, 
with promising outcomes [98].  An assay that utilises Aβ, tau and p-tau has made it 
to the market and manufactures claim a sensitivity of 90% and a specificity of 80% 
[56]. 
However despite the commercial availability, uptake of the procedure has been 
reported to be poor [56], and this is likely to be caused by two main factors.  Firstly, 
as previously mentioned, CSF is not an ideal biofluid, requiring collection via a 
procedure requiring specialist personnel, whilst being extremely uncomfortable 
for the patient.  Furthermore the commercial assay is extremely expensive at 
1075USD per sample (as quoted in reference [56]).  However, this is likely to be an 
inflated cost estimate, due to the commercial nature of the for profit American 
private healthcare market.  Typically, ELISA techniques have a far lower “cost” 
price, and may be an affordable option if adapted for a hospital/clinical testing 
environment. 
This report suggests a growing need for more accessible biomarkers, for example 
in urine or circulating blood that can be collected and analysed at a much lower 
cost. 
1.3.3.3 – Blood or Urine Based Biomarkers 
Biomarker research in non-invasive tissues such as blood or urine has thus far not 
been as promising as those identified via the approaches described in brain and 
CSF.  Aβ42 is one of the most frequent references in the literature, appearing in 
both plasma [82, 99] and urine [81] based studies, but publications have returned 
inconclusive results.  For example, some groups have reported an increase in Aβ42 
in the plasma of AD patients [82, 100], whilst others have noted no significant change 
[101-103] and a recent publication has even reported a reduction in plasma Aβ42 [104]. 
Introduction 28 
 
The conflict in results described above is interesting and highlights the need for 
preliminary results to be confirmed by an independent laboratory.  However, 
when comparing different publications, such as these, the design of the study 
should be scrutinised.  Recently, there have been discussions in the literature with 
regard to the evolution of study design in AD [105].  Predominantly in the literature, 
studies are completed in a traditional case(AD)-control design, with distinct 
patient classes, termed cross sectional.  However, recently, alternative approaches 
have been presented for the identification of biomarkers that aim to reflect disease 
state [105].  These alternatives are of particular importance in diseases such as AD, 
which develops over a long preclinical phase, and therefore there is a growing 
consensus that a proportion of controls are likely to have some degree of the early 
stages of AD pathology even in the absence of clinical symptoms [105].   
An example of an alternative approach is termed longitudinal study design.  In this 
instance patient samples are collected at the first visit (termed baseline) and then 
at various time points throughout disease progression, thus enabling a picture to 
be painted of potential markers over time. 
Studies that employ traditional case-control and longitudinal study designs can 
produce alternative interpretations using the same biomarker candidate.  An 
example of this can be found when comparing the previously cited publications 
regarding plasma levels of Aβ42.  As previously mentioned the majority of cross 
sectional publications report no statistical differences when comparing AD patient 
plasma with control plasma [101-103], however when analysed using a longitudinal 
approach higher plasma concentrations of Aβ42 were found in those patients who 
started the study as a control, but subsequently developed AD, than those who 
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remained as controls [82].  A similar result was reported in a second more recent 
longitudinal study [100]. 
Further plasma based candidate biomarkers include the proteins clusterin [106], 
complement factor H (CFH) precursor [107] and α2macroglobulin (α2M) [107], all of 
which have demonstrated promising potential.  However, in follow up studies the 
results have been disappointing with a recent publication reporting plasma 
clusterin as having no diagnostic potential [108]. 
Again however, the reported conflicting results are perhaps related to issues of 
study design previously discussed.  However, despite the longitudinal studies 
described above offering an alternative to the traditional cross sectional design, 
they still employ a classic case-control classification scheme, extended over 
multiple time points.  Therefore, there still exists the possibility that age matched 
controls may exhibit early AD pathology.  Therefore, recent studies have begun to 
correlate potential markers to known disease pathology, such as brain atrophy and 
brain Aβ concentration via PET scan [109, 110].  This offers a further development in 
study design and moves away from rigid case-control structure. 
The conflicting plasma concentrations of the clusterin, discussed above are an 
example of this in action.  In classic case-control experiments plasma clusterin has 
been reported to hold no diagnostic benefit when directly comparing between 
control, MCI or AD patient groups [108].  However, when investigating plasma 
clusterin using alternative disease progression points, the protein has been 
demonstrated to be associated with atrophy and Aβ burden in the entorhinal 
cortex, hippocampal volume and the rate of cognitive decline [106].   
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The implications of study design on result outcome are interesting, and highlight 
some of the challenges faced in the search for reliable markers of AD.  In addition 
to research groups beginning to innovate in study design, work is being completed 
combining marker panels in an attempt to improve accuracy of diagnosis.  A recent 
example of such is a biomarker panel of 18 markers incorporating both proteins 
(including ApoE, epidermal growth factor receptor (EGFR) and haemoglobin), and 
smaller molecules (including cortisol, calcium and zinc) [111].  However, a recent 
discussion piece in the Journal of American Medical Association (JAMA) has raised 
concerns regarding the use of this biomarker panel [112], due to the fact that an 
overlap of AD, MCI and controls was still observed, meaning no definitive 
classification could be achieved.  Further to this, with a panel of 18 biomarkers, 
concerns were raised regarding the over fitting of data [112].  In addition, the panel 
was only validated between control, MCI and AD, therefore for progression into 
routine clinical use, there is a requirement for further validation against other 
forms of dementia and neurodegenerative disorders. 
Another publication uses a similar biomarker panel approach.  Coincidently, a 18 
marker assay is again used as a predictor tool  for AD.  In this occasion the 
approach employs 18 signalling proteins such as interleukin-3 (IL-3), 1α (IL-1α) 
and 11 (IL-11), intercellular adhesion molecule-1 (ICAM-1) and platelet derived 
growth factor BB (PDGF-BB) [113].  The assay reported an accuracy of diagnosis of 
90%.  However once again early promise has not progressed to the routine clinical 
diagnosis environment, and a follow up study by an independent research group 
found a much lower rate of diagnosis of 63%, and, importantly, could not 




1.4 – Small Molecule Biomarkers 
As previously discussed, despite the extensive research already undertaken into 
biomarker discovery, currently no candidate, either individually or as a group, has 
been successful in fulfilling the required role and currently there is no laboratory 
test for the definitive diagnosis of AD in regular clinical use.  Therefore, it is a 
reasonable conclusion that a different angle of investigation is worth pursuing.  
The answer may be found in a growing field in biomarker discovery which 
employs the use of small molecules as markers of disease. 
1.4.1 – Definition of Small Molecules 
Small molecule biomarkers (SMB) are classed as molecules of approximately 
<1.5KDa in size and generally involve metabolite molecules such as amino acids, 
lipids and sugars.  In theory, small metabolites are ideal biomarkers due to the 
mechanisms of systems biology.  A simplistic explanation for this is depicted in 
Figure 1.6.  In summary, a single gene coding for a protein, for example an enzyme, 
can be transcribed to mRNA multiple times.  In turn, each strand of mRNA can be 
translated many times into the relevant proteins.  Finally, each resultant enzyme 
molecule could potentially lead to the catalysis of a large number of metabolic 
reactions resulting in an increase of small molecule metabolites.  Due to the 
various levels of amplification in the process, any imbalances at any stage of the 
cascade may be highlighted, resulting in the discovery of SMB capable of disease 
diagnosis. 
A simplified example of SMB in a clinical setting is in the case of type II diabetes 
mellitus.  To briefly summarise, in the disease a resistance to the hormone insulin 
develops.  Under normal circumstances in the liver, insulin levels regulate glucose 
levels by inhibiting glucose metabolism and its release from cells.  However, in 
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patients with insulin resistance, the liver inappropriately releases glucose into the 
blood amplifying the signal, which can then be measured and used in a clinical 
environment to diagnose the disease [33].  
 
Figure 1.6: Overview of Systems Biology 
A simplified overview of systems biology, highlighting the potential advantages of small 
molecules.  At each stage of the process amplification can occur. 
In addition the products of the metabolome can interact upstream, with genetic processes 
or with proteins, for example signalling.  Identifying these interactions and imbalances 
within the metabolome may lead to the discovery of biomarker candidates suitable for the 
diagnosis of diseases such as AD. 
A further potential advantage of the discovery of plasma SMB, especially in AD, is 
with regard to the blood brain barrier (BBB).  Despite evidence in the literature to 
suggest the BBB is more permeable in patients with AD [115-117], the BBB is still an 
important consideration when investigating plasma based biomarkers of AD, as 
the primary disease site is the brain.   Therefore, for any candidate molecule to 
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accurately reflect brain pathology it may be advantageous for markers to be able to 
cross the BBB.  Small molecules are considered advantageous for this compared 
with larger protein molecules, especially those lipophilic molecules which are 
more suited to crossing [118]. 
1.4.2 – Targeted Biomarker Discovery 
Method development for biomarker discovery tends to take one of two 
approaches.  Firstly, a targeted (hypothesis driven) approach can be made where 
the study is designed using a hypothesis based upon a specific molecule or group 
of molecules.  These then undergo specific analysis with a methodology designed 
with a target in mind. 
1.4.3 – Non-Targeted Biomarker Discovery 
Secondly, a non-targeted or top-down strategy can be used, which sets out to 
analyse a biofluid non-discriminately, identifying any differences in the 
concentrations of molecules detected.   
This hypothesis generating style of analysis has become increasingly important, 
especially as over recent years our traditional view of metabolism has altered from 
a simple linear structure to a more complex network, with many intracellular 
outcomes still not fully understood.  As non-targeted metabonomics/olomic 
studies improve and the discipline becomes commonly practised, data will be 
ideally combined with parallel genetic and proteomic studies to give us an overall 
picture of systems biology and the whole network processes (Figure 1.6). 
In order for a non-targeted approach to be interpreted in a reliable and useful 
manner the analysis of the raw data is heavily reliant on rigorous data processing 
methods followed by a series of mathematical models, for example partial least 
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squares [119], which are capable of grouping samples dependant on the severity of a 
disease differences, and highlighting any metabolite differences between the 
disease classification groups. 
These differences can then be identified, leading to the potential discovery of novel 
marker metabolites related to disease states.  An extremely informative table 
describing the various forms of data treatment and chemometric approaches 
available in metabolomic studies was compiled in a review by Madsen et al [120] 
and can be found in Table 1.1. 
     
 Technique Typical use Description and comments  




Univariate analysis where the corresponding p-values are the 
standard scientific measure of significance. Multiple testing is 




analysis (PCA) [122] 
Data overview 
Standard multivariate analysis method to provide an overview of 
a large dataset. Useful for identifying outliers, clusters and trends 









PCA model of each class, good prediction capabilities especially 
for inhomogeneous classes (class size and variance). Less 
straight forward interpretation of potential biomarkers 








Discrimination method related to multiple linear regression. 




Partial least squares 
discriminant analysis 




Classification variant of PLS. Works best with homogeneous 
classes. Biomarker identification possible, but not as straight 
forward as with OPLS-DA. 
 
 







Classification variant of OPLS method. Ability to separate 
between-class from within-class variability. Straight forward 
interpretation and identification of potential biomarkers 
 
 




High flexibility in modeling non-linear data, but prone for 
overfitting. Potential biomarker identification more complicated 
 
 
Self organizing maps 
(SOM) [129] 
Clustering method 
A neural network based method for identifying trends and 
clusters in the data. Can account for non-linearities in the data. - 
not there in the other descriptions. 
 
 




High flexibility in modeling non-linearities. Careful model 
selection reduces possibility of overfitting. Potential biomarker 
identification more complex compared with linear methods,, 
except when linear variant is used (LS-SVM) 
 
Table 1.1: Data Analysis Methods in Metabolomics 
Data analysis methods frequently employed for disease diagnosis and biomarker 






Non-targeted approaches are becoming more popular, with an increase in demand 
for hypothesis generating results.  Many publications are now available covering 
different conditions and disorders.  However, it is still a relatively new technique 
and disadvantages exist.  Firstly, the greatest issue is the problem of interference.  
The concept of the non-targeted approach is to extract and analyse a wide range of 
molecules as possible.  However, due to the nature of biological systems, 
metabolites exist at a wide range of concentrations and exhibit a number of 
physiochemical properties.  This can make extraction and analysis difficult, for 
example the extraction of highly abundant molecules may require a dilution step 
for accurate analysis, but those molecules at a low concentration will be diluted to 
below the limit of detection.  This can result in features being masked and 
overlooked.  Additionally, when extracting samples in a non-targeted manner, 
problems can arise in the LC-MS analysis, with co-elution of features resulting in 
mass spectrometry effects such as ion suppression. 
To counter this, improved separation techniques are required, for example by use 
of chromatography, or by specialised extraction techniques (See Chapter 4 for 
further investigations in this area). 
Further drawbacks include the cost, which can be elevated due to the increased 
time of project compared with targeted approaches.  This additional time comes in 
the form of the increased data treatment and statistical modelling required.  In 
addition, further adding to the time of the study is the length of time required to 
confirm any molecules of interest.  To date few groups have attempted non-
targeted techniques in AD biomarker discovery, although this is changing rapidly.   
The following sections contain an overview of the analytical techniques employed 
to investigate small molecule variation within AD, and examples of how they have 
Introduction 36 
 
been applied to both targeted and non-targeted study designs, with a summary of 
the results reported.  
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1.5 – Analytical Techniques in Small Molecule Biomarker 
Discovery 
The investigation of small molecules with regard to AD is a rapidly growing field.  A 
wide range of techniques have been published with the aim of investigating small 
molecule variation in AD, with vast improvements in recent years in the sensitivity 
and selectivity of analytical technologies including nuclear magnetic resonance 
(NMR), ultra-high performance liquid chromatography (UHPLC) and mass 
spectrometry (MS).  Not one technique is perfect and often a compromise has to be 
taken depending upon a range of criteria including speed, cost, properties of the 
analytes, sensitivity and the biofluid employed.  These approaches are now 
discussed below, with advantages and disadvantages with regard to each 
technique and are summarised in Table 1.2 found at the end of the section. 
The subsequent sections 1.6 and 1.7 then discuss examples of how these 
techniques have previously been applied to investigating small molecule variation 
in AD.  A summary table of these findings can be observed later in Table 1.3. 
1.5.1 – Nuclear Magnetic Resonance (NMR) 
NMR has become a highly useful and widely used analytical technique.  It works on 
the principle that individual atoms absorb a specific frequency of electromagnetic 
radiation when under the influence of a magnetic field.  The basic theory behind 
the technique is based upon a property that certain common atomic nuclei, such as 
1H, 13C, 15N, 19F, 29Si and 31P have, enabling them to “spin”.  This “spin” property 
also results in the nuclei alignment when placed under a magnetic field.  Radio 
frequency radiation is then applied to the sample which has the effect of providing 
energy that is absorbed, and therefore excitis the atoms, switching the nuclei 
between aligned and non-aligned states.  The frequency required for exciting each 
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nuclei is highly specific for certain chemical structures, which can then be 
measured and recorded allowing structural elucidation and the chemical 
identification of molecules present.  
A further advantage of NMR is that it is capable of analysing tissues in a non-
destructive and highly reproducible nature, often without the requirement of pre-
treatment such as metabolite extraction.   
However, the technique has some disadvantages which currently restrict NMR 
research.  The first and most important of which is its relative insensitivity, 
especially when compared with mass spectrometry methods (discussed in Section 
1.5.3), which can impose heavy restrictions on the range of molecules that can be 
analysed.   
A second disadvantage is that although the technique is capable of whole sample 
non-destructive analysis, in some instances pre-processing of the samples is still 
required.  For example those samples which contain high concentrations of water 
and are being analysed via 1H NMR technology can sometimes require water 
removal prior to analysis, as the high number of hydrogen atoms otherwise 
present in water molecules interfere with the spectra [131].  However, use of 
variations of NMR such as 13C, 15N, 19F, 29Si and 31P, is not effected by water content 
as they are not focused on 1H atoms, and therefore do not require this pre-
treatment.   
A further significant weakness of NMR is that within biological samples 
concentrations of molecular components are naturally variable.  As NMR generally 
analyses whole samples, the molecules found at high concentrations can overlap 
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those present at much smaller concentrations, meaning many potential biomarker 
candidates can be overlooked. 
Moreover, the high cost of purchasing and maintaining an NMR can mean the 
approach is an expensive option. Couple this with the fact that it can be difficult to 
interpret NMR spectrum unless specially trained expertise is employed, then the 
cost can escalate dramatically. 
However, despite these limitations the technique is still an extremely valuable 
biomarker tool, providing fast non-destructive analysis, which can lead to reliable 
structural elucidation of marker molecules.  
1.5.2 – Magnetic Resonance Spectroscopy (MRS) 
MRS is a similar technique utilising the theory of NMR combined with magnet 
resonance imaging (MRI), enabling quantification of metabolites in vivo via a scan 
of the live patient (usually the brain).  An interesting review of the MRS technology 
with a view to small molecule and biomarker discovery has been compiled by 
Gujar et al [132] and describes the approach in further detail.  MRS is a useful 
technique for the identification of marker molecules as it is relatively non-invasive 
and no biofluids have to be collected; however there are also limitations to the 
technique.  Interference is a major problem, particularly when scanning adjacent 
tissues which have major differences in magnetic susceptibility, for example brain 
tissue and bone, therefore scans of areas such as the base of the skull are very 
difficult to obtain [132].  The technique also has difficulties in producing spectra 
from mobile tissues such as peripheral blood or cardiac muscle and therefore is of 
no use in identifying peripheral biomarkers for AD [132].  As the brain, however, has 




1.5.3– Mass Spectrometry (MS) 
1.5.3.1 – Direct Infusion Mass Spectrometry (DI-MS) 
Mass spectrometry (MS) is a widely used technology which offers unequalled 
sensitivity in small molecule analyte detection, and can enable metabolite 
identification and quantification.  Initially, the mass spectrometer provides the 
analyte with a charge, via a process known as ionisation, which occurs in what is 
termed as the source.  Following this, the ions produced are transferred to a gas 
phase.  If samples are injected into the DI-MS in solvent a drying gas is applied to 
evaporate any liquid..  This enables the manipulation of the ions by the application 
of either electric or magnetic fields to enable separation within a mass analyser.  A 
mass analyser can come in many forms, for example time-of-flight (TOF), triple 
quadrupole (QQQ) or ion trap (TRAP).  Mass analysers are able to separate ions by 
their mass to charge ratio (m/z).  Finally, a detector records the electronic current 
generated when a charged particle hits the detector to obtain a mass spectrum.  
Mass spectrometry is a highly useful technique due to its high specificity, 
sensitivity and ability to identify biomarker candidates, either through database 
matching, fragmentation patterns or via comparison to external or internal 
standards.   
However, there are some disadvantages which are associated with MS.  One such 
disadvantage of the technique is known as ion-suppression, which occurs in the 
ionisation stage of the analysis.  This is an analytical effect which can occur when a 
large number of different species enter the source and consequently compete for 
charge and ionisation.  This can inhibit the ionisation efficiency of some molecules 
in the mixture, meaning they can go to waste, without undergoing detection.  
However, it should be noted that ion suppression is not a certainty and depends on 
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the competing analyte in the source, the design of the source and other variables 
such as mobile phase used and ionisation polarity.  Often this is overcome by the 
addition of a separation technique such as chromatography prior to MS detection 
(discussed below Section 1.5.3.2). 
A second disadvantage when compared with NMR is that whole samples cannot be 
analysed without extensive pre-treatment.  It is a requirement of the technique 
that analytes must be extracted from the biofluids into a compatible solvent prior 
to analysis, which can lead to an increase in analytical variation [133]. 
Within the literature, MS is widely used in targeted small molecule and metabolite 
biomarker identification due to its sensitivity, relative ease of use for quantitation 
and ability to detect a wide range of analytes.  The technique can be utilised as 
standalone and referred to as direct infusion (DI) [134], or coupled to a 
chromatographic system such as gas chromatography (GC) [135, 136] or liquid 
chromatography (LC) [137-139]. 
1.5.3.2 – Chromatographic Separation Prior to Mass Spectrometry 
LC utilises a solid stationary phase housed within a stainless steel column (typical 
length ≤150mm and ID ≤5mm).  The column is filled with porous particles, 
normally consisting of a silica bead base with a bonded molecular side chain on the 
surface.  This side chain is selected depending on the mixture of analytes for 
separation.  For example, C18 or C8 are commonly selected for the separation of 
non-polar compounds.  This is termed reversed-phase chromatography.   
Liquid solvent is then passed through the column at a high pressure.  Components 
of a molecular mixture travel down the column at different rates depending on 
their interaction with both the stationary solid phase and the mobile liquid phase.  
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For example, in reversed-phase LC a polar compound will interact with a mobile 
phase with a high percentage aqueous content, rather that the non-polar carbon 
chain stationary phase.  Therefore the transition through the column is relatively 
quick.  Conversely a non-polar compound, for example a lipid with a long carbon 
side chain, will interact more with the non-polar stationary phase, and its 
transition along the column will be slower.  Hence the two compounds elute off of 
the column for MS detection at different times and a separation is achieved. 
GC works in a similar way, however, the liquid mobile phase is replaced with an 
inert gas (helium or nitrogen are typical) and the stationary phase column is 
replaced with a longer stainless steel or glass column which contains either a 
stationary solid or a stationary liquid phase.  The separation occurs within an oven 
and is based upon analyte volatility, with the more volatile compounds eluting 
faster.  Separation can be refined by ramping the temperature from low to high.  
Therefore, those compounds that are more volatile at lower temperatures will 
progress along the column and elute earlier. 
Complex mixtures require greater separation and this can be achieved by 
increasing the analysis time or by using a solvent gradient in LC or a temperature 
gradient in GC which introduces variable separation conditions enabling greater 
control of component elution.  However, the introduction of a separation technique 
does have the disadvantage of adding time to sample analysis. 
With GC a further step of analysis is required as it is only suitable for volatile 
compounds, therefore often an extra derivatisation step is required, increasing 
analyte volatility.  This is a disadvantage to the technique as it introduces a further 
step in the sample preparation which not only increases analysis time but 
increases the chance of analytical variation.  
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However, the increased sensitivity of the techniques makes separation a necessity 
in SMB analysis, especially due to the low trace levels and varied concentration 
range involved in the nature of the work.  The technology is continually advancing, 
in particular recent advances in LC have greatly improved speed, resolution and 
sensitivity [133].  This is discussed in further detail in Chapter 4. 
1.5.4 – Alternative Small Molecule Analytical Techniques 
1.5.4.1 – Chromatography with Alternative Detection 
Despite reducing costs mass spectrometry is still generally considered to be an 
expensive approach.  However there are alternative detectors available which can 
be coupled to LC instruments that are often more affordable and still capable of 
investigating small molecules from biological tissues. 
An example is ultra violet (UV) detection.  UV light is absorbed when molecules 
that contain a chromophore region in their structure pass though the detector.  
The higher the concentration of molecules, the more UV light is absorbed and 
therefore the greater the response recorded.  Generally UV detectors are very cost 
effective and easy to obtain.  However they have two major disadvantages 
compared with MS methods: less sensitivity and specificity.  Further examples of 
LC detection include electrochemical (EC) and fluorescence. 
Due to the low specificity that alternative detectors possess, methods developed 
using them are only suitable for targeted analysis. 
1.5.4.2 – Immunoassay 
Immunoassays come in a variety of formats however the theory behind them is 
similar.  They employ an antibody labelled by the addition of a fluorescent or 
radioactive tag.  The antibody is specific for the molecule of interest and binds to 
Introduction 44 
 
any molecules which are present.  The sample is then washed to remove excess 
material and viewed under the appropriate detector, with the intensity of 
detection directly related to the concentration of target molecule present.   
A wide range of immunoassay technology and design is available.  One of the most 
widely used is termed an enzyme-linked immunosorbent assays (ELISA).  ELISAs 
work on the principle of binding an enzyme to an antibody designed for a specific 
target.  Examples of enzymes used include horseradish peroxidase, alkaline 
phosphatase or glucose oxidase.  Following antibody binding to a target, the 
enzymes allow for detection because of an observable colour change in the 
reagents which are catalysed by the bound enzyme.  In some cases these enzymes 
are exposed to reagents which cause them to produce light or chemoluminescence.  
An example of the principle behind ELISAs can be found in Figure 1.7. 
 
Figure 1.7: Example of ELISA Immunoassay 
Principle theory behind an ELISA immunoassay.  An enzyme covalently bound to an 
antibody is prepared for a specific target.  The antibody binds to its target, and a reagent is 
added to the plate.  The enzyme catalyses a conformation change of the reagent, resulting 




Alternatives to enzyme linked immunoassays include antibodies bound to radio-
isotope and fluorescent tags.  The same principle applies, however detection is via 
radioisotope detection, or measurement of fluorescence. 
In addition to the variety of detection tags, there are a number of different 
antibody methods that can be used in immunoassay analysis.  For example, in 
Figure 1.7, the target virus is found on the surface of the plate.  The enzyme bound 
antibody is then added and binds to the target, and is termed a direct 
immunoassay.  Alternatives include indirect, where a secondary antibody is first 
introduced and binds to the target molecule. Finally a tagged antibody then is 
added to the assay and targets the initial antibody/target complex.  This is referred 
in the literature as indirect immunoassay.   
A further approach that is found in the literature is termed sandwich immunoassay 
and involves “capture” antibodies bound to the plate surface.  When molecules in 
solution are added, the targets are bound to the “capture” antibodies.  The plate 
undergoes a wash step to remove undesired molecules, before the tagged antibody 
is added, and detection and measurement is made. 
The highly specific nature of immunoassays enables their use as a suitable 
technique for targeted metabolite biomarker identification; furthermore, the 
assays are capable of quantification analysis when coupled to the labelled tags. 
Despite incurring some disadvantages, including the high cost of some forms of 
commercial assays and the relatively slow development and low throughput of 
analysis, there are instances within the literature where immunoassays have been 
used to quantify small molecules in biological samples from AD patients. 
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• Provides detail on chemical 
structure 
• Good for metabolite identification 
• Can analyse whole biological 
samples 
• Highly reproducible 
• Relatively insensitive 
• High instrument and operation 
costs 
• Specialist operator required 
• High concentration metabolites 








• In vivo technique – 100% non-
invasive 
• Provides detail on chemical 
structure 
• Good for metabolite identification 
• Highly reproducible 
• Interference between adjacent 
tissues 
• Cannot produce spectra in mobile 
tissues (e.g. blood) 
• Instrumentation can be 
confusing/frightening for elderly 
(especially dementia patients ) 
• Relatively insensitive 
• Highly expensive 








• Highly sensitive 
• Fragmentation provides some 
structural data 
• Confirmation possible with 
comparison to standards 
• High throughput 
• Samples must be pre-treated to 
extract metabolites 
• Interference and ion-suppression 
issues 
• Less structural information than 









• Separation prior to MS reduces 
interference and ion-suppression 
• Easy to operate 
• Highly sensitive 
• High selectivity 
• Confirmation possible with 
comparison to standards 
• Fragmentation provides some 
structural data 
• Samples must be pre-treated to 
extract metabolites 
• Less structural information than 
NMR and MRS 
• Separation adds time to analysis, 
especially with complex non-
targeted approaches 
• Generates high quantities of 
organic solvent waste – can be 









• Separation prior to MS reduces 
interference and ion-suppression 
• Easy to operate 
• Highly sensitive 
• High selectivity 
• Confirmation possible with 
comparison to standards 
• Fragmentation provides some 
structural data 
• Samples must be pre-treated to 
extract metabolites 
• Extra time consuming 
derivatisation step also a necessity 
to increase analyte volatility 
• Less structural information than 
NMR and MRS 
• Due to high temperatures 
molecule stability issues can arise 
• Aqueous solutions and salts 
cannot be injected into the 
instrument 








• Considerably cheaper than LC-MS 
• High throughput methods can be 
developed 
• Easy to operate 
• High selectivity 
• Poor sensitivity 
• Poor specificity 
• Samples must be pre-treated to 
extract metabolites 
• Generates high quantities of 
organic solvent waste – can be 
expensive to dispose of 
• No structural information – must 
be compared with standards 
• No non-targeted approach 
possible 
 
 Immunoassays Targeted 
• Highly specific antibody approach 
• Highly sensitive 
• Relatively easy to complete 
• Can pre-buy many “kits” for 
specific molecule identification 
• Can be expensive 
• Only targeted analysis possible 
• Low throughput 
 
Table 1.2: Analytical Techniques in Small Molecule Biomarker Discovery 
Summary table comparing the various analytical techniques available to small molecule biomarker discovery 
and Alzheimer’s Disease.  Discussed are the approaches available to the technique as well as the strengths and 
limitations of each technology.  Table reproduced from publication by Whiley and Legido-Quigley [141]. 
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1.6 – Literature Review of Targeted Alzheimer’s Disease 
Biomarkers 
The following section discusses the available literature on AD, which has 
investigated variations in small molecular species in a variety of tissues and 
biofluids. 
1.6.1 – Nuclear Magnetic Resonance and Magnetic Resonance 
Spectroscopy 
Typically the brain is the main tissue of study when using NMR and MRS in AD 
research.  Due to the nature of the techniques, NMR tends to be used to analyse 
post mortem brain homogenates, whilst MRS is generally used to scan the brains of 
living patients.  Considering that the brain contains the second highest 
concentration of lipids in the body (after adipose tissue) it is of no surprise that a 
constant reoccurring factor in the literature is the apparent abnormal presence of 
lipids and their metabolites in samples of AD patients.   
An example of this in the literature utilised a 31P-NMR approach and reported 
differences in post-autopsy brain membrane phospholipids.  Results suggested 
significant reductions in total phosphatidylethanolamine (PE) and 
phosphatidylinositol (PI) compounds, as well as increases in sphingomyelin (SPH) 
and phosphotidylethanolamine-plasmalogen (PE-P) [142].   
Neuronal acids and their metabolites also regularly occur in AD biomarker 
literature.  As discussed in Section 1.3.1, the aspartic acid metabolite, NAA, has 
been suggested to be helpful in the diagnosis of AD in combination with imaging 
data.  Use of NAA was investigated as a marker for AD as it is considered a 
neuronal marker thought to reflect condition and integrity of neurons [143].  This is 
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a typical approach to designing a targeted analysis investigation.  Studies which 
apply NMR and MRS targeted methodologies have demonstrated a significant 
decrease in the levels of NAA in a number of brain regions [144-146] suggesting 
neuronal damage.  
However, a challenge in using metabolite concentrations such as NAA is that it can 
be difficult to comprehensively quantify in vivo using NMR/MRS as there is no 
access to an internal standard.  To combat this, biomarker studies often focus on 
NAA ratios with creatine [143], although it should be noted that worryingly for the 
accuracy of studies, creatine has also been identified at increased levels in AD 
patients [146].  Within the literature, there are a number of examples which 
demonstrate reductions in the NAA/creatine ratio when comparing AD with 
control subjects in different brain regions [147-151]. 
A further small molecule metabolite of interest in AD is the carbohydrate myo-
inositol (MYO-IN).  MYO-IN is abundant within the brain and has been shown to 
exist at significantly increased levels in the brains of AD patients via the use of MRS 
[146, 152].  As with NAA, when MYO-IN is analysed via MRS, ratios with other small 
molecules are often used to enable quantification.  The ratio between MYO-
IN/creatine and NAA/MYO-IN has been shown to significantly change in those 
patients who suffer from AD [148, 151, 153]. 
Metabolite ratios have also been analysed in a recent 1H-MRS study which 
identified a reduction in glutamate in the hippocampus region of patients with AD.  
Three groups of patients underwent analysis; controls, MCI and AD.  As with 
previous targeted methods which employed MRS, metabolite ratios were also 
calculated reporting decreased glutamate/creatine, glutamate/MYO-IN, 
glutamate/NAA, and NAA/creatine ratios in AD compared with control.  The article 
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also reported reduced glutamate/MYO-IN ratio in AD compared with MCI [154].  
This finding suggests potential for the metabolites to be used as a marker for AD, 
particularly if significant changes are observed between AD and MCI.  
As previously discussed in Section 1.2.3, an advantage that an accurate laboratory 
biomarker can provide is the ability to track the response to treatment.  An 
example of this in action is the use of the NAA/creatine in the investigation of the 
effects of Rivastigmine treatment in AD.  Rivastigmine is an acetylcholinesterase 
inhibitor designed for patients with mild to moderate AD.  AD is known to have a 
number of cholinergic deficits, which inhibit the signalling effect of acetylcholine 
[155].  Treatment with acetylcholinesterase inhibitors prevents the metabolism of 
acetylcholine, therefore increasing its bioavailability, and improving signalling 
function.   
The ratio of NAA/creatine was monitored throughout rivastigmine treatment via 
MRS of the brain, with results showing a significant increase in the NAA/creatine 
ratio in patients taking the drug compared with those without.  The publication 
concluded that MRS may be suitable for the future monitoring of response of 
patients undergoing treatment programs [156]. 
The literature currently contains no targeted studies which use plasma or urine as 
the source biofluids, possibly because of the relative insensitivity of NMR as an 
analytical technique and the relatively low concentrations of small molecule 




1.6.2 – Mass Spectrometry 
Examples of MS in the literature are frequent with regard to targeted analysis in 
AD.  Many examples use DI-MS, which has been used to demonstrate a number of 
lipid abnormalities in AD.   
An investigation into a lipid extract of post mortem brain material identified a 
significant decrease in the subclass of glycerophospholipids known as 
plasmalogens.  This decrease was particularly apparent in extracts of white brain 
matter where the total plasmalogen level was approximately 40% lower in AD 
than in control patients.  In grey matter a decrease was also witnessed, although 
not as extreme with a decrease of approximately 10%.  Interestingly correlation 
between disease severity and plasmalogen level was significantly apparent in the 
grey matter, with levels decreasing in accordance with increased severity.  In 
contrast, in white matter levels quickly decreased and remained relatively 
constant regardless of AD severity [157].  These findings are of particular note as 
plasmalogens are a major component of nerve tissue, with the ethanolamine 
plasmalogens sub-group responsible for approximately 32% of total phospholipids 
in myelin, the material which forms the outer layer (myelin sheath), around the 
axon of a neuron. It is essential for the proper functioning of the nervous system 
[158] suggesting loss within the brain may play a role in AD pathology.   
Continuing the lipid imbalance theme, DI-MS analysis was previously completed on 
a lipid extract from from brain tissue taken from 22 subjects whose cognitive 
status at time of death varied from no dementia to very severe dementia to analyse 
levels of sulphatides (sulphated metabolites of the glycosphingolipid, 
galactocerebroside).  Sulphatides are again found in the central nervous system, 
predominantly as a component of the myelin sheath [159] and were depleted up to 
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93% in the grey matter and 53% in the white matter of post-mortem confirmed AD 
patients compared with controls [160].  In the same study, a second potential 
galactocerebroside metabolite product, ceramide, was found elevated 3-fold in AD 
patients, further highlighting the irregularities in the metabolism of neuronal 
glycosphingolipids in the disease pathology [160]. 
Whilst results from these two brain studies are clearly not transferable to the clinic 
due to the impracticality of completing a brain biopsy in living patients, it is a clear 
example of how DI-MS can be used in a biomarker research capacity. 
As well as abnormalities in lipid metabolism, disruptions in glucose utilisation [161, 
162] and deficiencies in mitochondrial function [163] are thought to occur in AD, 
subsequently leading to an energy deficit within the brain.  A GC-MS based study 
analysed patient CSF and investigated the concentration of a range of molecules 
that require mitochondrial metabolism, with results demonstrating that AD 
patients have an increase in CSF lactate as well as a decrease in CSF succinate and 
fumarate [164]. 
The process of oxidative stress, particularly the modification of lipids, is also 
thought to play a major role in AD pathology [165, 166], therefore GC-MS has been 
used with this in mind to identify biomarkers formed as a result of this free radical 
oxidation process.  An ideal group of molecules for this purpose are isoprostanes 
that are chemically stable metabolites formed via the lipid peroxidation of various 
fatty acids during oxidative stress.  GC-MS has been used to demonstrate an 
elevation of a number of isoprostanes in many biofluids including various brain 
region homogenates [136, 167], CSF [135, 136, 168-171], plasma [135] and urine [135, 172].  
However, interestingly when using an LC-MS approach to analyse F2-isoprostanes 
in urine, no significant differences were observed when comparing between AD 
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and control [139], conflicting with the results identified in the previously mentioned 
GC-MS study. 
Isoprostanes have also been investigated as an example of a biomarker for use in 
the tracking of the response of a patient to therapeutic treatment.  A GC-MS study 
was designed to monitor the therapeutic effect of antioxidant vitamin supplements 
on oxidative stress in AD.  Those patients who were dosed with increased vitamin 
E and C showed less signs of isoprostane oxidative damage than those taking no 
treatment [173]. 
Oxidation of fatty acids in AD is also the cause of a significant rise in the levels of 
hydroxyoctadecadienoic acid, found via a GC-MS analysis of both plasma and 
erythrocyte extracts.  Interestingly the level of hydroxyoctadecadienoic acid also 
correlated with patient clinical dementia ratings [174], again suggesting a possible 
role in tracking disease progression using this biomarker. 
The neurosteroid dehydroepiamdrosterone (DHEA) is also thought to be 
susceptible to oxidative stress [175].  This theory was examined by applying GC-MS 
analytical methods to serum samples and resulted in the identification of a 
significant increase in 7-hydroxylated metabolites of DHEA in AD patients [176]. 
A further investigation into oxidative stress of lipid species has been completed 
using an LC-MS method. The method was designed to quantify glutathione 
conjugates of trans-4-hydroxy-2-nonenal, a known product of lipid peroxidation in 
oxidative stress.  The analysis was completed using a range of post mortem brain 
regions from control and AD patients.  The study found a significant increase of the 
conjugate in hippocampus and substantia innomina of AD patients [138], providing 
yet further evidence of oxidative stress, particularly of lipids, playing a major 
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pathological role within AD.  Once again the result was in brain samples, making it 
impractical to directly transfer to the clinic, however it highlights the potential for 
LC-MS to be used in biomarker discovery. 
Oxidative stress in AD also affects DNA.  Wang et al. [177] applied a GC-MS approach 
to AD brain samples in a targeted attempt aimed at investigating oxidised DNA 
bases in AD.  The study identified a significant increase in 8-hydroxyguanine as 
well as an increase in multiple oxidised DNA bases.  This suggests products of DNA 
oxidation may be able to play a role as AD biomarkers. 
Small molecule products of protein oxidation, glycation and nitration have also 
been previously investigated with regard to AD [178].  Analysis of the CSF from AD 
and control patients was completed in a targeted manner.  The study identified a 
number of small molecules at increased levels including 3-nitrotyrosine, Nɛ-
carboxymethyl-lysine, 3-deoxyglucosone-derived hydroimidazolone, N-
formylkynurenine, methylglyoxal-derived hydroimidazolone and glyoxal-derived 
hydroimidazolone, suggesting extensive oxidation, nitration and glycation of 
protein products occurs in AD pathology.   
1.6.3 – Alternative Analytical Methods in Targeted Study Design 
1.6.3.1 – Chromatography with Alternative Detection  
The first of these examples is LC-UV which has previously been used to report 
decreases in uric acid [179, 180], vitamin C [179, 180], vitamin A [181], and vitamin E [181] 
in plasma of AD patients as well as a decrease in the plasma carotenoid 
antioxidants including lutein, zeaxanthin, α-carotene, and β-cryptoxanthin [181].  
Lutein levels were also found at decreased levels in AD plasma in a second study 
along with another carotenoid, β-carotene [182].  Interestingly, the decrease of these 
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two antioxidants appeared to correlate with patient MMSE score and disease 
severity suggesting potential for monitoring disease progression.  These findings 
suggest support for previously reported increases in metabolites of oxidative 
stress, and it therefore stands to reason that a decrease in antioxidants may play a 
role in this process. 
In continuation of this theme, the antioxidant vitamin A has also been 
demonstrated to exist at lower concentrations in AD plasma by using LC-
fluorescence detection (method described in [180]), whilst a study using LC-EC has 
reported a reduction in the concentration of antioxidant species (vitamin C and 
uric acid) in AD [181].   
LC-EC was also used to identify a decrease in the CSF concentration of two 
monoamine metabolites of AD patients; 5-hydroxyindoleacetic acid and 
homovanillic acid [183].  Homovanillic acid is of particular interest as it can be used 
as a marker of metabolic stress in relation to irregularities in glucose metabolism, 
which as discussed previously is pathologically linked to AD.   
LC-EC detection methods have determined significantly increased concentrations 
of phosphatidylcholine (PC) molecules within the CSF of AD subjects compared 
with controls.  Of these, glycerophosphocholine was demonstrated to be 
significantly increased by 76%, phosphocholine by 52% and free choline by 39% 
[184].  This result, again, suggests irregularities in membrane phospholipid 
metabolism potentially playing a role in AD pathology. 
1.6.3.2– Immunoassay 
One such developed method purified the steroid, dehydroepiandrosterone, using 
HPLC then quantified the isolated sample using a specific radio-labelled 
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immunoassay.  The results found increased levels in samples taken from various 
AD brain regions and CSF, with the findings thought to indicate the presence of an 
alternative metabolic pathway linked to oxidative stress and therefore more 
common in AD patient brains [175].   
An enzyme linked immunosorbant assay (ELISA) method was published capable of 
quantifying the level of F2-isoprostanes in human plasma [185], however reported 
no significant changes between controls and AD.  As discussed earlier, different 
studies have produced conflicting reports about the levels of F2-isoprostanes in AD, 
with GC-MS results suggesting a significant elevation in a range of biofluids [168-171] 
whilst LC-MS results suggested no significant change in urine [139].  Therefore, the 
immunoassay adds to the conflicting reports, suggesting isoprostanes would not 
be a reliable biomarker for AD. 
The same study also analysed uric acid by a similar immunoassay and found this to 
be at a significantly lower concentration in AD plasma than in control plasma [185].  
This finding complemented results found via LC methodologies discussed 
previously [179, 181]. 
One study that tested the hypothesis that within AD there is a down regulation of 
the adrenal pituitary hormonal axis, used an immunoassay to quantify the levels of 
the hormone cortisol in the plasma of AD patients [186].  The significantly increased 
levels of the hormone observed suppored the initial hypothesis.  These results 
present evidence that suggests further investigation into this hypothesis may yield 




Smith et al. [187] developed an immunoassay that quantified levels of nitrotyrosine, 
a small molecule product of tyrosine nitration that can act as an indicator of the 
presence of peroxynitrite, a powerful oxidant molecule which is capable of not only 
nitrating tyrosine, but also directly oxidising proteins and other macromolecules.  
Levels of nitrotyrosine were reported to significantly increase in brain 
homogenates of AD patients when compared with controls suggesting potential to 
act as biological marker for the disease. 
1.6.4 – Targeted Biomarker Discovery in Alzheimer’s Disease – 
Conclusions 
There are clearly many different approaches that can be taken when planning a 
biomarker investigation with a molecular target in mind.  Each technique has its 
own relative advantages and disadvantages depending on the user requirements.  
For example, approaches involving MS are certainly more sensitive, but do not 
allow the analysis of whole samples in a way that NMR analysis can achieve.  When 
designing a non-targeted study, the advantages and disadvantages of each 
technique should be considered.   
However, it should be noted that of concern are the discrepancies that have arisen 
between different publications and the analytical approaches used.  For example 
isoprostane analysis by GC-MS found a significant increase in many biofluids, 
including various brain region homogenates [136, 167], CSF [135, 136, 168-171], plasma [135] 
and urine [135, 172], but there was no significant change in LC-MS analysis of urine 
[139] and an immunoassay analysis of plasma [185].  This is of particular importance 
as inter technique variability and conflicting results will not lead to the 
development of a reliable marker molecule. 
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Whilst not without problems, the technology required for targeted analysis is 
improving constantly as time progresses.  Combine this with the falling costs of 
accurate instrumentation and it is certain that targeted approaches will play a role 
in the future of AD small molecule biomarker research.  This is likely to be 
especially apparent if a biomarker progresses to the clinic and therefore requires 
routine analysis in a diagnostic capacity.  
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1.7 – Literature Review of Non-Targeted Alzheimer’s Disease 
Biomarkers  
1.7.1 – Nuclear Magnetic Resonance and Magnetic Resonance 
Spectroscopy 
A preliminary study comparing patient and control CSF samples by NMR has been 
published.  The method was capable of investigating a wide variety of components, 
the results of which were processed by principle component analysis (PCA), and 
was able to partially separate the diagnostic groups (control and AD) based on the 
concentrations of metabolites found.  Further analysis of the data resulted in the 
identification of citrate as one of the metabolites contributing most to the model 
classification.  It was later demonstrated that citrate existed at significantly 
decreased concentrations in AD compared with controls [188].  
Jukarainen et al [131] also completed a non-targeted CSF metabolite analysis via 
NMR analysis.  Differences in metabolite concentrations were observed in the 
study, with a significant increase in creatinine concentrations reported in AD 
compared with controls.  This results complement a targeted study discussed 
earlier (Section 1.6.1) where creatine (the parent molecule of creatinine) was 
identified at increased concentrations in brain, suggesting possible irregularities in 
this metabolic pathway in AD [146]. 
Analysis of AD patient CSF via NMR is a consistent theme in the literature.  An 
investigation by Kork et al [189] took this approach in a proof-of-concept study, and 
reported promising findings.  Following multivariate data-processing, results 
highlighted various NMR peaks from the spectrum that were of significant 
influence to the models.  Interestingly, the paper took the unusual approach of not 
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attempting to identify the molecules that the peaks corresponded to.  However the 
authors concluded that 1H-NMR spectroscopy, as an analytical technique, is a 
capable method for the detection and quantification of features in CSF and may be 
applied to biomarker marker research, even without the knowledge of molecular 
structures [189].   
Interestingly, the same author more recently utilised NMR raw data peaks as 
biomarkers for AD.  Again no identification was attempted, but the two 
publications demonstrate the potential for NMR to be utilised as a biomarker 
discovery tool in AD [190]. 
A further non-targeted study has been published analysing serum samples via a 
1H-NMR method [191].  In this instance the patient population did not contain any 
AD patients, but consisted of those diagnosed with MCI (as described in Section 
1.1.3).  The study reported a decrease in the relative amount of ω-3 fatty acids 
present in MCI, concluding that this irregularity may possibly indicate an increased 
risk of AD [191]. 
To date these are the only examples of non-targeted NMR approaches applied to 
human tissue samples, however there are examples in the literature that 
investigate samples obtained from animal models of the disease.  The first of these 
investigated small molecule variation in the brain of TgCRND8 mice models 
developed to produce amyloid deposits in the brain within 2-3 months of birth.  
Extracts were examined from a variety of brain regions using 1H-NMR methods 
before data analysis was completed via a multivariate model, producing a principle 
component analysis and a partial least squared analysis [192]. 
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Reported results from the comprehensive study indicated a decrease in many 
different small molecule metabolites including NAA, glutamate, glutamine, taurine, 
γ-amino butyric acid, choline and phosphocholine (co-resonance), creatine, 
phosphocreatine and succinate, as well as an increase in lactate, aspartate, glycine, 
alanine, leucine, iso-leucine, valine and finally a group of soluble free fatty acids 
[192].  This mouse study highlighted the ability of non-targeted analysis to identify a 
wide range of metabolite variations within AD, supporting the potential for NMR to 
improve our understanding of the disease and to assist the development of 
biomarker molecules.  
NMR and MRS are clearly useful in the discovery of biomarker candidates with 
regard to AD with numerous candidates already reported in the literature that are 
discussed above.  Currently the most promising approach combines these 
metabolite data with imaging data.  However, as can be seen, the technique still 
relies on CSF and brain samples, although this should improve as the technology 
advances and increases its sensitivity.   
In contrast, mass spectrometry is known for its sensitivity, the literature examples 
of which are now discussed below. 
1.7.2 – Mass Spectrometry 
DI-MS has been used in a non-targeted manner to analyse plasma lipids in AD.  
Often termed “shotgun” analysis, the publication infused a lipid extract directly 
into the MS without the application of pre-separation techniques.  The results 
suggested significant variations in sphingolipid species, with eight demonstrating a 
significant reduction in AD (p=<0.05), whilst two ceramide species (C16:0 and 
C21:0) were significantly higher in AD (p=<0.05).  Interestingly MMSE scores were 
correlated with altered mass levels of both SM20:2 and ceramide25:0 
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(p<0.004) [193].  This finding demonstrates the potential of DI-MS analysis, as 
candidate molecules were identified, without the requirement of a lengthy 
separation method.  This saves analytical time, and therefore cost. 
A preliminary LC-MS non-targeted study was developed to analyse plasma samples 
from AD, MCI and control patients [119].  Although a diagnostic model utilising the 
complete fingerprint could not be validated, the potential of non-targeted LC-MS 
within AD was demonstrated by the identification of a number of molecules of 
interest recommended for further investigation.  The first, glycerophosphocholine, 
as discussed previously is a metabolite of the membrane phospholipid 
phosphatidylcholine, and is thought to play a role in neuronal membrane 
degradation in AD.  To date no link has been determined between AD and the 
second molecule of interest identified in the study, D-glucosaminide, therefore 
more work on this molecule could lead to pathological clues about the mechanism 
of AD disease.  
In addition, a trio of bile acids (GCA, GDA and GCDCA) were identified at increased 
concentrations in the plasma of AD subjects compared with controls.  The authors 
commented that although a trend was noted, due to the small number of patient 
samples the resultant data could only be treated as a preliminary result, requiring 
more work before being statistically significant [119]. 
A GC-MS analysis was combined with multivariate data treatment to analyse serum 
free fatty acids in a semi-targeted study [194].  Although the study focused upon 
fatty acids as an area of particular analysis it had no particular target acid, and 
aimed to analyse a wide selection in a non-biased manner.  Following intensive 
data treatment and the creation of analytical models the paper identified a number 
of fatty acids that had significantly decreased in samples derived from AD, these 
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included; myristic acid (C14:0), palmitic acid (C16:0), oleic acid (C18:1), linolenic 
acid (C18:3) and docosahexaenoic acid (C22:6). 
A current approach in experimental design is the initial screen of samples using a 
non-targeted method in order to identify any biomarker candidates.  This can then 
be followed by the development of a targeted method designed to validate any 
findings.  This study design was applied to a recent plasma analysis using LC-MS 
technology.  From the initial screen results, a decrease in desmosterol in AD 
plasma versus controls was identified.  Following this, an analytical method was 
established to measure desmosterol and cholesterol.  This targeted validation 
presented findings suggesting that desmosterol and desmosterol/cholesterol ratio 
are significantly decreased in AD.  In addition, the publication reported an 
observed difference between mild cognitive impairment and control samples.  Of 
particular interest, the decrease of desmosterol was somewhat more significant in 
females.  Statistical analysis using a receiver operating characteristic (ROC) model 
between controls and AD, using plasma desmosterol as a marker, returned a 
promising area under the curve (a representation of specificity and sensitivity) of 
0.80.  Further data mining presented a significant correlation of plasma 
desmosterol with the Mini-Mental State Examination scores [195]. 
The development of non-targeted biomarker discovery is constantly evolving and 
improving as both the technology and the data treatment progresses.  This is 
reflected in a recent publication of note.  The article initially utilised both LC-MS 
and GC-MS results to analyse patient serum in an attempt to identify biomarker 
candidates for AD.  The results reported a number of decreased concentrations of 
several lipid classes, including PC, SPH, plasmalogens, and sterols [196].   
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In addition, the publication analysed the serum of MCI patients who were re-
visited, with the conversion to AD noted.  The authors then set out to develop a 
model of baseline data in an attempt to find marker candidates capable of 
predicating conversion from MCI to AD.  Initial statistical analysis identified an 
individual molecule, 2,4-dihydroxybutanoic acid, to be the most promising 
predictor of conversion.  The acid was found to be up regulated in those patients 
who progressed to AD (p=0.0048).  The publication statistics were then expanded 
with the development of metabolite “clusters”.  These clusters were formed of a 
combination of three or four individual metabolite features, with the overall 
changes of the cluster panel accounted for in the predictor model.  The most 
promising of these clusters consisted of four metabolites: PC18:0/18:2 and 
PC16:0/20:4, lactic acid and ketovaline.  In addition, the data was further 
combined with APOE genotype data.  The cluster model provided a specificity and 
sensitivity of 0.67 and 0.76 respectively.  This was an interesting approach in order 
to combine a vast amount of data taken from seven LC-MS methods and one GC-MS 
method [196] and goes to highlight the novel methods and progressions in both the 
analysis of small molecules and the treatment of the data collected. 
1.7.3 – Non-Targeted Biomarker Discovery in Alzheimer’s Disease – 
Conclusions 
Non-targeted analysis is a relatively new approach to biomarker discovery, hence 
there is less data available when comparing with those constructed with a 
molecular target in the design.  However it has been demonstrated here that the 
approach can be successful, with a number or publications already available which 
can identify small molecules via data modelling approaches.   
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Currently, investigations based upon a non-targeted approach are generally more 
time consuming than those with a target.  This is because of a combination of 
requirements including the know-how, longer analysis time, more intensive data 
treatment, identification involving database searches and finally study 
confirmation using standards.  This extended time obviously has other 
implications too, including increased man hours and increased cost of analysis.   
Despite these disadvantages, the technologies, methods and statistical models are 
constantly improving, and it is likely that non-targeted approaches will become the 
starting point for many future discovery studies and may lead the way to small 




1.8 – Aims 
With the findings of this literature review in mind, a project plan was designed to 
investigate SMB of AD.  The research was designed using a case-control strategy,  
Initially, both mouse model and human bio-samples underwent analysis in a 
targeted hypothesis driven approach.   
As the project progressed, a hypothesis generating non-targeted analysis was also 
employed, with the aim of identify novel biomarker candidates of AD.  At this stage 
of the project, the focus was on human plasma, again in a case-control design. 
LC-MS was selected as the initial analytical technology due to the advantage of 
sensitivity, and the techniques ability to complete both targeted and non-targeted 
analysis, covering a wide range of small molecular species. 
The overall aim of the project was to identify novel biomarker candidates in 
circulating plasma, which may be able to play a future role in the diagnosis and 
progression monitoring of AD.  Plasma from control, MCI and AD patients was 
analysed, with the ideal outcome a marker that can help differentiate between the 




        











 4 Metabolite Cluster Plasma N/A Non-targeted LC-MS [196]  
 2,4-dihydroxybutanoic Acid Plasma Increase Non-targeted LC-MS [196]  
 5-hydroxyindoleacetic Acid CSF Decrease Targeted LC-EC [183]  
 Dehydroepiamdrosterone  Serum Increase Targeted GC-MS [176]  
 Dehydroepiamdrosterone  CSF Increase Targeted GC-MS [137]  
 8-hydroxyguanine Brain Increase Targeted GC-MS [177]  
 Bile Acids (GCA, GDA, GCDCA) Plasma Increase Non-targeted LC-MS [119]  
 Ceramide Brain Increase Targeted DI-MS [160]  
 Citrate CSF Decrease Non-targeted 1H-NMR [188]  
 Creatine Brain Increase Targeted 1H-MRS [146]  
 Creatinine CSF Increase Non-targeted 1H-NMR [131]  
 Dehydroepiamdrosterone CSF Increase Targeted GC-MS [137]  
 Dehydroepiandrosterone Brain/CSF Increase Targeted Immunoassay [175]  
 Desmosterol Plasma Decrease Non-targeted LC-MS [195]  
 Desmosterol/Cholesterol Ratio Plasma Decrease Targeted LC-MS [195]  
 Fatty Acids Serum Decrease Non-targeted GC-MS [194]  
 Fumarate CSF Decrease Targeted GC-MS [164]  
 Homovanillic Acid CSF Decrease Targeted LC-EC [183]  
 Hydroxyoctadecadienoic Acid Plasma Increase Targeted GC-MS [174]  
 Hydroimidazolone CSF Increase Targeted LC-MS [178]  
 Isoprostanes Brain Increase Targeted GC-MS [136, 167]  
 Isoprostanes CSF Increase Targeted GC-MS [135, 136]  
 Isoprostanes CSF Increase Targeted GC-MS [168-171]  
 Isoprostanes Plasma Increase Targeted GC-MS [135]  
 Isoprostanes Plasma No change Targeted Immunoassay [185]  
 Isoprostanes Urine Increase Targeted GC-MS [135, 172]  
 Isoprostanes Urine No change Targeted LC-MS [139]  
 Lactate CSF Increase Targeted GC-MS [164]  
 Lutein Plasma Decrease Targeted LC-UV [181, 182]  
 Myo-inositol Brain Increase Targeted 1H-MRS [146, 152]  
 Myo-inositol/Creatine Ratio Brain Increase  Targeted 1H-MRS [148, 151, 153]  
 Myo-inositol/NAA Ratio Brain Decrease  Targeted 1H-MRS [151, 153]  
 NAA Brain Decrease Targeted NMR/MRS [144-146]  
 NAA /Creatine Ratio Brain Decrease Targeted 1H-MRS [148-151]  
 Nɛ-carboxymethyl-lysine CSF Increase Targeted LC-MS [178]  
 N-formylkynurenine CSF Increase Targeted LC-MS [178]  
 Nitrotyrosine Brain Increase Targeted Immunoassay [187]  
 Nitrotyrosine CSF Increase Targeted LC-MS [178]  
 Phosphatidylcholine CSF Increase Targeted LC-EC [184]  
 Phosphatidylcholine Plasma Decrease Non-targeted LC-MS [196]  
 Phosphatidylethanolamine Brain Decrease Targeted 31P-NMR [142]  
 Phosphatidylethanolamine-P Brain Increase Targeted 31P-NMR [142]  
 Phosphatidylinositol Brain Decrease Targeted 31P-NMR [142]  
 Phospholipid Plasmalogens Brain Decrease Targeted DI-MS [157]  
 Sphingomyelin Brain Increase Targeted 31P-NMR [142]  
 Sphingolipids Plasma Decrease Non-targeted DI-MS [193]  
 Succinate CSF  Decrease Targeted GC-MS [164]  
 Sulphatides Brain Decrease Targeted DI-MS [160]  
 Uric Acid Plasma Decrease Targeted LC-UV [179]  
 Uric Acid Plasma Decrease Targeted LC-EC [179, 181]  
 Uric Acid Plasma Decrease Targeted ELISA [185]  
 Vitamin A Plasma Decrease Targeted LC-UV [181]  
 Vitamin A Plasma Decrease Targeted LC-F [179]  
 Vitamin C Plasma Decrease Targeted LC-UV [179]  
 Vitamin C Plasma Decrease Targeted LC-EC [181]  
 Vitamin E Plasma Decrease Targeted LC-UV [181]  
 Zeaxanthin Plasma Decrease Targeted LC-UV [181]  
 α-carotene Plasma Decrease Targeted LC-UV [181]  
 β- carotene Plasma Decrease Targeted LC-UV [182]  
 β-cryptoxanthin Plasma Decrease Targeted LC-UV [181]  
Table 1.3: Small Molecule Biomarkers Previously Reported in the Literature 
Summary table presenting previously published SMB candidates of Alzheimer’s disease.  It is particularly 
interesting to note the high number of lipid based species in the literature.  Of further interest is the 
reported finding of isoprostanes that have conflicting reports depending on technique used, with GC 
reporting an increase, but LC and immunoassay reporting no change.  Table reproduced from a 
publication by Whiley and Legido-Quigley [141] 
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Chapter 2:  
Fatty Acids in Alzheimer’s Disease – A 
Targeted Study 
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2.1 – Introduction 
2.1.1 – Introduction to Fatty Acid Species 
Fatty acids (FA) are highly abundant molecules throughout all of living systems, 
and are found everywhere from cell membranes to peanut oils.  Structurally, FA 
consist of a carboxylic head group, attached to varying length side chains 
consisting of a carbon backbone (Figure 2.1).  
 
Figure 2.1: Structural Features of Fatty Acids 
The fatty acid structure can be seen with a carboxylic head group (COOH) attached to a 
carbon backbone tail.  The tail can vary in length, and finalises in a methyl (CH3) end 
group.  Carbon atoms in the backbone can either be linked by a single bond (-CH2-CH2-) or 
a double bond (-CH=CH-). 
FA nomenclature can become complex due to a variety of terms an individual 
species can be referred as.  The most widely used of these is the “common name”.  
These are non-systemic names, and are the most frequent referred to in the 
literature.  FA are also designated a systemic name, and is the official name 
referred to by the International Union of Pure and Applied Chemistry (IUPAC), the 
organisation responsible for officially naming organic and inorganic compounds.  
In addition each FA also can be named by the number of carbon chains in its 
backbone, along with the total number of double bonds, i.e. a FA with 20 carbons 
and 4 double bonds would be named 20:4.  The initial double bond is also added to 
the description and is counted from the methyl carbon at the tail.  For example a 
double bond between the third and fourth carbons counting from the tail on the 
backbone, would be termed 20:4ω3.  These FA would be referred to as being part 
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of the ω3 family.  Table 2.1 includes some FA examples and the nomenclature 
associated with each one.  From here onwards the thesis will use the “common 
name” in order to maintain consistency, however the discussion of nomenclature is 
important as different referenced articles may employ alternative names in their 
work, particularly between the common name and numerical name. 
      
 


































Table 2.1: Nomenclature of Fatty Acids 
Three examples of fatty acids and the options that can be applied to name them.  The 
common name is most often found in the literature but the other two examples can be 
used, and are perfectly acceptable when describing FA.  The thesis has employed the 
common name from this point forward to avoid confusion.  
It is commonly known that FA are vital for mammalian system function, for 
example they are major components of cell membrane structures [197], cell 
signalling pathways [198, 199], and a mammalian source of energy via β-oxidation 
[200].  Furthermore they are key components of larger mammalian molecules such 
as PC and PE. 
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2.1.1 – Terminology: Free and Bound Fatty Acids 
It is important to note the differences in terminology used to describe FA when 
discussed in the literature.  Due to the nature of FA, they can be found as described 
below: 
• Free Fatty Acids (FAFREE): FAFREE are the FA molecules present in a tissue or 
biofluid in their simple standard FA form. 
• Bound Fatty Acids (FABOUND):  FABOUND occur when FA are found as part of a 
larger lipid molecule, for example membrane triglycerides or 
phosphatidylcholines.  FABOUND play important roles in many cellular 
processes, particularly cellular membranes, and are therefore target for 
many investigations.  In order to analyse FABOUND a hydrolysis reaction is 
often completed prior to quantification in order to release the FA from the 
larger parent lipid. 
• Total Fatty Acids (FATOTAL): FATOTAL is the combination of FAFREE and 
FABOUND and is the complete sum analysis of FA within a tissue or biofluid. 
2.1.2 – Fatty Acids in Alzheimer’s Disease 
The apparent irregular metabolism of lipid species within AD pathology was 
previously discussed Chapter 1.  As expected with the abundance of FA and their 
metabolites throughout lipid biochemistry, there are a great number of 
publications, discussing FA in AD, covering a plethora of research areas including: 
• FA levels correlating with reduced risk of AD 
• Abnormal levels of FA in biological samples 
• Abnormal levels of FA metabolites 
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Most significantly from the perspective of biomarker research, a major population 
study in 899 patients has previously demonstrated that having a high baseline 
level of an important brain FA, docosahexaenoic acid (DHA), reduces the risk of 
progressing to AD.  Initially, at visit one, all 899 patients showed no signs of 
dementia. Levels of DHABOUND to PC parent species were extracted from plasma 
using a multi-stage process.  Initially chloroform was used to extract total lipid 
content.  This was followed by a HPLC method designed to isolate PC species.  
Finally, DHABOUND were released from the PC via a hydrolysis reaction, and 
derivatised prior to GC analysis.  Patients had a follow up visit on average 9.1 years 
later, where mental cognition was assessed.  Patients were divided into quartile 
groups based on baseline plasma DHABOUND to PC levels, with those in the upper 
quartile found to have a 47% reduced chance of progressing to a dementia case 
[201].  This is an important observation, as it provides evidence that baseline FA in 
plasma could be influenced by disease state, and therefore could potentially play a 
role in a biomarker capacity for AD. 
Interestingly the publication also reported dietary habits for a subset of the cohort, 
with 488 patients completing a dietary questionnaire.  Results suggested that fish 
consumption correlated with plasma DHABOUND to PC levels (p=<0.001).  In 
addition, those who ate fish twice a week had a 50% reduction in the relative risk 
of developing AD [201].  This finding is interesting, because although it suggests 
dietary habits may effect baseline levels of FABOUND, those levels still correlate to 
AD progression, and it is this property that suggests their potential as baseline 
predictors for AD. 
More support is provided throughout the literature with regard to the potential of 
FA molecules to act as biomarker molecules, with many examples of specific FA 
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species observed to vary in AD when compared with controls.  These observations 
have been reported in a variety of biofluids, from both human and mouse models.  
Sanchez-Mejia et al. [202] investigated FA metabolism in brain samples from human 
amyloid precursor protein (hAPP) in J20 mouse models.  J20 hAPP mice are 
transgenic mice that are specifically designed to over-express hAPP, leading to an 
increase in Aβ, one of the major features in human AD pathology, thereby 
modelling aspects of AD pathology [203].  The study reported an increase in free 
arachidonic acid (AAFREE), a ω6 FA, and its metabolites in the hippocampus of those 
mice with the mutation compared with wild-type mice.  This analysis was 
completed using an LC-MS targeted analysis.  In addition Sanchez-Mejia et al. 
linked this change to an increase in the activity of a group IV isoform of the 
phospholipase A2 (PLA2) enzyme, responsible for releasing the fatty acid from 
larger membrane phospholipids.  This was found to be due to an increase in the 
activation of the PLA2 in the hippocampal region of the mice identified using a 
targeted immunoassay approach,  
The same group IV PLA2, (also referred to in literature as cytosolic PLA2), has also 
been shown to increase in activity in human AD brain cerebral cortex regions [204] 
and human AD brain glial cells [205].  Additionally the presence of Aβ proteins 
associated with AD pathology, has been shown to directly activate group IV PLA2 in 
astrocytes [206]. 
In direct contrast, Prasad et al. [207] reported significant decreases in AA in human 
brain.  The study looked at both AAFREE, as well as AABOUND  existing as components 
of larger lipid molecules, including PC, PE and, PI.  Significant decreases were 
observed in the hippocampus and inferior pareto lobule.  AAFREE analysis was 
completed using a targeted GC method, whilst AABOUND included a preliminary step 
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using thin-layer chromatography (TLC) designed to separate the individual parent 
lipid classes, followed by a hydrolysis step designed to release the AABOUND for 
analysis.  Significant decreases in the hippocampus brain region were found with 
the AAFREE and AABOUND to both PE and PI parent lipids (p=<0.005).  No significant 
differences were observed in AABOUND to PC parent species. 
In addition the publication also investigated levels of both FAFREE and FABOUND of 
four further FA: Palmitic (PA), stearic (SA), oleic (OA) and docosahexaenoic acid 
(DHA).  Observations included significant decreases in the hippocampus of FABOUND 
to PI parent lipids (OA) and PE parent lipids (SA, OA, DHA). 
FA have also been investigated in the plasma of human AD patients.  As discussed 
in Chapter 1, plasma is an ideal biofluid for any predictive biomarker molecule due 
to its relative non-invasive nature and ease of collection.  Conquer et al. [208] 
investigated levels of FABOUND to total plasma phospholipids.  Patient groups 
included those suffering from AD (n=19), Controls (n=19), other dementia (n=10) 
and non-demented but loss of mental cognition (n=36).  Results reported a 
reduction in AD patient plasma of the levels of EPABOUND, DHABOUND and lignoceric 
acidBOUND (LGABOUND) to total plasma phospholipid species.  Further analysis 
revealed reductions in total ω3 FABOUND and ω3/ω6 FABOUND ratio in AD patients 
compared with the other groups.  
Additionally the publication also analysed FABOUND to individual subgroups of 
phospholipids, including parent PC, PE and lyso-phosphatidylcholine (LysoPC).  In 
order to achieve this individual lipid classes were isolated using TLC.  Again 
FABOUND were released from the parent lipids via the use of a hydrolysis reaction 
step.  Results suggested significant reductions (p<=0.05) in those FABOUND to PC 
(EPA, DHA, total ω3 and ω3/ω6 ratio) and PE (EPA, DHA and total ω3) [208]. 
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A recent publication investigated a range of FA species from both plasma and brain 
samples via the use of GC analysis.  The paper compared matched plasma and 
brain samples from control, MCI and AD subjects, and reported levels of FAFREE and 
FABOUND to PC and PE parent lipids species.  Total plasma FAFREE reduced 43% in 
MCI patients and 52% in AD subjects compared with controls.  Particular 
reductions were reported in plasma OAFREE (70% in MCI and 80% in AD) and 
LAFREE (50% in MCI 80% in AD).  Reductions in AD compared with controls were 
also observed in Plasma FABOUND to total phospholipid parent species, with 
significant reductions reported in PABOUND, EPABOUND and DHABOUND (p=<0.05).  In 
brain tissue (matched to the plasma) differences were less apparent between 
disease groups.  However, DHABOUND to phosphatidylserine (PS) was reported at 
significantly reduced concentrations (p=<0.05) in AD patients compared with 
controls [209].  
As discussed in Chapter 1, for a biomarker to be used in a clinical environment for 
diagnostic purposes, a sample that is obtainable from patients, often suffering from 
reduced mental cognition, is required. As the pathology of AD and MCI is brain 
related , it suggests a biomarker candidate capable of crossing the BBB would be 
advantageous. 
Although the exact mechanism is unknown it has been previously demonstrated 
that FA are capable of crossing the BBB, with a detailed review of current literature 
findings published by Hamilton et al [210].  This mechanism has also been 
hypothesised to be a two-way transport system, suggesting equilibrium is 
maintained [211].  It has also been demonstrated that daily turnover of AA and DHA 
in mammalian brain is 3-5% and 2-8% respectively, and in human brain AA is 
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0.3% [212].  This would imply levels of FA in plasma are influenced by brain levels, 
therefore suggesting that they could have potential as biomarker candidates. 
It is clear from the literature that FA and the biological pathways surrounding 
them are altered in AD, suggesting their potential use as biomarkers of AD.  
Therefore, considering the existing conflicting findings on the relationship 
between FA levels and AD, and with no previous known investigation into FATOTAL 
in AD, a pilot study was designed to investigate FATOTAL in both mouse brain and 
human plasma. 
2.1.3 – Study Design 
The study was designed with a targeted approach.  As discussed in Chapter 1 
targeted approaches employ a hypothesis and select specific molecules for 
analysis.  In this instance a method was adapted from a previously published and 
validated an LC-MS method by Salm et al. [213].  The method was ideal for 
adaptation as it was focused on AATOTAL, DHATOTAL and EPATOTAL, all three of which 
have been discussed in AD literature in either their FREE or BOUND forms [202, 208, 209].  
The method had already been fully validated in the original publication, meaning it 
could be applied to AD samples. 
2.1.4 – Sample Selection 
Two available samples sets (described in more detail in Section 2.2.3) were 
selected for analysis by the method published by Salm et al.[213].   
• Mouse Brain – Mice brain samples were collected from n=1 hAPP transgenic 
mouse, and n=1 wild-type control.  Six brain regions were isolated from 
each mouse for analysis.  The initial objective was to investigate the 
variation of AATOTAL, DHATOTAL and EPATOTAL between brain regions.  FA 
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concentrations for each brain regions were compared between the 
transgenic and wildtype control mice.  From this point forward the analysis 
of mouse brain samples will be referred to as MB2.  For method testing and 
validation purposes, mouse brain was replaced with more readily available 
pig brain. 
• Human Plasma – Plasma samples from (n=30) patients were selected for 
analysis based on age and gender matching.  The initial objective here was 
to investigate the variation of AATOTAL, DHATOTAL and EPATOTAL, i.e. total 
FAFREE combined with FABOUND bound to larger lipid molecules.  This differs 
from other work in the area as previous publications have focused either on 
FAFREE in plasma or FABOUND from particular lipid parent fractions.  Further 
to this the analysis includes patients diagnosed with MCI, in an attempt to 
evaluate whether AATOTAL, DHATOTAL and EPATOTAL changes in this condition, 
as well as comparing AD with Controls.  From this point forward to avoid 
confusion the analysis of human plasma will be referred to as HP30. 
2.1.5– Method Testing (MTEST) 
In order to ensure the method was transferable to the available analytical setup a 
series of tests were employed to examine reproducibility and linearity.  The first of 
these involved a replica extraction (n=6) of a pool of human plasma, and pig brain.  
Pig brain was selected as a substitute for mouse brain for method testing.   
MTEST was designed to ensure batch reproducibility across repeat extractions 
using biological tissues employed in later stages of analysis.  The second aspect of 
suitability testing, involved extracting the three FA standards at a range of 
concentrations as described in the original manuscript, to ensure linearity across 
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an expected range.  This was to ensure that any response observed between 
biological extracts is a true linear reflection of FA levels.  
Figure 2.2 shows the study outline.  
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Figure 2.2: Study Experimental Design 
An experimental pipeline, providing an overview of fatty acid analysis in a mixture of 
samples related to Alzheimer’s disease.  Initially a previously published method was tested 
on an available LC-MS system to ensure cross system compatibility.  This sample set is 
referred to as MTEST.  Secondly mouse brain samples were analysed to investigate total 
arachidonic acid (AATOTAL), total docosahexaenoic acid (DHATOTAL) and total 
eicosapentaenoic acid (EPATOTAL) variation between brain regions.  This sample set is 
referred to as MB2.  Finally n=30 plasma samples were analysed, investigating variation in 




•Testing of previous published and validated method on LC-MS system available
•Repeat extractions (n=6) from a pool of human plasma and pig brain
•Extraction of concentration range to ensure extraction is linear
Mouse Brain 
(n=2) MB2
•Analysis of six brain regions from Control (n=1) and AD (n=1) mouse brains







different brain regions, and compare between transgenic and control mice.
Human Plasma 
(n=30) HP30
•Analysis of human plasma samples (n=30) from Control (n=10), MCI (n=10), and 
AD (n=10)
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2.2 – Materials and Methods 
The method was adapted from a previously developed publication by Salm et 
al.[213]. 
2.2.1– Materials 
LC-MS Grade methanol was purchased from VWR (Leicestershire, UK) and high 
purity water deionised water was obtained from an in house Millipore filtration 
system (EMD Millipore, MA, USA).  AA, DHA and EPA standards, were purchased 
from SIGMA-ALDICH (Gillingham, Dorset, UK).  Deuterated AA (d8-AA) was 
purchased as an internal standard from Cambridge Bioscience (Cambridge, UK). 
Formic acid, hydrochloric acid, ammonium acetate, chloroform and HPLC grade 
acetonitrile were purchased from Fisher Scientific (Loughborough, UK).  Crimp top 
HPLC vials for the extraction were purchased from Chromacol (Cambridge, UK). 
2.2.2 – Instrumentation 
Instrumentation settings were constant for all three sample sets (MTEST, MB2, 
HP30).   
LC-MS analysis was completed using a Waters Acquity® LC (Waters, Milford, USA) 
coupled to a Waters Xevo® MS (Waters, Milford, USA).  The column used was a 
Thermo HyPURITYTM Elite C18, (50mm x 2.1mm, 3µm), which was maintained at 
30°C.  The separation utilised a linear gradient composed of 15% 2mM ammonium 
acetate in 0.1% formic acid/water and 85% methanol.  Solvent was passed through 
the column at a rate of 0.4mL/min, with an overall runtime of 3.5 minutes. 
Mass spectrometry analysis was completed in negative ionisation mode with a 
capillary voltage of 3.2kV.  A cone voltage was employed at 35V, with the extractor 
setting set at 2.0.  Capillary temperature was 120°C, and gas desolvation 
Chapter 2 81 
 
temperature was 400°C.  Desolvation gas flow was 900L/min and the cone gas was 
set at 50L/min.  Data was collected between 100Da and 1000Da, with a scan time 
of 0.1sec.  A reference solution (leucine enkephalin) was infused at regular 
intervals (every 15 seconds), and use to update accurate mass to charge ratio 
(m/z) data values.  
2.2.3 – Sample Collection 
2.2.3.1 – MTEST Samples 
For the MTEST segment of study, both a pool of plasma and pool of brain was 
employed.  The plasma pool was created by using spare plasma from a healthy 
volunteer.  Brain samples were obtained from a pig, and were donated by Sillfield 
Farm Foods (Kendal, UK). 
A concentration range of standards of AA, DHA and EPA in acetonitrile/water 
(75:25) also underwent extraction (0.625, 1.25, 2.5, 5, 10, 20, 40, 80, 160, 
320µg/mL) as described in the initial validation [213].  This involved 25µL of the 
standards in acetonitrile/water undergoing the same extraction procedure as 
described in 2.2.4. 
2.2.3.2 – MB2 Samples 
Mouse brain samples were collected from a collaboration project based a King’s 
College London, Denmark Hill, UK.   
Heterozygote TASTPM transgenic mice over expressing both the hAPP695swe 
mutation (TAS10) and the presenilin-1 M146V mutation (TPM) were generated by 
standard techniques as previously described [214]. Wild type animals were of the 
C57BL/6 line.  Animals were maintained and euthanized at King's College London 
under appropriate Personal and Project Home Office Licenses. 
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Six brain regions were harvested from two mice (n=1 wildtype, n=1 TASTPM AD 
model): Hippocampus, cerebellum, olfactory bulb, cortex, thalamus and striatum.  
After collection, the individual brain regions were treated with phosphate buffered 
saline (PBS) and placed at -80°C until extraction. 
2.2.3.3 – HP30 Samples 
Human plasma samples (n=30) were acquired from the Institute of Psychiatry, 
Denmark Hill, London, UK, sample store.  The samples consisted of Controls 
(n=10), MCI (n=10) and AD (n=10).   
Plasma samples were collected from two clinical cohorts, AddNeuroMed and the 
King’s College London Dementia Case Register (DCR), which are described in detail 
in Figure 2.3.  All patients from the cohorts underwent standardised assessments, 
which included collection of general demographic and medical data as well as 
cognitive assessment.  Internationally recognised cognition tests are completed 
including the MMSE, ADAS-Cog and CERAD.  Further to the cognition tests, scales 
were conducted on function, behaviour and global levels of severity, including the 
Clinical Dementia rating (CDR).   
Patients were diagnosed with probable AD and amnesic MCI according to criteria 
from NINCDS-ADRDA [27]. 
Normal elderly controls were defined as having no evidence of cognitive 
impairment, and had MMSE scores of >28.  Their recruitment was initiated from 
primary care patient lists.   
For each patient 10mL of blood was collected in tubes coated with sodium 
ethylenediaminetetraacetic acid (EDTA).  Prior to blood collection patients were 
required to fast for 2 hours.  Post collection blood samples underwent 
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centrifugation, to produce a plasma supernatant.  Plasma was split into aliquots 
and frozen at -80°C until further use.  Ethical approval was awarded for all cohorts 
in the corresponding countries of collection.  Full details on AddNeuroMed and 
DCR cohorts can be found in publications [106, 107, 215, 216].   
 
Figure 2.3: Overview of Clinical Plasma Cohorts 
Two clinical cohorts were used to collect the human plasma samples, the details for each 
one are described here 
  
•Samples were collected from a cross European cohort from patients with AD 
and MCI as well as healthy controls. Patients were assessed annually, except 
AD patients who were assessed every three months in their first year, and 
annually thereafter.  All subjects were white Europeans from six centres in 
the UK, Italy, France, Finland, Poland and Greece. 
AddNeuroMed
•Collection of DCR samples was completed since 2001, and contained samples 
from AD, MCI and healthy control individuals.  All subjects were white UK 
citizens, with grandparents born in the UK.  Patients were assessed annually.  
The patients were London based, and were referred through the South 
London and Maudsley Trust (SLAM).    
King's College London - Dementia Case Register (DCR)
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Samples were selected to ensure age and gender matching across the disease 
groups.  A summary of patients selected can be seen in Table 2.2. 
      
  Control MCI AD  
 Total Samples 10 10 10  
 Male/Female 5/5 5/5 5/5  
 % Male/%Female 50/50 50/50 50/50  
 Age Mean 77.30 83.64 83.32  
 Age Stan Dev 6.37 6.56 8.11  
 MMSE Mean 28.9 24.7 15.4  
 MMSE Stan Dev 1.60 2.98 5.72  
Table 2.2: Patient Data for Study HP30 
Summary of patient data of plasma samples included in the study HP30.  Samples were age 
and gender matched as much as possible to reduce external influences of analysis.  Mini 
Mental State Exam (MMSE) results are also presented. 
2.2.4 – General Sample Extraction 
Brain samples were prepared by adding 10µL of 0.1% ammonium acetate buffer 
(pH7) per 1µg of wet brain mass as used by Matyash et al in lipid brain extractions 
[217], followed by vortex mixing.  25µL of this mix was added to a crimp top glass 
2.5mL HPLC vial for the extraction procedure. 
Plasma samples simply underwent a vortex mix after defrosting.  25µL was added 
to a crimp top 2.5mL HPLC vial for the extraction procedure. 
The following applies for both tissue types: 
50µL of 5N hydrochloric acid was added to the HPLC vial containing samples.  To 
this 500µL of acetonitrile was added containing 2µg/mL of d8-AA to be used as an 
internal standard.  Vials were tightly crimp-top capped and placed at 100°C in a 
water bath for 1 hour.  This stage initiated the hydrolysis reaction required for 
releasing all of the FABOUND from parent lipids. 
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Samples were allowed to cool, before de-capping and the addition of 500µL of 
chloroform and 500µL of high purity water.  Samples were re-capped and vortex 
mixed for 10 minutes, before centrifugation at 2500g for 5 minutes. 
Samples were de-capped, the upper aqueous phase removed, and 500µL of high 
purity water again added.  Samples again underwent re-capping, and vortex mixed 
for 10 minutes, before centrifugation at 2500g for 5 minutes.  The addition of 
chloroform step extracts the FA present.  Both FAFREE and the previously FABOUND 
and released from parent lipid in the hydrolysis step are extracted, meaning 
FATOTAL undergoes extraction. 
100µL of the lower phase was extracted and transferred to a fresh HPLC vial 
containing a glass insert (Chromacol, Cambridge, UK).  This was dried under a 
stream of nitrogen, and re-suspended in mobile phase.  5µL was injected onto the 
LC for analysis. 
For both tissue types samples were extracted and analysed by LC-MS in random 
order.  Pooled samples made from corresponding tissue samples were included as 
quality controls.  These were extracted and analysed at regular intervals (before, 
consistent middle intervals, and after). 
2.2.5 – Data Treatment 
Raw mass spectrometry data was collected using MassLynx v4.1 (Waters, Milford, 
USA).  FA peaks were extracted using QuanLynx software included in MassLynx 
v4.1 (Waters, Milford, USA).  Statistical independent two tailed t-test validation 
was calculated by SPSS v20 (IBM, Portsmouth, UK) 
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2.3 – Results 
2.3.1 – MTEST Samples 
Initially repeats were completed on pooled human plasma and pig brain.  Ratios 
were calculated for FA/internal standard (d8-AA) peak areas.  Mean peak areas, 
standard deviation and relative standard deviations (RSD) figures were calculated 
and can be seen in Table 2.3 (a) and (b).  RSD of the three FA in the plasma were 
AATOTAL (0.97%), DHATOTAL (1.41%) and EPATOTAL (2.45%).  RSD of the two major 
FA in brain were AATOTAL (4.03%) and DHATOTAL (4.21%).  EPATOTAL is far less 
prevalent in brain, and was not at a sufficient concentration to be detected. 
A linearity study was also completed on the MTEST samples.  FA standards (0.625, 
1.25, 2.5, 5, 10, 20, 40, 80, 160, 320µg/mL) in ACN/H2O were extracted using the 
method described.  Linear plots can be seen in Figure 2.4 (a), (b) and (c), with R2 
values of 0.9982 (AA), 0.9980 (DHA) and 0.9963 (EPA) being reported. 
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 AATOTAL 271.9 272.9 276.4 277.4 273.9 278.4 275.1 2.6 1.0  
 DHATOTAL 20.6 20.2 20.6 21.5 21.3 20.9 20.9 0.5 2.2  
 EPATOTAL 149.1 152.3 142.3 152.3 148.2 149.3 148.9 3.7 2.5  
            























 AATOTAL 475.4 516.4 519.9 509.4 525.4 533.9 513.4 20.4 4.0  
 DHATOTAL 197.9 213.3 216.5 212.6 221.2 223.3 214.1 9.0 4.2  
 EPATOTAL BLQ BLQ BLQ BLQ BLQ BLQ N/A N/A N/A  
Table 2.3: Extraction Reproducibility Study 
Results from a study to investigate extraction reproducibility in (a) Pooled Plasma and (b) 
Pooled Brain.  Concentration values (µg/mL) for the three fatty acids of interest 
(arachidonic acid – AA, docosahexaenoic acid – DHA and eicosapentaenoic acid – EPA) 
along with values for mean concentration, standard deviation (Std. Dev) and relative 
standard deviation (RSD).  EPA was not detected in brain samples using this method and is 
therefore labelled BLQ (below limit of quantitation (2.5µg/ml)). 
 
  






Figure 2.4: Extraction Linearity Plots of Individual Fatty Acids 
Linearity plots for (a) arachidonic acid (AA), (b) docosahexaenoic acid (DHA) and (c) 
eicosapentaenoic acid (EPA).  Figure values are a ratio of FA peak area over internal 
standard (d8-AA) peak area.  Concentrations extracted were 0.625, 1.25, 2.5, 5, 10, 20, 40, 
80, 160 and 320µg/mL.  Acceptable R2 values of 0.9982 (AA), 0.9980 (DHA) and 0.9963 
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2.3.2 – MB2 Samples 
2.3.2.1 – Quality Control 
Quality control (QC) samples were analysed at regular intervals during the 
analytical run. Before (n=2), every four injections (n=1) and after (n=2) (total n=6).  
Reproducibility was calculated in the same manner as section 2.3.1.  Peak area 
ratios and corresponding concentration values were calculated for the individual 
FA.  Values for RSD (%) across the analytical run were, 4.93% (AATOTAL) and 3.02% 
(DHATOTAL).  As in the MTEST section EPATOTAL was not detected at a quantifiable 
concentration. 
2.3.2.2 – Fatty Acids in Brain Tissue 
EPATOTAL was below the limit of quantification in all brain regions within the brain 
samples.  Peak areas for AATOTAL and DHATOTAL were extracted using QuanLynx 
package in MassLynx (Waters, Milford, USA).  Concentration values were then 
calculated for each of the six brain regions, the results of which can be seen in 
Table 2.4 and visualised in Figure 2.5. 
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 Arachidonic AcidTOTAL Concentrations in Mouse Brain  
 Brain Region Wild Type (µg/mL) AD Model (µg/mL)  
 Cerebellum 420.05 458.63  
 Cortex 543.60 589.12  
 Hippocampus 562.53 513.71  
 Olfactory 418.77 399.08  
 Striatum 326.35 472.65  
 Thalamus 372.72 465.04  
 
 Docosahexaenoic AcidTOTAL Concentrations in Mouse Brain  
 Brain Region Wild Type (µg/mL) AD Model (µg/mL)  
 Cerebellum 269.52 321.05  
 Cortex 294.15 330.33  
 Hippocampus 262.40 259.80  
 Olfactory 285.07 270.94  
 Striatum 148.31 241.63  
 Thalamus 192.01 264.21  
Table 2.4: Arachidonic Acid and Docosahexaenoic Acid in Mouse Brain Regions 
Concentration values for (µg/mL) of Arachidonic Acid (AATOTAL) and Docosahexaenoic Acid 




Figure 2.5: Arachidonic Acid and Docosahexaenoic Acid in Mouse Brain Regions 
Concentration values of the two major fatty acid species in six mouse brain regions – 
Arachidonic (AATOTAL) and Docosahexaenoic acid (DHATOTAL).  Brain regions included are 























































Chapter 2 91 
 
2.3.3 – HP30 Samples 
2.3.3.1– Quality Control 
Quality control (QC) samples were analysed at regular intervals during the 
analytical run. Before (n=2), every six injections (n=1) and after (n=2).  
Reproducibility was calculated in the same manner as section 2.3.1.  Peak area 
ratios to internal standard (d8-AA) and the corresponding concentration values 
were calculated for the three individual FA.  Values for RSD (%) across the 
analytical run were, 2.55% (AATOTAL), 2.40% (DHATOTAL) and 2.78% (EPATOTAL) 
respectively. 
2.3.3.2 – Fatty Acids 
Concentration values for AA, DHA and EPA were determined by comparing FA/d8-
AA peak area ratios to a known calibration curve.  Samples were grouped by 
disease status, with the results presented in Figure 2.6.  Statistical significance was 
calculated by comparing FA mean concentration values in an independent samples 
t-test using SPSS v20 (IBM, UK).   
Comparison of EPATOTAL levels between the control and AD groups provided a 
statistically significant difference (p=0.023).  The concentration of EPATOTAL was 
recorded as Control (708.31µg/mL), MCI (684.36µg/mL) and AD (456.86µg/mL).  
No other comparison revealed any significant differences.   
Mean concentration values of AATOTAL were consistent across all three groups – 
Control (426.82µg/mL), MCI (425.70µg/mL) and AD (423.73µg/mL).   
DHATOTAL was reported to decrease in AD samples compared with control and MCI 
groups, however this change was not statistically significant (p=0.107 Control  
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AD and p=0.075 MCI  AD).  Results reported concentration values of: 
Control (48.52µg/mL), MCI (50.35µg/mL) and AD (35.39µg/mL. 
Ratios between each of the FA were also calculated.  AATOTAL/DHATOTAL = Control 
(2.52), MCI (2.57), AD (3.23).  AATOTAL/EPATOTAL = Control (4.68), MCI (5.46), AD 
(7.07). DHATOTAL/EPATOTAL = Control (1.80), MCI (2.04), AD (2.20).   
Control  AD (AATOTAL/EPATOTAL) was a significant increase (p=0.05). 
  
 
Figure 2.6: HP30 Results Overview 
Overview of results from investigation into total fatty acid levels in human plasma sample 
set HP30.  Sample numbers are Alzheimer’s disease (AD) n=10, mild cognitive impairment 
(MCI) n=10, and control n=10.  * signifies statistical significance of p=0.023.  No other 
comparisons provided significant results.  Values for Quality Controls (QC) were taken 
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2.4 – Discussion 
2.4.1 – MTEST Samples 
Although the study employed a previously published and fully validated method 
[213] it was vital that it underwent re-evaluation on the available laboratory setup 
and LC-MS instrumentation.  The original authors utilised an analytical setup 
comprising of an Agilent 1100 Series LC (Agilent Technologies, Waldbronn, 
Germany) coupled to a 4000 QTrap linear ion trap quadrupole mass spectrometer 
(Applied Biosystems/MDS Sciex Instruments, Concord, Canada).  This contrasts to 
the Waters Acquity® LC and Waters Xevo® MS utilised here.   
Column selection was altered slightly due to laboratory availability, with a Thermo 
HyPURITYTM Elite C18, (50mm x 2.1mm x 3µm) being used in place of the published 
Varian PursuitTM C18 (50mm x 2mm x 3µm), however due the similarity of phases 
and dimensions this did not have a major impact on method transferability. 
Similarly LC systems were programmed to apply the reported isocratic flow rates 
and column oven temperatures (isocratic 0.4mL/min and 40°C respectively), well 
within their maximum constraints, and therefore it was expected to have no major 
impact on the overall chromatography.   
This was reflected in comparison of retention times, with the initial publication 
reporting AA (2.4min), DHA (2.4min) and EPA (1.9min).  The analytical set up 
reported here recorded retention times of AA (2.11min), DHA (2.01min) and EPA 
(1.57min) and are sufficient in comparison (see Figure 2.7).  As can be seen in the 
figure, peaks AA, DHA and d8-AA co-elute. This is due to their similar structure, 
carbon chain length, and physiochemical properties.  Despite this co-elution, from 
both the original manuscript and in the findings reported here, there was found no 
Chapter 2 94 
 
effect on linearity, or reproducibility of analysis.  Major modifications to the 
original method would have been required to obtain a complete separation of the 
three FA species, and would have required time intensive testing and validation.  
The authors reported no problem in their validation due to the co-elution, 
therefore similar linearity values were achieved on the Waters Xevo® 
instrumentation. 
 
Figure 2.7: Overlaid Chromatogram of Extracted Fatty Acids 
Three fatty acids extracted from plasma:  (1) Eicosapentaenoic acid (EPA) (Retention time 
– 1.57) (2) Docosahexaenoic acid (DHA) (RT – 2.01) (3) Arachidonic acid (AA) (RT – 2.11).  
Also included is a deuterated internal standard (4) d8-arachidonic acid (d8-AA) (RT – 
2.11).  Chromatography closely reflects the original manuscript by Salm et al.[213].  Peak co-
elution occurs due to similar carbon chain lengths and properties and has no adverse 
effect on analysis. 
To test the Waters Xevo® MS, six replicate extractions were completed on 
individual pools of plasma and brain tissue homogenate.  Variation (RSD %) in 
plasma for the three extracts were all well below 5% (AATOTAL 0.97%, DHATOTAL 
1.41% and EPATOTAL 2.45%).  Similarly variation (RSD %) in pooled brain for the 
two detected extracts was also lower than 5% (AATOTAL 4.03% and DHATOTAL 
4.21%).   
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This demonstrates a high level of reproducibility between extractions and was 
deemed acceptable to progress onto sample analysis. 
EPA was below the limit of quantification in brain samples.  In an attempt to detect 
the FA a four-fold increase of brain material underwent attempted extraction 
(100µL).  However, although a small peak of EPA was detected it was below the 
level of quantification required.  It was not possible to extract more material, due 
to the small sample sizes of the mouse brain, and therefore EPA was classed as 
below the limit of detection for the brain samples. 
To test the linearity on the Waters analytical set up a range of FA standards in 
ACN/H2O were extracted.  This approach was employed in the original manuscript 
to demonstrate linearity across the expected range of endogenous FA.  When 
tested on the Waters Xevo® QTOF the three FA provided acceptable R2 values 
across a range 0.625-320µg/mL – AA (R2=0.998), DHA (R2=0.998) and EPA 
(R2=0.996).   
These R2 values demonstrate that the extraction and analysis on the QTOF 
instrumentation are more than acceptable over the required range.  Peak areas for 
each FA from the plasma samples from the pool fell comfortably within the peak 
areas for the range.  These observations combined with the highly reproducible 
findings in the pooled extraction repeats of plasma and brain suggest that the 
method is suitable for use investigating changes of total FA, with application to 
different tissue samples in AD.  
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2.4.2 - MB2 samples 
The examples discussed in Section 2.4.2 are summarised in Table 2.5. 
MB2 was designed as a preliminary pilot study, in order to see if any major 
changes in FATOTAL were apparent in individual brain regions of wild type and 
TASTPM AD model mouse.  In the study sample availability was low (n=1 per 
group).  Therefore the project was treated as a proof of concept study. 
TASTPM mouse models were used as a comparison in study MB2.  The model is an 
amyloid based transgenic model, with a double APP mutation on the APPswe and 
the PS1.M146V genes. This double mutation enables the early detection of amyloid 
deposits within three months, leading to cognitive impairment comparable to that 
in AD within six to eight months [214].  The advantage of using this double mutant 
model is that not only are Aβ protein deposits found in the brain, but there is also a 
decline in cognitive impairment, both aspects of which are not always observed in 
single APP transgenic mice models [214].  This property makes the samples used in 
study MB2 ideal to explore FA disruption as brain pathology relates to AD disease 
in human cases. 
The TASTPM mice are designed to model AD pathology, with Aβ plaques forming 
in the cerebellum [214], similar to that described by Braak and Braak [74], who first 
described the stages of Aβ proliferation in human AD brain.  They reported initial 
deposits in the cerebral regions, particularly the isocortex (Braak stage A), and 
spreading throughout the frontal and parietal lobe (Braak stage B), before finally 
spreading to the striatum, thalamus and hypothalamus (Braak stage C).  This 
progress is also observed in the TASTPM models, with Howlett et al. reporting Aβ 
deposits mainly observed in the cortex regions [214].   
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Decrease N/A  
Table 2.5: Summary of Fatty Acids in Alzheimer’s Disease Mouse Model Literature 
The above table highlights the fatty acids of interest in the literature.  Examples are 
provided for arachidonic acid (AA) and docosahexaenoic acid (DHA) to enable comparison 
with the results reported in study MB2. 
Ref = reference, TPL = total phospholipid, NSC = no significant change, HC = Hippocampus, 
CX = Cortex 
Results from study MB2 appear to reflect the Aβ deposition pathology reported by 
Howlett et al. in the TASTPM mouse model [214] with an increase of AATOTAL and 
DHATOTAL in AD compared with controls in the cortex, thalamus and striatum 
regions. The results of the analysis in the hippocampus region analysis reported no 
change in FATOTAL levels between the wild type and AD TASTPM model.  . 
Concentration values of AATOTAL were reported to be increased in AD model mouse 
brain in the thalamus, cortex, striatum and cerebellum regions.  The largest 
increase was found in the striatum and the thalamus.   
The TASTPM models used in study MB2 have also been employed in a 
metabonomic non-target analytical publication, which analysed whole brain 
homogenate extracts, alongside those of plasma.  Although the study was not 
specifically designed to target AAFREE, the FA was investigated.  Results reported 
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that AA did not significantly change between wild-type and TASTPM model brain 
homogenates [218].  Interestingly however, a decrease in AAFREE in the plasma of the 
transgenic AD mice was observed.  As the results were reported in whole brain 
homogenate extracts rather than specific isolated regions, it is difficult to directly 
compare with the findings of MB2 reported here, however an interesting future 
study would be to compare individual and total brain region AATOTAL to see if it 
correlated to the finding of AAFREE reported in [218]. 
A further relevant publication, analysed AAFREE levels in brain regions from an 
alternative mouse model (J20 hAPP mice).  The J20 model utilises a strain of mice 
with single hAPP gene mutation.  The data showed an increase in AAFREE in both 
the hippocampus and cortex regions [202].  This outcome was discussed to be due to 
a difference in the activity of phospholipase A2, the enzyme responsible for the 
release of AA from larger lipid species.  This contrasts with the findings of MB2, 
which showed no variation in the hippocampus.  However this could be due to a 
number of reasons, for example a difference in the mouse model used.  An 
expansion to the study could be employed using a range of mice models in order to 
see if FA levels are consistent between different strains of mice model.   
It is also interesting to note the decrease identified in the plasma of the AD mice 
models.  This perhaps suggests that an imbalance exists between brain and plasma, 
with an increase in brain levels of AA, countered by a decrease in that of plasma. 
FA have also been investigated in other AD mouse models.  Petursdottir et al. [219] 
analysed FA in SAMP8 mice, a line of mice selectively bred, to have over expression 
of Aβ, compared with the wildtype, and thus is thought to model aspects of AD 
pathology [220].  The study reported concentrations of a number of FA, including 
DHABOUND and AABOUND.  This was achieved by the completion of a pre-separation 
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by TLC that allows isolation of individual large molecule lipid species followed by 
the hydrolysis release of the FABOUND.  This study reported levels of FA in both the 
hippocampus and amygdala regions of SAMP8 mice brains, focusing on FA changes 
with aging rather than comparing AD and Control mice.  The results presented, 
show that DHABOUND decreases in hippocampus regions during aging of the AD 
model mice, indicating that FA metabolism perhaps plays an important role in 
mammalian aging, and it may be this effect that is observed in studies regarding 
AD, not as a response to AD pathology.   
MB2 was developed as a proof of concept pilot study, and returned interesting 
observations regarding the level of FATOTAL in six mouse model brain regions.  
Despite the low sample size, differences of AATOTAL and DHATOTAL were apparent, 
supporting a justified expansion of the project to a larger sample set. 
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2.4.3– HP30 Samples 
A summary table of the findings discussed in the following sections can be found at 
Table 2.6. 
2.4.3.1– Quality Control  
QC samples were included as replicate extractions of a pool of plasma (n=8).  
During the extraction procedure, samples were included at random, to ensure no 
group bias.  These samples underwent analysis at regular intervals across the 
analytical run, 2x before, 1x every six injections during the run and 2x at the end of 
the run.  Three FA molecular species (AATOTAL, DHATOTAL and EPATOTAL) were 
extracted as per patient samples, and the corresponding concentration values 
were calculated.  Variation was found to be >3% in all cases, suggesting the method 
was highly reproducible across the run and any differences observed in HP30 
groups is therefore due to differences in patient physiology as opposed to 
analytical variation. 
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 [209] Plasma  AA Bound (TPL) NSC NSC  
 [208] Plasma AA Bound (TPL) NSC NSC  
 [208] Plasma AA Bound (PC, PE, LysoPC) NSC NSC  
 [221] Plasma AA/DHA Ratio Free High Ratio NSC  
 [221] Plasma AA Free NSC NSC  
 [209] Plasma DHA Bound (TPL) Decrease NSC  
 [209] Plasma DHA Free NSC NSC  
 [208] Plasma DHA Bound (TPL) Decrease NSC  
 [222] Serum DHA Bound (PC) Decrease NSC  
 [223] Plasma DHA Bound (TPL) NSC NSC  
 [201] Plasma DHA Free Low Baseline NSC  
 [224] Plasma DHA Free Low Baseline NSC  
 [209] Plasma EPA Bound (TPL) Decrease Decrease  
 [208] Plasma EPA Bound (TPL) Decrease Decrease  
 [208] Plasma EPA Bound (PC, PE, LysoPC) Decrease Decrease  
 [221] Plasma AA/EPA Ratio Free NS Increase  
 [225] Serum EPA Free Aging Decrease N/A  
Table 2.6: Summary of Fatty Acids in Alzheimer’s Disease Human Literature 
The above table highlights the fatty acids of interest in the literature.  Examples are provided for 
arachidonic acid (AA), docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) to enable 
comparison with the results reported in study HP30. 
Ref = reference, TPL = total phospholipid, PC = phosphatidylcholine, PE = 
phosphatidylethanolamine, LysoPC = lysophosphatidylcholine, NSC = no significant change  
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2.4.3.2 – Arachidonic Acid 
AA, along with DHA is one of the most predominant FA in the human brain, and 
therefore is a major metabolite at the centre of AD pathology. The findings here 
reported no significant change of plasma AATOTAL between any of the diagnostic 
groups (AD, MCI, Control) with a relatively consistent concentration between all 
three. This finding appears to complement previous studies of human plasma.  
Cunnane et al. investigated a range of plasma AABOUND in control, MCI and AD 
patient groups.  The study found that no significant differences of AABOUND to 
phospholipids, despite demonstrating a slight decreasing trend in AABOUND 
concentrations (Control  MCI  AD) [209].  FA levels in plasma were then 
correlated to levels in corresponding human brain samples, however in the case of 
AA no significant patterns emerged. 
A further study investigated the variation of plasma AABOUND between four groups 
of patients; normal controls, AD, cognitive impairment but non-demented and 
other non-AD dementia cases [208]. The study looked at AABOUND to plasma 
phospholipid species, and of AABOUND to individual lipid classes including PC, PE 
and LysoPC.  AABOUND was found not to vary significantly in any of the extractions 
from different groups. 
A large population study (n=1214) that recorded baseline polyunsaturated FAFREE 
levels at an initial visit, and two follow up visits, two and four years later to check 
for progression of dementia, identified plasma AAFREE as a risk factor.  Those 
patients who exhibited a high ratio of AAFREE to DHAFREE were shown to have an 
increased risk of progressing to AD over the 4 years (p=0.004).  AAFREE on its own 
was demonstrated to be non-significant (p=0.45) [221].  This result appears to show 
that it is an imbalance of AAFREE compared with other FAFREE that alters more in 
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dementia cases.  When data in study HP30 was analysed in a similar manner, using 
FA ratios, the only ratio to provide significance was AA/EPA (p=0.05), which 
increased in samples from the AD patient cohort.  Ratio AA/DHA showed no 
significant differences between controls and AD (p=0.08), contradicting the 
findings in the larger population study. 
In general previously published examples correlate to findings reported here in the 
HP30 study. This would suggest that despite AA being shown to vary significantly 
in human (temporal cortex) [226] and mouse model brain (hippocampus) [202] as 
well as previously being shown to cross the BBB [212], the trend does not apply to 
human plasma, and therefore results suggest that AATOTAL is unable to distinguish 
between disease groups in plasma. 
2.4.3.3 – Docosahexaenoic Acid 
Along with AA, DHA is also one of the major FA found in the brain.  In the HP30 
samples the mean concentration values of DHATOTAL were found to decrease 
between control  AD and MCI  AD, however this was not found to be significant 
when comparing means using the student’s t-test. 
This result relates to a previous study that investigated the plasma DHA of 
individuals in control, MCI and AD patient groups, where it was reported that 
DHAFREE displayed no significant differences between disease groups.  However in 
contrast, the same study also demonstrated a significant decreasing trend between 
control  AD and MCI  AD, when comparing DHABOUND to phospholipid species 
(p=<0.05) [209].  A decreasing trend was also observed for DHABOUND to total plasma 
lipids, however this was non-significant.  Interestingly the same study found that 
DHABOUND in human brain was significantly lower as a % of total phospholipids.  It 
Chapter 2 104 
 
was found to be reduced by 14% in the mid-frontal region and 12% in the 
temporal cortex.   
Of particular interest from a biomarker perspective is that the study investigated 
the correlation between plasma and brain fatty acid compositions, however only 
identified one significant trend, reporting %DHABOUND to total plasma lipids, 
compared with % DHABOUND to brain PE. These reported findings in both plasma 
and brain appear to suggest that brain changes can be reflected in the plasma of 
individuals, increasing the chance that they may play a role as suitable biomarkers. 
A further study into human plasma has found that DHABOUND to phospholipids is 
present at significantly lower concentrations in cases of AD, cognitive impairment 
but non-demented and other non-AD dementia cases (p=<0.05).  This significant 
reduction is also observed in DHABOUND to plasma PC and plasma PE (p=0.05) [208]. 
Providing further support to this finding, serum DHABOUND to PC has been shown to 
be present at significantly lower concentrations in dementia cases.  193 patients 
were organised into five different patient groups; controls, AD (MMSE upper 
quartile), AD (MMSE second quartile), AD (MMSE third quartile) and AD (MMSE 
lower quartile), with significant reductions in DHABOUND to PC being observed 
when comparing controls with each of the MMSE quartiles (p=<0.001 for all 
quartiles) [222].  However, the article found a significant difference when comparing 
the ages of the MMSE quartiles with those from the control group (p=<0.001).  This 
could potentially affect the outcome of the results and should be considered when 
judging the reported observations. 
A non-significant result was observed in a cross sectional population study.  
DHABOUND to phospholipids were quantified, with comparisons between patients in 
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groups of controls, cognitively impaired but non-demented and AD.  What is 
interesting with regard to this study is that a sub-group of these patients were also 
revisited on average four years later, with those progressing from control to AD 
having a 30% higher baseline level of DHABOUND to phospholipids, however this 
was statistically non-significant (p=0.07) [223].  This provides evidence that a cross 
sectional study like HP30 might not provide significant differences, but 
longitudinal studies, may be more informative. 
A further study that investigated 899 initially dementia free men and women 
quantified DHAFREE levels at visit one to record a baseline reading, and at a follow 
up visit on average 9.1 years later.  It was shown that those with plasma baseline of 
DHAFREE in the upper quartile had a 47% lower chance of progressing to AD [201].  
Although the results of HP30 were not significant, a decrease in DHA was observed 
in the cognitively impaired groups (MCI and AD) compared with controls, which 
would complement the results in the large cohort follow up study. 
In a similar study, Lopez et al. also found a trend of increased DHAFREE plasma with 
a reduced risk of progressing to Alzheimer’s disease or other dementia types [224].  
The study took plasma levels of DHA from 266 individuals.  The study reported 
that those with DHAFREE levels in the upper tertile were found to have 65% 
reduced risk of being an all type dementia case, and 60% reduced odds of being an 
AD case.  Although results in HP30 were non-significant, the overall trend is again 
in agreement with these findings, with a decrease of DHATOTAL identified in patients 
with AD.   
In addition, another study reported baseline DHAFREE in 1214 patients, who were 
re-visited after two and four years to track for progression to AD.  No significant 
relationship between baseline DHAFREE levels, and the progression to AD was 
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reported [221].  However, the ratio of AAFREE to DHAFREE was found to lead to a 
significant reduction of risk, where those with lower ratio tended to have a 
reduced risk of AD progression (p=0.004).  This was not the case in HP30 with 
ratios of AATOTAL/DHATOTAL, found to be non-significant between the disease 
groups (p=0.08). 
Despite a number of studies reporting significant changes in both DHAFREE and 
DHABOUND, the result presented here in HP30 of combined DHATOTAL suggests that it 
does not significantly change between the patient groups of control, MCI and AD.  
Therefore it would seem that it is not suitable for progression in a biomarker 
capacity in AD. 
2.4.3.4 – Eicosapentaenoic Acid 
EPA was the only FA of the three analysed in HP30 to demonstrate a significant 
change in concentration values for Control  AD (p=0.023), with an overall trend  
of diminishing levels observed for Control  MCI  AD.   
A recent study, investigated plasma and brain FA profiles in both MCI and AD.  A 
significant decrease was observed when comparing EPABOUND to phospholipids in 
Control  AD (p=<0.05) and MCI  AD (p=<0.05) [209].  A similar trend was also 
seen in HP30 with a decrease in EPATOTAL  between Control  AD as well as MCI  
AD, however in this instance only controls and AD comparisons proved significant 
(p=0.023). 
A further study provided more support to these findings [208], reporting significant 
changes of EPABOUND when comparing controls with AD (p=<0.05), dementia cases 
other than AD (p=<0.05), and non-dementia cases with cognitive impairment 
(p=<0.05).  This finding applied to both EPABOUND as part of total plasma 
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phospholipids, as well as individual EPABOUND to PC and PE parent species.  The 
authors went on to hypothesise that this decrease of EPA in the cognitively 
impaired groups was due to dietary factors, however provided no data to support 
this discussion. 
However, this hypothesis is contradicted by findings from the Chicago Health and 
Aging Project [227] where dietary intake of EPA was not associated with 
development of AD in a patient cohort of 815 patients.  The study has particular 
weight due the size of the patient cohort.  This would therefore suggest differences 
in EPA observed in AD could be due to a pathological function of the disease 
mechanism rather than dietary factors. 
Previously it has been demonstrated in a large population study (n=1214) where 
the patients were visited after two and four years to track progression to AD, that 
those with a high plasma concentration of EPA had a significantly reduced risk of 
progressing to AD (p=0.02) [221].  This is in agreement with the results in HP30.  
However, the publication, differed in relation to the findings on ratio analysis, with 
AA/EPA found to be non-significant, whilst in the study HP30, this ration 
significantly increased in patients with AD (p=0.05). 
EPA, as part of serum cholesterol esters has also been demonstrated to decrease in 
patients with AD.  Tully et al. [222] analysed the serum of 193 patients, which were 
organised into five different patient groups; controls, AD (MMSE upper quartile), 
AD (MMSE second quartile), AD (MMSE third quartile) and AD (MMSE lower 
quartile).  The study reported a significant reduction in the concentration of EPA 
extracted from cholesterol esters when comparing each MMSE quartile with the 
control (p=<0.05 quartile 1, p=<0.001 quartiles 2-4).  Interestingly, as discussed 
previously (Section 2.4.3.3), the publication reports that the mean age of the 
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dementia groups was significantly older than the controls (p=<0.001), which could 
undermine the statistical significance of the finding. 
An interesting extract from the Proceedings of the eighth international symposium 
on the neurobiology and neuroendocrinology of aging published in the journal 
Experimental Gerontology (2007) also discussed EPA concentrations in serum, and 
compared levels between Japanese centenarians (n=200) and gender matched 
young healthy controls (n=150).  Thus reported a significant decrease in serum 
EPA found in the elder group (p=<0.05).  Importantly, the EPA concentrations in 
the centenarian group, also significantly correlated with MMSE scores (p=<0.05) 
suggesting that although EPA levels are associated with age, they are also 
associated with cognitive state [225].   
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2.5 – Conclusions 
2.5.1 – MTEST 
The method adapted from a previous literature source was proven to be suitable 
for the analysis of three FA species in human plasma and mouse brain.  It was 
demonstrated that the extraction was reproducible and linear across the range 
observed in the two studies, and therefore was useful in determining any changes 
that occur between sample groups. 
2.5.2 – MB2 
Despite the small samples size of the study (n=2), DHATOTAL and AATOTAL variation 
was demonstrated across brain regions of each individual mice, highlighting that 
each individual brain region is likely to hold different metabolic pathways.  These 
results appeared to correlate to AD related progression of Aβ throughout the brain, 
with the largest FA differences shown to be in regions known to be most at risk of 
Aβ development.  Although the small sample size makes it difficult to discuss with 
any statistical significance, important questions are raised, leading the way to 
hopeful future investigations and collaborations. 
2.5.3 – HP30 
Numerous studies have linked abnormal levels of FA both in human brain and 
plasma to AD.  Despite this, to the author’s knowledge this is the first time the 
three FA have been considered in their entirety (free and bound) with regard to 
AD. However the results only showed significant decreases in EPATOTAL.  Literature 
sources on FA in the circulatory system often contradict one another, with no clear 
pattern emerging.   
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It is clear that there is conflicting information in the literature, some that supports 
the finding of HP30, and some that directly contradicts it.  This could be due to a 
number of factors such as effects relating to general cognitive function, or even 
general aging differences.   
With this finding in mind, there is a suggestion that a requirement for AD 
predictive markers is that they are more specific to the pathology of AD.  Therefore 
the strategy of biomarker discovery was progressed to a non-targeted lipid 
analysis, in an attempt to identify novel small metabolite markers of disease, which 
perhaps have yet to be reported in the literature (see chapter 3).  
A decision was made to focus directly on human plasma samples due to better 
sample availability and because of the greater relevance if future findings show 
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Chapter 3:  
Preliminary Non-Targeted Biomarker Screen 
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3.1 – Introduction 
Chapter 2 described a targeted approach in order to observe the total plasma 
levels of three abundant FA species.  Despite the observation of a significant 
reduction in EPATOTAL (p=0.023), and a significant increase in the ratio 
AATOTAL/EPATOTAL (p=0.05) in AD patients compared with controls, a decision was 
made to adjust the project strategy in an attempt to identify a novel biomarker 
previously not published in the literature.   
Therefore, the next step of the investigation was to perform non-targeted 
biomarker discovery.  An overview and comparison with targeted approaches can 
be observed in Figure 3.1. 
 
Figure 3.1: Comparison of Non-Targeted to Traditional Target Approaches 
3.1.1 – Terminology  
When discussing non-targeted approaches the terminology employed can become 
confusing due the large number of definitions found in the literature, with the most 
common of these being metabolomics and metabonomics.   
• Completely hypothesis driven
• Targeted approach was employed in the FA profile in Chapter 2
• Hypothesis of significant FA variation in AD, therefore could play a role 
as biomarker, hence the study methodology specifically analysed FA 
species
Targeted Approach
• Does not employ a specific hypothesis
• Non-targeted approaches aim to analyse a wide range of metabolites 
in a single run
• Molecular variation  between disease groups is observed using both 
multivariate and univariate data analysis in on the complete data set
Non-Targeted Approach
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Recently, a definition structure has begun to take shape, with metabolomics now 
commonly defined as the “comprehensive detection and quantitation of all the 
low-molecular-weight molecules and metabolites present in cells, tissues or 
organisms under a set of given conditions”, and metabonomics described as the 
“quantitative analysis of the metabolic response of living systems to 
pathophysiological stimuli or genetic modification over time” [228]. 
Further common terms that are encountered in the literature and add to the 
confusion include, metabolic profiling, metabolic fingerprinting and metabolic 
phenotyping.  Although referenced literature examples discussed herein may refer 
to any one of these terminologies, they will be referred to as non-targeted 
analytical approaches. 
A further important terminology that is commonly used when it comes to non-
targeted analysis includes what is known as a molecular “feature”.  A feature is an 
individual molecular species.  For example in LC-MS non-targeted approaches, an 
unidentified molecular structure is often referred to as a feature, meaning a 
specific mass at a specific retention time. 
3.1.2– Non-Targeted Literature Examples in Alzheimer’s Disease  
A review of non-targeted approaches employed in biomarker research with regard 
to AD is presented in the main introduction to the thesis and can be found in 
Section 1.7.  However, to summarise briefly, a number of publications are available 
in the literature that utilise NMR [131, 188, 191, 192], GC-MS [229] and LC-MS [119, 193, 196] 
techniques in a range of biofluids, from both human patients and animal AD 
models.   
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Important findings included a significant reduction in particular plasma bile acids 
[119], CSF citrate [188] and creatinine [131], an increase in plasma ceramide (CER16:0) 
levels and a decrease in plasma sphingolipid (SP16:0) levels [193] and a significant 
variation of serum FA between MCI and control patients [191]. 
A high number of these findings, particularly by NMR approaches, identified many 
polar metabolites such as citrate and creatinine.  However, as discussed in Chapter 
1 and Chapter 2, there is a bulk of literature linking lipid abnormalities to AD.  
Examples of non-polar candidate to come from non-targeted methods include bile 
acids [119], ceramide 16:0 [193], sphingomyelin C16:0 [193], as well as those in a 
publication by Oresic et al [196], who statistically grouped three or four similar 
metabolites in what was termed “clusters”, with the most promising cluster 
containing one non-polar PC.  Further to this, the application of LC-MS techniques 
to AD biomarker discovery in a non-targeted manner is in its infancy, with only a 
handful of publications to date. 
Therefore, with this in mind, an LC-MS study was designed to encapsulate a wide 
range of plasma molecular species, with a consideration on the non-polar element 
of the extraction, and the aim of identifying novel biomarker candidates for AD.  In 
addition, MCI samples underwent comparison, with the aim of identifying any 
biomarkers that may be intermediate between the condition and AD or control.   
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3.2 – Materials and Methods 
The screening method discussed within this chapter was adapted and modified 
from a publication previously published by Raineville et al. [230]. 
3.2.1– Materials 
LC-MS Grade acetonitrile was purchased from VWR (Leicestershire, UK) and high 
purity water deionised water was obtained from an in house Millipore filtration 
system (EMD Millipore, MA, USA). Analytical grade ammonium formate was 
purchased from Fisher Scientific (Loughborough, UK).  
3.2.2 – Instrumentation 
LC-MS analysis was completed using a Waters Acquity UPLC® (Waters, Milford, 
USA) coupled to a Waters Xevo® G1 QTOF (Waters, Milford, USA).  Analysis was 
completed in both positive and negative ionisation.  Both LC and MS settings were 
specifically designed for each phase and are described below.   
3.2.2.1 – Positive MS Ionisation Analysis 
The chromatographic column used was a Waters UPLC-BEH C18 (2.1×100mm, 
3µm) maintained at 60°C.  Mobile phase A was H2O (10mM ammonium formate) 
and B was acetonitrile (10mM ammonium formate).  A gradient analysis was 
employed as follows: 0min (30%B); 15min (100%B).  A 5min re-equilibration at 
the initial 30%B was employed before injection of the next sample.  Solvent was 
passed through the column at a rate of 0.6mL/min. 
The Waters Xevo® MS was operated in the positive ion mode with a capillary 
voltage of 3.2kV and a cone voltage of 35V.  The extraction cone was set to 2.0V.  
The desolvation gas flow was 900L/hour and maintained at 350°C.  The source 
temperature was 120°C and cone gas was set to 50L/hour.  All analyses were 
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acquired using the reference solution to ensure accuracy and reproducibility; 
leucine enkephalin was used as a reference mass (m/z 556.2771 and 278.1141) at 
a concentration of 500ng/mL and a flow rate of 10μL/min. Data was collected in 
the centroid mode over the mass range 50–1000Da with an acquisition time of 0.1 
seconds per scan. 
3.2.2.2 – Negative MS Ionisation Analysis 
The chromatographic column used was a Waters UPLC-BEH C18 (2.1×100mm, 
3µm) maintained at 60°C.  Mobile phase A was H2O (10mM ammonium formate) 
and B was acetonitrile (10mM ammonium formate).  A gradient analysis was 
employed as follows: 0min (30%B); 2min (60%A); 10min (100%B).  A 5min re-
equilibration at initial 30%B was employed before injection of the next sample.  
Solvent was passed through the column at a rate of 0.35ml/min. 
The Waters Xevo® G1 QTOF MS was operated in the negative ion mode with a 
capillary voltage of -2.6kV and a cone voltage of 45V.  The extraction cone was set 
to 2.0V.  The desolvation gas flow was 800L/hour and maintained at 350°C.  The 
source temperature was 120°C and the cone gas was set to 20L/hour. All analyses 
were acquired using the lock spray to ensure accuracy and reproducibility; leucine 
enkephalin was used as a lock mass (m/z 554.2615 and 276.0985) at a 
concentration of 500ng/mL and a flow rate of 10μL/min.  Data was collected in the 
centroid mode over the mass range 50–1000Da with an acquisition time of 0.1 
seconds per scan. 
3.2.3 – Waters MSe Data Collection 
In both polarities data was collected using Waters MSe technology, meaning data 
was collected at two constantly interchanging collision cell energy ranges.  This 
enables data collection in two “levels”.  Level one is acquired using a low collision 
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energy (4V) enabling MS data with parent molecular ionisation.  Level two applies 
a high collision energy (50V) within the MS collision cell, which has the effect of 
causing molecular fragmentation, meaning accurate mass fragmentation data can 
be collected simultaneously to accurate mass parent ion data.  Importantly, this 
can assist with structural elucidation (discussed later in Chapter 5 – Section 5.3.3) 
with only a single analytical run required, thus preventing the need for repeat 
extractions and analyses, vital for valuable sample preservation and also reducing 
analytical time and cost.    
3.2.4 – Sample Preparation  
Human plasma samples were acquired from the Institute of Psychiatry, Denmark 
Hill, London, UK.  The samples were obtained from the two clinical cohorts 
AddNeuroMed and DCR.  These cohorts are described in full detail in Chapter 2, 
Section 2.2.3.3.   
Sample sets were selected based on age and gender.  Full details of each of the 
sample sets used for the analysis can be found in Table 3.1. 
QC samples were prepared by creating a pool of aliquots taken from all samples.  
Lipids were extracted from patient plasma by precipitating the plasma protein 
with acetonitrile (ratio 1:3 plasma:acetonitrile).  Samples were centrifuged at 
2500g for 5mins.  The supernatant was removed and 5µL was injected for LC-MS 
analysis.   
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Positive Ionisation Negative Ionisation  
 Control MCI AD Control MCI AD  
 Age(years) 
Mean 
78.05 84.57 81.69 79.19 83.73 78.17 
 
 
Age Std Dev 6.35 6.45 8.56 7.44 6.63 6.76 
 
 
MMSE Mean 28.87 25.50 16.40 28.3 25.1 17.1 
 
 MMSE St 
Deviation 




15 10 10 12 10 7 
 
 Number of 
Male/Female 




33/66 50/50 50/50 42/58 50/50 43/57 
 
Table 3.1: Patient Data for The LC-MS Screening Study 
Summary of patient data of plasma samples included in the study.  Samples were age and 
gender matched as much as possible to reduce external influences of analysis.  Mini Mental 
State Exam (MMSE) results are also reported here.  
3.2.5 – Data Processing 
Following LC-MS analysis of the samples, the mass spectrometry raw data 
underwent feature alignment using Waters MarkerLynx software, a package within 
Waters MassLynx 4.1 (Waters Corporation, Milford, USA).   
The alignment procedure results in an output of peak height values, which in turn 
are normalised.  The MarkerLynx software applies a normalisation algorithm 
which takes into account total ion counts of each chromatogram, and adjusts all 
marker intensities so that the sum of intensities within each sample is the same. 
The alignment procedure was completed separately for each ionisation sample set 
(positive and negative).  The marker outputs of these, was then transferred to 
SIMCA-P+ 12.0 (Umetrics, Umeå, Sweden), where they were subjected to 
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multivariate data modelling, including pareto scaled principle component analysis 
(PCA) and orthogonal partial least squares discriminate analysis (OPLS-DA).   
QC samples were included in the PCA models for each ionisation mode to 
demonstrate reproducibility across the sample run.  If QC samples grouped within 
15% of the total t[1] and t[2] on the unsupervised PCA model, then the run was 
considered to be acceptable for further use.   
Once the models had been accepted the two data sets progressed to and 
underwent OPLS-DA modelling.  An OPLS-DA model was initially created for 
Control vs. MCI vs. AD.  The completion of a corresponding S-plot analysis then 
enabled those features that had the highest magnitude of variation between 
groups, therefore influencing the OPLS-DA models, to be isolated. 
These individual metabolite features were then individually re-extracted from the 
raw data using Waters QuanLynx, a package within Waters MassLynx 4.1 (Waters 
Corporation, Milford, USA).  These features then underwent univariate means 
testing and were analysed for significance using a standard “students” t-test in IBM 
SPSS (IBM, Portsmouth, UK). 
3.2.6 – Putative Identification of Features 
All features that were observed to influence the models and therefore underwent 
univariate data analysis, were also preliminarily identified using the human 
metabolome database (HMDB) [231-233] and the equivalent METLIN (METabolite 
LINk) database [234].  Using the HMDB allowed an indication of the molecular 
classes, enabling a decision on the progression of the project. 
Due to the high number of database hits generally returned by the database search, 
a number of rules were enforced in the identification database searching process 
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in order to be as consistent as possible.  These rules are listed and explained 
below: 
• 0.05 Dalton (Da) error:  
o The error of the search on the database searches was set to 0.05Da 
error, as this was well within the accuracy of the Waters Xevo® MS 
and confirmed by our external calibration. 
• Polarity: 
o The feature in each instance must realistically ionise in the polarity 
being observed.  For example FA, are generally only observed in 
negative ionisation mass spectrometry (unless they have formed 
adducts in the ionisation source). 
• Human biology: 
o Features in the search must be metabolites from human biology and 
have been observed in human biology, preferably in the circulatory 
system, for example plasma or whole blood.  HMDB lists instances 
where the molecules have been extracted from human tissue and 
previously reported in the literature. 
• Retention Time 
o Retention time of each feature is considered, for example molecules 
with a similar structure often elute in the same region of the 
chromatogram, and this was taken in consideration when 
completing the database search.  
Chapter 3 121 
 
3.3 – Results 
Results from the positive ion screen are discussed in Section 3.3.1, whilst the 
results of the negative ionisation screen are discussed later on in Section 3.3.2. 
3.3.1– Positive Ionisation Screen 
Following adaptation of the chromatographic method, combined with positive 
ionisation MS detection, a final 15 minute chromatogram was developed that was 
suitable for a screening analysis.  Following alignment of all of the data using 
Waters MarkerLynx software, a final list of 950 features (m/z at a retention time) 


























Figure 3.2: Example Screen Chromatograms of QC Samples 
The upper figure presents a total ion chromatogram (TIC) of a QC sample analysed under 
negative ionisation chromatographic and mass spectrometry settings.  A 10 minute 
gradient was applied, which gave a rapid LC-MS plasma screen.  The gradient time had to 
be increased due to the increased number of features in the positive ionisation mode 
(lower TIC), resulting in a 15 minute plasma metabolite screen.  Both methods were fully 
reproducible as demonstrated by QC clustering on the relevant PCA models (Figure 3.3a 
Figure 3.7a). 
Time
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3.3.1.1– Principle Component Analysis to Demonstrate Reproducibility of 
Intra-Run QCs for Acquired Positive Ionisation Data 
Following the alignment of the raw positive ionisation data, an unsupervised 
pareto scaled PCA model was produced in SIMCA-P+ (Umetrics, Sweden), to show 
QC grouping and reproducibility across the analytical run (Figure 3.3a).  Clustering 
of the QC samples was required to be within 15% of the total model (both t[1] and 
t[2]). 
From the PCA it could be observed that the QCs grouped within the model as 
expected from a reproducible run.  Therefore the data was accepted for further 
analysis.  As would also be expected in age and gender matched samples in a 
complex matrix such as human plasma, no obvious disease groupings or 
separations occurred on the PCA model (Figure 3.3b).  This also suggests no inter-
group differences due to analytical or extraction irregularities or patterns.  This 
would also be expected from a randomised run. 
  






 = Quality Control  = Control  = Mild Cognitive Impairment  = Alzheimer’s Disease 
Figure 3.3:  Principle Component Analysis of Positive Ionisation Screen Study Data 
Unsupervised Principle Component Analysis (PCA) positive mass spectrometry dataset (n=41 respectively).   
(A) Quality control (QC) samples can be seen as orange inverted triangles.  QCs were excepted if clustering on 
the PCA =<15% for the total t[1] and t[2]. 
(B) PCA with diagnostic class colour coded.  No outliers were observed. 
The PCA model demonstrates no diagnostic group clustering.  This would also indicate no differences or 




















SIMCA-P+ 12.0.1 - 2013-06-20 21:55:00 (UTC+0) 
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3.3.1.2 – Orthogonal Partial Least Squares Discriminate Analysis of Positive 
Ionisation Data 
Pareto scaled OPLS-DA models were produced for the positive ionisation data.  The 
samples were grouped by class (Control or MCI or AD), with an initial model to 
compare all three within the same model (Figure 3.4a).  A clear separation was 
observed between AD samples and the rest of the sample set (MCI and Control).  
SIMCA-P+ software assigns each model it produces two values as an assessment of 
the models validity – R2 and Q2.  The R2 value represents the models ability to 
separate into classified groups whilst the Q2 value is a figure designed to represent 
the prediction capabilities of an unknown feature into the model.  The perfect 
predictive model score would be R2 = 1.0, Q2 = 1.0.  Umetrics recommend that 
when using SIMCA-P+ an acceptable biological PCA model for use as a fully 
validated predicative tool, should return scores of R2 = 0.5, Q2 = 0.4.  A negative Q2 
value means the model has no predictive capabilities at all [235]. 
The OPLS-DA created from the positive data returned an R2 and Q2 value of 0.321 
and 0.298 respectively.  This figure is below recommendations for a validated 
predictive model, however, in the case of this study, the aim is to identify potential 
candidate biomarkers, and therefore, for use as a data-mining tool the values are 
acceptable. 
From the OPLS-DA model an S-plot was produced (Figure 3.4b) to illustrate the 
features that varied the most between disease classes.  Features were selected that 
had a magnitude of variation value (p[1]) of >0.15 in the model.  The models for 
positive ionisation produced 8 eight such features.  




 = Control  = Mild Cognitive Impairment  = Alzheimer’s Disease 
(b) 
 
Figure 3.4: OPLS-DA model of Positive Ionisation Data 
The figure presents supervised pareto scaled OPLS-DA model (a) for positive data. 
A clear visual separation of groups was achieved between AD and both Control and MCI 
with model validation values of R2 = 0.298 and Q2 = 0.034.  
S-plot analysis (b) highlights those features which had the greatest magnitude of variation 
(p[1]) within the corresponding OPLS-DA model (a).  Features with a p[1] value >0.15 are 
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As a further data mining approach, models were also created for individual disease 
comparisons.  Again visual separation was observed in each comparison (Figure 
3.5).  Results returned the following R2 and Q2 values.  
• Control vs. MCI:  R2 = 0.660 and Q2 = -0.475 
• Control vs. AD:  R2 = 0.708 and Q2 = 0.214 
• MCI vs. AD: R2 = 0.763 and Q2 = 0.257 
Again, the values are below the recommended value for use as a validated 
predictor tool, but are acceptable for use a data-mining tool for biomarker 
discovery. 
S-plot analysis was completed for each model, which again revealed those features 
that varied most in the model (p[1]>0.15).   Many of these features overlapped 
with those from the initial model; however some new features were presented.   
Table 3.2 lists the highlighted features of interested obtained from the positive 
ionisation S-plot analysis. 
  














 = Control  = Mild Cognitive Impairment  = Alzheimer’s Disease 
Figure 3.5: Individual OPLS-DA Models of Positive Data 
The above figure displays OPLS-DA of positive ionization data, illustrating the intergroup 
separation of each disease class.  R2 and Q2 values for each model are as follows: 
• Control vs. MCI =  R2 = 0.660 and Q2 = -0.475 
• Control vs. AD =  R2 = 0.708 and Q2 = 0.214 
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 Table 3.2: Features of Interested from Positive Ionisation Models 
The table presents those features that have the largest influence on the positive ionisation orthogonal partial 
least squares discriminate analysis (OPLS-DA) models.  Features were extracted from the corresponding S-plots 
which exhibited a magnitude of variation value (p[1]) of >0.15, for example those features highlighted in red 
squares in Error! Reference source not found..C. 
Each feature is linked to a specific model, for example if it provided influence to the Control vs. AD analysis, a  
is placed in the relevant column.  
Peak areas for each feature were extracted from the raw data and are also presented here.  These peak areas 
then underwent testing for significance by univariate mean analysis using “Student’s” t-test in SPSS. 
Putative identification was provided for each feature of interest using the Human Metabolome Database 
(HMDB).  A number of rules were applied in order to filter the search results in the HMDB, these are discussed in 
greater detail in the methods section (Section 3.2.6 (Page 119)). 
MPA = Mean Peak Area, DAG = Diacylglyceride, TAG = Triacylglyceride, LysoPC = Lysophosphatidylcholine, PC = 
Phosphatidylcholine, PE = Phosphatidylethanolamine and SPH = Sphingomyelin. 
The most promising features were m/z 780.5578, 806.5746 and 834.6026, which indicated a significant 
decrease in AD compared with controls ((a) p=<0.05, (b) p=<0.01, (c) p=<0.001).  These features returned a 
putative identification of phosphatidylcholines or phosphatidylethanolamines. 
  
Chapter 3 129 
 
3.3.1.3 – Univariate Data Mining of Acquired Positive Ionisation Data 
In addition to the multivariate modelling, univariate analysis was also completed 
on those features shown to have a high magnitude of variation in the S-plot 
models.  Those features that p[1] = >0.15 from each of the S-plot models 
underwent extraction from the raw chromatographic data using Waters QuanLynx, 
a package found in MassLynx 4.1 (Waters, Milford, USA).  After extraction the data 
underwent means analysis in SPSS (IBM, Portsmouth, UK), the overall results of 
which are summarised in Table 3.3. 
Three features provided a significant change between each of the disease groups.  
These are displayed in Table 3.3. found below.  Example extracted ion 
chromatograms can be found in Figure 3.6. 
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Table 3.3: Significant Features From Positive Ionisation Data 
The mean peak areas (MPA) presented here were extracted from the raw data using 
Waters QuanLynx Software.  The three features (molecular m/z at a retention time) were 
found to be significantly reduced in Alzheimer’s disease (AD) compared with mild 
cognitive impairment (MCI) and controls. (a) p=<0.05, (b) p=<0.01, (c) p=<0.001.  Putative 
identification was completed via database matching using the accurate mass.  This 
indicated the three features were phosphatidylcholine (PC) or phosphatidylethanolamine 
(PE) molecules. Example extracted ion chromatograms can be found in Figure 3.6. 
  








Figure 3.6: Example Extracted Ion Chromatograms 
(a) Feature with m/z 780.5578 at 9.51 minutes 
(b) Feature with m/z 806.5746 at 9.80 minutes 
(c) Feature with m/z 834.6026 at 10.37 minutes 
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3.3.1.4 – Putative Identification of Features from Positive Ionisation Models 
and Analysis 
Features that were found to influence the OPLS-DA models, listed in Table 3.2 , also 
underwent putative identification.  The results of which are also included in the 
tables.   
Identification was achieved by database accurate mass searching.  The databases 
often provide multiple options for the identification per m/z, therefore the 
identification is only preliminary as an aim to generalise the type of molecules 
thought to alter in the disease groups.  Listed in the table are general molecule 
classes that the m/z refers to.   
The three significant features after univariate analysis underwent further 
identification at a later stage, however this is discussed in more detail alongside 
further validation work in Chapter 5 (Section 5.3.3). 
Positive ionisation MS produced a number of different classes of molecule that 
affected the model.  Most commonly phosphatidylcholine (PC) and 
phosphatidylethanolamine (PE) molecules were identified.  It was from these two 
molecular classes that the molecules of most interest were observed.  As 
previously reported in section 3.3.1.3, three m/z were observed to significantly 
decrease in AD compared with controls, and initial database identification pointed 
at PC and PE. 
Further lipid classes that demonstrated an influence in the multivariate models 
were diacylglyceride (DAG), triacylglyceride (TAG), sphingomyelin (SPH) and 
lysophosphatidylcholine (LysoPC).  
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3.3.2 – Negative Ionisation Screen 
Following adaptation of the chromatographic method, combined with negative 
ionisation MS detection, a final 10 minute chromatogram was developed that was 
suitable for a screening analysis.  Following alignment of all of the data using 
Waters MarkerLynx software, a final list of 420 features (m/z at a retention time) 
was produced.  Figure 3.8 presents an example negative ionisation 
chromatographic trace. 
3.3.2.1 – Principle Component Analysis to Demonstrate Reproducibility of 
Intra-Run QCs for Acquired Negative Ionisation Data 
Following alignment of the negative ionisation data, an unsupervised pareto scaled 
PCA model was produced in SIMCA-P+, to show the clustering of QC samples and 
therefore reproducibility across the analytical run (Figure 3.7a).  On visual 
inspection of the PCA it demonstrated clear QC grouping at the centre of the model.  
This would be the expected result from a reproducible run and therefore was 
accepted for further analysis.  As would also be expected in age and gender 
matched samples in a complex matrix such as human plasma, no obvious disease 
groupings or separations occurred on the PCA model (Figure 3.7b). 
Upon observation of the PCA however, it is clear that one sample (highlighted 
inside a red box) is a major outlier compared with the rest of the samples within 
the model (Figure 3.7b).  The outlier is a sample extracted from a control patient.  
Following further investigation and inspection of the raw data it was clear that the 
chromatogram was at a significantly reduced signal compared with QC samples 
and other typical chromatograms from the disease classes (Figure 3.8).  Therefore 
based on these two items of information the individual sample in question did not 
progress to OPLS-DA modelling.  






 = Quality Control  = Control  = Mild Cognitive Impairment  = Alzheimer’s Disease 
Figure 3.7:  Principle Component Analysis of Negative Ionisation Screen Study Data 
Unsupervised Principle Component Analysis (PCA) negative Mass Spectrometry Dataset (n=36 respectively).   
(A) Quality control (QC) samples can be seen as orange inverted triangles.  QCs were excepted if clustering on 
the PCA =<15% for the total t[1] and t[2]. 
(B) PCA with diagnostic class colour coded.  The PCA contains a major outlier, highlighted by a red box.  Upon 
investigation of the raw data, this sample was excluded from further analysis due to the poor quality of the 
chromatographic data, suggesting analytical error (Figure 3.8). 
The PCA model demonstrates no diagnostic group clustering.  This would also indicate no differences or 
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Figure 3.8: Negative Ionisation Mass Spectrometry Chromatogram (Outlier) 
Chromatograms from the raw negative ionisation mass spectrometry.  The upper 
chromatogram is of a QC sample and demonstrates typical intensities of peaks.  The lower 
chromatogram is on the same axis scale and is of the control sample identified as an 
outlier in the initial PCA analysis (Figure 3.9).  It is clear that there has been an analytical 
error, for example a miss injection of sample, or an irregularity during the sample 
extraction. 
3.3.2.2– Orthogonal Partial Least Squares Discriminate Analysis of for 
Acquired Negative Ionisation Data 
A pareto scaled OPLS-DA model was produced with the remaining samples.  These 
samples were grouped by class (Control or MCI or AD), with an initial model made 
comparing all three (Figure 3.9a).  It can be seen that separation on the model was 
not as distinct as when using positive ionisation, however MCI appear to separate 
from both AD and control class groups.  R2 and Q2 values reported at 0.341 and -
0.170 respectively. 
An S-plot analysis was completed in order to isolate those features which varied 
the most in magnitude (p[1]) between groups in the models (Figure 3.9b).  
Features were selected that had a p[1] value of >0.15 in the model.  The models for 
negative ionisation produced 14 such features. 
Time












 = Control  = Mild Cognitive Impairment  = Alzheimer’s Disease  
(b) 
 
Figure 3.9: OPLS-DA model of Negative Ionisation Data 
The figure presents supervised pareto scaled OPLS-DA model (a) for negative data. 
A visual separation of groups was achieved between MCI and both Control and AD with 
model validation values of R2 = 0.341 and Q2 = -0.170.  
S-plot analysis (b) highlights those features which had the greatest magnitude of variation 
(p[1]) within the corresponding OPLS-DA model (a).  Features with a p[1] value >0.15 are 























SIMCA-P+ 12.0.1 - 2013-02-01 10:40:02 (UTC+0) 
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Once again, to increase the data mining output of the investigation models were 
produced for individual comparisons (Control vs. MCI, Control vs. AD and MCI vs. 
AD). 
Visual separation was observed in each comparison (Figure 3.10), however as with 
the initial all three group OPLS-DA, low R2 and Q2 values suggested overall poor 
model properties.  
• Control vs. MCI:  R2 = 0.426 and Q2 = 0.203 
• Control vs. AD:  R2 = 0.523 and Q2 = -0.147 
• MCI vs. AD: R2 = 0.662 and Q2 = -0.255 
Again, the values are below the recommended value for use as a validated 
predictor tool, but are acceptable for use a data-mining tool for biomarker 
discovery. 
S-plot analysis was completed of each model, which again revealed those features 
that most varied in magnitude between groups in the model (p[1]>0.15).   Many of 
these features overlapped with those from the initial three disease group OPLS-DA 
model; however some new features were presented.  A summary of the findings 
from the S-plot analysis can be found in Table 3.4. 
  














 = Control  = Mild Cognitive Impairment  = Alzheimer’s Disease 
Figure 3.10: Individual OPLS-DA Models of Negative Data 
The above figure displays OPLS-DA of positive ionization data, illustrating the intergroup 
separation of each disease class.  R2 and Q2 values for each model are as follows: 
• Control vs. MCI =  Negative ionisation  R2 = 0.426 and Q2 = 0.203 
• Control vs. AD =   Negative ionisation  R2 = 0.523 and Q2 = -0.147 
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790.5332 7.70   - - 
61.36    
±21.62 
62.79    
±23.37 





802.5570 7.77   - - 
29.33      
±6.96 
26.61       
±7.42 





804.5704 8.00   - - 
40.27       
±9.22 
37.59    
±11.09 





818.5770 7.99   - - 
119.68   
±33.69 
114.65    
±40.46 





824.5424 7.58   - - 
8.15         
±3.58 
10.03        
±4.34 





838.5541 7.58   - - 
32.09    
±12.98 
33.66      
±17.60 




Table 3.4: Features of Interested from Negative Ionisation Models 
The table presents those features that have the largest variation in magnitude between groups on the negative 
ionisation orthogonal partial least squares discriminate analysis (OPLS-DA) models.  Features were extracted 
from the corresponding S-plots, for example those features highlighted in red squares in Error! Reference 
source not found..D. 
Each feature is linked to a specific model, for example if it provided influence to the Control vs. AD analysis, a  
is placed in the relevant column.  
Peak areas for each feature were extracted from the raw data and are also presented here.  These peak areas 
then underwent testing for significance by univariate mean analysis using “Student’s” t-test in SPSS.  No features 
returned significant differences between disease groups during the univariate data analysis. 
Putative identification was provided for each feature of interest using the Human Metabolome Database 
(HMDB).  A number of rules were applied in order to filter the search results in the HMDB, these are discussed in 
greater detail in methods section (Section 3.2.6 (Page 119)). 
MPA= Mean Peak Area, FA = Fatty Acid, MAG = Monoacylglyceride, LysoPC = Lysophosphatidylcholine, LysoPE = 
Lysophosphatidylethanolamine PE = Phosphatidylethanolamine, PS = Phosphatidylsphingomyelin and Cer = 




3.3.2.3 – Univariate Data Mining of Negative Ionisation Data 
Those features that were obtained from the S-plot analysis from each of the models 
underwent univariate extraction from the raw chromatographic data using Waters 
QuanLynx, a package found in MassLynx 4.1.  After extraction the data underwent 
means analysis using SPSS, the overall results of which are summarised in Table 
3.4. 
None of the features provided significant mean value alterations between disease 
groups. 
3.3.2.4 – Putative Identification of Features from Negative Ionisation Models 
and Analysis 
Features that were found to influence the OPLS-DA models listed in Table 3.4, also 
underwent putative identification.  The results of which are also included in the 
table.   
As with the positive ionisation analysis, identification was achieved by database 
accurate mass searching.  The databases often provide multiple options for the 
identification per m/z, therefore the identification is only preliminary as an aim to 
generalise the type of molecules thought to alter in the disease groups.  Listed in 
the table are general molecule classes that the m/z possibly refers to. 
The negative ionisation screen produced a number of lipid families in the database 
identification process.  On this occasion no feature provided a significant variation 
in any disease group in the univariate statistics, but preliminary identification was 
completed nonetheless. 
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The database search returned hits for FA, LysoPC, PE, PS and Ceramide (CER). 
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3.4 – Discussion 
3.4.1 – Biological Observations 
From the results in Table 3.2 and Table 3.4 the it can be seen that preliminary 
identification suggests that all of the features of major influence to the models are 
lipid molecules.  The findings of these and their previous links to AD are discussed 
below.  
3.4.1.1 – Phosphatidylcholines and Lysophosphatidylcholines 
Following the HMDB preliminary identification of those features isolated in the S-
plot model, one of the most common returns from the search was a group of 
molecules termed phosphatidylcholines (PC) and their metabolites 
lysophosphatidylcholines (LysoPC). 
PC and LysoPC molecules have been previously shown to be detected using 
positive ionisation [236], however sensitivity in negative mode is poor, often 
producing no detectable ions [237].  It is for this reason that PC species were filtered 
from the HMDB negative ionisation search and only appear in Table 3.2 from the 
positive screen. 
PCs are a class of glycerophospholipid, consisting of a choline head group and fatty 
acid side chains (Figure 3.11).  They are an essential component of cell 
membranes, and make up ~ 95% of total choline containing compounds in the 
majority of tissues [238, 239]. They have a common zwitterionic structure, with the 
variation in the length and saturation of their hydrophobic side chains defining 
their structural roles since chain length differences can affect cell membrane 
fluidity [240]. Along with their structural roles, they are also found as components of 
lipoproteins, in particular of high-density lipoproteins (HDL). PCs interact with 
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ApoE as part of the HDL group, and are implicated in cholesterol transport [241].  
This is of interest as ApoE is heavily linked with AD [242, 243], and the ε4 allele of the 
ApoE gene is a well-established predictor and is often considered one of the most 
significant risk indicators of AD [244]. 
 
Figure 3.11: Phosphatidylcholine Structure 
An example figure of a phosphatidycholine (PC) molecule.  PC consist of a choline head 
group and two FA side chains. 
Gaudin et al identified two PCs - 32:0 and 34:1, which were decreased in the 
presence of senile plaques, when extracted from post-mortem AD brain compared 
with controls. The group concluded that PC regulation was affected in AD and that 
it could be linked to the roles of PLA2 and PLD1 in Aβ activation [245]. This result 
complements previous findings where total PC species were found decreased in 
the frontal and parietal cortex of AD patient brain by 12-15% (p=<0.05) [246]. 
A previously published metabolomic based study employed a cluster style analysis 
which investigated the use of groups of similar molecules, rather than individual 
species as markers for conversion from MCI to AD [196].  The most promising 
cluster identified in the analysis, consisted of three molecules that demonstrated 
significant changes in the progression from MCI to AD. These included a 
PC16:0/16:0, alongside 2,4-dihydroxybutanoic acid and an unidentified molecule 
[196]. 
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A further PC molecule, PC16:0/20:5 was included in a separate cluster analysis, 
however in that example, no significant prediction properties (p=0.27) as a group 
were found [196]. 
LysoPC (Figure 3.12) are metabolites formed by partial hydrolysis of one of the FA 
side chains of PCs by the phospholipase family of enzymes.  Irregularities in this 
family of enzymes in AD has previously been demonstrated in AD mouse models, 
where an increase in arachidonic acid was attributed to an over activity of 
phospholipase enzymes [202]. 
 
Figure 3.12: Lysophosphatidylcholine Structure 
An example figure of a lysophosphatidycholine (LysoPC) molecule.  LysoPC consist of a 
choline head group and a single FA side chain.  They are formed by hydrolysis release of a 
FA from a PC. 
The ratio of total LysoPC to PC has been shown to significantly vary when 
comparing the CSF obtained from controls and AD patients, although no significant 
changes of total PC and LysoPC on their own were observed [247].   
Interestingly, LysoPC have also been demonstrated to enhance Aβ plaque 
formation by decreasing the required threshold for Aβ coagulation into fibrils, as 
well as enabling the increasing of Aβ fibril length [248].  As Aβ is one of the major 
protein deposits in AD brain, it perhaps is no surprise that abnormal LysoPC 
metabolism is therefore linked to AD.  This would lead to the hypothesis that an 
increase in LysoPC may occur in AD brain, and therefore result in an increase in 
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the deposit of Aβ plaques, however no current publication has reported this trend 
as yet. 
The results reported here from the LC-MS data set, present five possible LysoPC 
features, and nine PC features, suggesting these families of molecules as candidates 
for biomarkers of AD, which would complement those findings reported in 
previous publications. 
3.4.1.2 – Sphingomyelin and Ceramide 
As with PC and LysoPC, SPH species consist of a choline head group (Figure 3.13), 
and therefore also ionise in positive ionisation mode [249].  SPH are found in cell 
membranes, particularly those that make up the myelin sheath in neuronal cells, 
and is also thought to act as a secondary cell messenger [250]. 
 
Figure 3.13: Sphingomyelin Structure 
An example structure of a sphigomyelin (SPH) molecule.  SPH consist of a choline head 
group, and a FA sidechain.  SPH also consist of a sphingosine side chain alongside the FA. 
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CER are a molecular group that are structurally similar to SPH, but do not have the 
phosphocholine head group (Figure 3.14).  They have been shown to be detected 
by both positive and negative ionisation mass spectrometry [251]. 
 
Figure 3.14: Ceramide Structure 
An example structure of a ceramide (CER) molecule.  CER consist of a FA and a 
sphingosine.  Unlike SPH molecules, CER do not have choline head groups. 
SPH have been shown to vary in AD patients.  A study that utilised 31P NMR 
technology demonstrated a significant increase in SPH in brain samples of AD 
patients compared with controls [142].  These findings were complemented by those 
in a publication that identified significant increases of SPH in AD brain, particularly 
in the middle frontal gyrus (MFG) region.  Increases in SPH C16:0, C18:0, C22:0 and 
C24:0 were observed in the grey matter of the MFG regions.  No differences were 
reported in white matter.  Interestingly the paper also reported patient ApoE data, 
and found that the presence of the ε4 allele of the ApoE gene is not associated with 
irregular brain sphingolipid biochemistry, unless patients already had an 
underlying neurological disorder such as AD.  These suggest it is not just the 
polymorphism in the ApoE gene that contributes to abnormal lipid metabolism 
within the brain [252].  
This elevation in AD of SPH and metabolites is complemented by a publication 
reporting significantly increased SPH levels (p=0.003) in the CSF from individuals 
with prodromal AD compared with cognitively normal controls.   However, no 
changes in the CSF SPH levels between mild and moderate AD groups and 
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cognitively normal controls were observed [253].  This result of increased SPH in AD 
CSF was also reflected in another publication [254].  This suggests that brain 
variation of SPH is reflected in other biofluids other than brain, an important 
consideration when investigating candidate biomarker molecules. 
These findings appear to correlate to results published that suggest increased 
levels of plasma SPH correspond to a reduced rate of progression in AD, and a 
reduction in cognitive decline [255].     
Further work has also been reported in AD patient plasma with a non-targeted 
“shotgun” lipidomics designed study.  In shotgun lipidomics, lipid extracts undergo 
direct MS injection followed by statistical analysis. It was reported that eight SPH 
molecules, particularly those with 22 and 24 carbon atom side chains, significantly 
decreased (p=<0.05) in AD patient plasma.  Further to this two ceramide molecules 
(C16:0 and C21:0) were shown to significantly increase (p=0.05).  Interestingly the 
paper correlated these significant findings to two “categories” of AD, mild (MMSE 
>20) and moderate (MMSE <20) reporting a correlation for SPG C20:2 (p=0.003) 
and CER C25:0 (p=0.004) [193]. 
SPH metabolites have also come under investigation, with reported findings of 
abnormal sulphatide variation in AD brain.  Sulphatides are sulphated metabolites 
of galactocerebrosides, a form of glycosphingolipid, and are present in the central 
nervous system (CNS) as a component of the myelin sheath [159].  The publication 
reported a depletion of sulphatides of up to 93% in brain grey matter and up to a 
53% depletion in the white matter of autopsy confirmed AD brains compared with 
controls [160].  The same publication also examined a further group of SPH 
metabolites, CER that were reported to be elevated threefold in the brain samples 
of AD patients compared with controls [160].   
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Therefore SPH have been shown to generally increase in a variety of biofluids 
(brain, plasma and CSF) in patients suffering from AD.  Due to the differences in 
variation in metabolites of SPH molecules (CER elevated, Sulphatides depleted), it 
would suggest irregularities in particular metabolic pathways potentially playing a 
role in the pathogenesis of the disease, and/or perhaps general cognition. 
Some work has been published regarding these pathways in an attempt to identify 
any abnormal pathways in the disease.  He et al. [256] reported the levels of brain 
SPH and some of its metabolites, along with the activity of a number of lipid related 
enzymes.  The publication reported elevated activation of the enzymes acid 
sphingomyelinase (ASM) and ceramidase, leading to a reduction in SPH, an 
increase in CER as well as the elevation of the metabolite sphingosine, and the 
reduction of the metabolite sphingosine-1-phosphate.  The elevated ASM enzyme 
and reduced S1P levels in AD were highly correlated with the levels of Aβ and 
hyperphosphorylated tau protein. The publication also reported that the addition 
of Aβ to neuronal cell cultures mimicked the sphingolipid changes and induced 
apoptosis [256].  These findings suggest, that it is the presence of Aβ plaque deposits 
that result in the activation of the enzymes responsible for SPH metabolism, and 
therefore SPH markers could play a role as tracking AD progression and the 
progression of Aβ deposits. 
3.4.1.3 – Phosphatidylserines, Phosphatidylethanolamines and 
Lysophosphatidylethanolamines 
PS and PE are a class of phospholipid found as structural components of cell 
membranes.  PE (Figure 3.15a) make up approximately 20% of mammalian 
phospholipids, and importantly with regard to AD are found at high concentrations 
in cells of the CNS, particularly in the white matter of the brain, where they form 
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45% of all phospholipids [257]. PS (Figure 3.15c) make up approximately 3-15% of 







Figure 3.15: Example PE, PS and LysoPE Structures 
(a) An example structure of a phosphatidylethanolamine (PE) molecule.  PE consist of an 
ethanolamine headgroup, and two fatty acid sidechains.  (b) An example structure of a 
lysophosphatidylethanolamine (LysoPE).  LysoPE consist of an ethanolamine headgroup 
and a single FA sidechain. (c) An example structure of a phosphatidylserine (PS).  PS 
consist of a serine headgroup and two fatty acid sidechains.  
LysoPE (Figure 3.15b) are metabolites of PE that have undergone a hydrolysis 
reaction and a release of a fatty acid side chain.  LysoPE can also act as precursor 
molecules to PE, and therefore are also involved in PS biosynthesis [257]. 
PE and LysoPE have previously been shown to ionise readily in positive ionisation 
mode [236], whilst PE and PS have also both been shown to ionise in negative 
ionisation [258], and therefore appear in the appropriate preliminary identification 
tables presented previously. 
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Many examples exist of decreased PE in AD brain samples, with a decrease being 
observed in frontal and parietal cortex of AD patient brain compared with controls 
(p=<0.05) [246].  Further to this, a targeted method which employed an NMR 
analytical approach to brain samples described a significant reduction in PE 
(p=0.007) when comparing AD brain homogenates with age matched control 
samples, specifically in the superior temporal gyrus region of the brain (p=0.01) 
[142].  The same publication also identified a significant increase in the metabolite 
PE-plasmalogen (p=0.0006) [142].  This finding would suggest a possible 
abnormality in the metabolism of PE, resulting in decreased PE and increase 
metabolites of the cell membrane lipid. 
This result was reflected in an animal model study that employed an LC based 
method to analyse brain phospholipid levels. The study investigated the 
hypothesis that the accumulation of Aβ had a direct influence on the distribution of 
phospholipids within the brain.  In order to achieve this the group analysed 
phospholipid content including PE in transgenic mouse model of AD expressing 
both mutant hAPP and human PSEN-1 genes.  The results were compared with 
brains from wild-type mice after four months and nine months.  Results 
demonstrated a significant reduction in PE after nine months (p=<0.01), but no 
statistically significant changes were observed after four months [259].   
The study also reported significant decrease in PS species after nine months.  Again 
after four months, no significant differences were observed.  This would suggest 
that Aβ accumulation over the longer time period could be directly responsible for 
abnormal PE and PS levels in AD brain.. 
However, this result was not reflected in a study of human CSF comparing AD with 
controls, with no significant differences observed for PE species [254] providing 
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possible evidence that the physiological changes of PE species in the brain may not 
be detected in CSF. 
The previously discussed reports of decreased PS in mouse brain [142] contradicts 
that of a publication investigating various lipid fractions from human brain.  The 
study reported significant increases of a group of lipids it describes as serine 
glycerophospholipids, in membrane fractions from synaptosomes (p=0.0011) and 
a combination of glial and neuronal cell bodies (p=0.016).  Results regarding PE 
complemented those discussed above, with a significant decrease observed in both 
fractions in AD brain (p=0.0041 and p=0.0001) [260], suggesting potential 
differences between the disease in humans and corresponding mouse models. 
Work has been published investigating potential reasons for the decrease in PE 
species in AD brain with a recent article examining the role of the enzyme 
phosphatidylethanolamine-N-methyltransferase (PE-N-MT).  Findings reported 
that the activity of PE-N-MT was decreased in the frontal cortex of brain samples 
affected with AD [261].  PE-N-MT catalyses the synthesis of PC via the stepwise 
transfer of methyl groups to the amino head group of PE.  However, as can be seen 
from the literature previously published and reported here, generally PE species 
are reported to decrease in AD, as are PC species.  With this finding of PE-N-MT 
activity decreasing in AD, it would be expected that although PC may decrease, PE 
would not be transformed as rapidly and therefore may increase.  This would 
suggest a more complex imbalance occurring in AD brain than just the decrease in 
activity of PE-N-MT. 
Although it appears PE therefore may be able to play a role as candidate 
biomarkers in AD the majority of the work published reports PE as a total non-
specific value.  However, as with PC species, it would certainly be of interest to see 
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if any specific PE with particular fatty acid side chains is present at abnormal 
concentrations in AD.  It would appear from the findings presented here in Chapter 
3 that a number of different PE species are presented, suggesting expansion of the 
LC-MS screen may present further answers toward PE in AD. 
3.4.1.4 – Mono-, Di- and Tri-acylglycerol 
Acylglycerol are a family of lipids that consist of a glycerol head unit, and can 
contain one, two or three FA side chains, hence mono, di and tri-acylglycerol (MAG, 
DAG and TAG) (Figure 3.16).  They play a role in mammalian physiology as 
secondary cell signalling molecules, and are often an intermediate stage in PC, PE 
and PS synthesis and metabolism [262].  
They have all been shown to commonly ionise in positive MS [263], however 
negative ionisation has a low sensitivity and ionisation success and therefore is 
excluded from the results table. 
Acylglycerols are not as commonly linked to AD as the previously discussed 
phospholipids, however a few examples exist in the literature regarding the 
disease.  An investigation into the synaptic plasma membranes isolated from the 
cerebral cortex of adult rats reported findings that observed a non-significant 
reduction of DAG species after the introduction of Aβ peptides.  The paper 
concluded that the pathway being influenced by the Aβ was the degradation of PI, 
particularly those with side chain consisting of AA [264].  The paper presents 
evidence that the enzymes affected by Aβ are those in the Ca2+ and cholinergic 
receptor mediated pathways via phospholipase C.   








Figure 3.16: Mono-, Di- and Tri- acylglycerol Structures 
(a) An example of a monoacylglycerol (MAG) structure.  MAG consist of a single fatty acid 
sidechain and a glycerol headunit. (b) An example of a diacylglycerol (DAG) structure.  
DAG consist of two fatty acid sidechains and a glycerol headunit. (c) An example of a 
triacylglycerol (TAG) structure.  TAG consist of three fatty acid sidechains and a glycerol 
headunit 
Further studies into the enzyme pathways regarding acylglycerols have also been 
shown to alter in AD.  Differences in the activity of monoacylglycerol lipases (MAG-
Lip) and diacylglycerol lipases (DAG-Lip) were identified in specific brain regions 
when comparing AD brain to normal controls.   MAG-Lip was shown to decrease in 
activity in the nucleus basalis (p=<0.01), frontal cortex (p=<0.05), occipital cortex 
(p=<0.05) and hippocampus regions (p=0.01).  DAG-Lip activity decreased in 
nucleus basalis (p=<0.01) and hippocampus (p=<0.01), whilst it was increased in 
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the parietal cortex (p=<0.05) and occipital cortex (p=<0.05) [265].  This provides 
further support that a specific lipid metabolism pathway is affected in AD, and this 
suggests that MAG, and DAG molecules may have suitable properties enabling 
them to act as biomarker candidates, reflecting any pathway irregularities. 
As previously discussed in 3.4.1.2, a shotgun lipidomics approach was applied to 
plasma lipids in AD patients.  As part of this investigation TAG species were also 
investigated for alterations in AD, however no significant differences were 
reported between controls, mild AD (MMSE >20) and moderate AD (MMSE <20) 
[193]. 
Although major differences in MAG, DAG and TAG species in AD are not reported in 
the literature, the observations discussed above regarding enzymatic pathway 
abnormalities, combined with the results presented here, with five features 
returning DAG, or TAG putative identification, suggests that they should not be 
discounted at this stage. 
3.4.1.5 – Fatty Acids  
Fatty acids were discussed in great detail in Chapter 2, and are therefore not 
discussed here. 
3.4.2– Analytical Observations 
The LC-MS parameters used for the positive ionisation screen resulted in a 
reproducible chromatogram suitable for preliminary non-targeted biomarker 
discovery.  A 15 minute runtime provided 950 aligned features using the Waters 
MarkerLynx data processing package. 
In contrast, only a 10 minute analytical run was required for negative ionisation.  
This reduction in time is possible because of fewer species ionising in the negative 
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mode.  For example, the larger DAG and TAG do not ionise successfully, and 
therefore do not require separation time.  Using these parameters, the MarkerLynx 
data processing package aligned 420 features. 
In both ionisation modes, the MS analysis was set to record m/z from 50Da to 
1000Da.  The analysis was a general chromatographic method utilising a C18 
column and a wide ranging gradient that in both cases progressed from 30%B to 
100%B meaning that a variety of molecules with a range of structures, properties 
and polarities were catered for. 
In the pareto scaled PCA models both methods provided acceptable QC clustering, 
suggesting good overall reproducibility across the course of the analysis.  QC 
samples consisted of a pool of plasma extracted concurrently with the patient 
samples, and analysed at regular intervals throughout the LC-MS worklist.  As a 
PCA model is unsupervised, high quality reproducible runs will cluster.  This is 
because, in theory each extract will contain exactly the same molecular features as 
each one comes from the same identical pool.  This approach to ensuring non-
targeted analytical methods are reproducible is commonly used in a number of 
previous plasma based publications [266-268]. 
The chromatographic separation time of both the positive and the negative 
ionisation stages of the analytical procedure are similar to a previously published 
article, which was previously successfully used in the non-targeted analysis of 
plasma [230].  However, despite this, it can clearly be seen from the results Table 3.2 
and Table 3.4 that a number of features of influence in the multivariate models 
shared the same retention time.  A particular example of this is observed in Table 
3.3..  Two of the features which were reported to significantly decrease in AD 
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patient plasma had co-eluting retention times, with m/z 780.5578 and 806.5746 
eluting at 9.53 and 9.81 minutes respectively. 
Co-elution in LC-MS can cause detector effects, for example ionisation suppression 
or enhancement.  As features from the chromatographic separation elute off of the 
column they enter the MS source, where they become charged.  If an un-resolved 
mixture of molecules enter the source at the same time then they are competing 
for charge, and therefore ionisation effects can occur.  This effect may not always 
be consistent, and therefore may skew the data and subsequent analysis.   
It should, however, be noted that these in-source effects of co-eluting peaks are not 
necessarily always an issue, for example the publication adapted for use in Chapter 
2 [213] encountered no quantification issues when two of the analysed FA species 
co-eluted, and were able to report linear calibration ranges.  Furthermore an 
approach often taken in non-targeted biomarker strategies is direct infusion mass 
spectrometry where tissue extracts are directly injected into a MS source without 
prior chromatographic separation.  Although this obviously greatly increases the 
risk of ionisation effects, direct infusion has previously been successful in 
identifying plasma biomarker candidates for Alzheimer’s  disease, identifying 
significant differences in circulating plasma sphingolipids [193].  Further to this, 
direct infusion has been used in specific metabolite target driven methodologies, 
demonstrating abnormal concentrations of lipid plasmalogen, sulphatide and 
ceramide metabolites from Alzheimer’s disease brain samples [157, 160]. 
Despite these exceptions, general recommendations in the literature suggest an 
optimised LC separation in order to reduce any ionisation effects in the MS source 
[269, 270] and therefore, in order to improve the confidence in the reported findings 
of this screen, a longer analytical method with increased component separation an 
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therefore less co-elution was sought and developed.  The full details of this 
analytical development can be found in Chapter 4, and the results when applied to 
a high-throughput project discussed in Chapter 5. 
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3.5 – Conclusions 
An LC-MS screen was successfully completed comparing Control, MCI and AD 
plasma.  The multivariate data treatment highlighted a number of features of 
interest that progressed to putative identification using a combination of database 
matching combined with a number of rules employed to filter results.  Of these 
features three were of particular interest, as after univariate statistical analysis, 
significant reductions were reported.  These were 780.5578 (p=<0.001), 806.5746 
(p=<0.01) and 834.6026 (p=<0.01).  Of these two were also significantly reduced 
when comparing MCI with AD, 780.5578 (p=<0.05) and 834.6026 (p=<0.05).  
These were putatively identified as being PC or PE species, both of which have 
been heavily linked to AD previously, and therefore provided further investigation. 
From these it is clear that lipid species are the small molecule features most likely 
to be altered in AD pathology, particularly when considering it has been published 
that the common trend is that Aβ concentrations in the brain appear to correlate to 
lipid abnormalities [248, 256, 264].  This finding would suggest a possible role for 
biomarkers in AD, with the potential to track disease progression as Aβ 
accumulates. 
However, it is clear that although the employed method was suitable as a screening 
technique a number of co-eluting peaks occurred.  Therefore to support the 
findings with further evidence an improved method is required.  Further to this a 
larger sample set would also provide greater significance to any reported findings.   
With this in mind, a collaboration was proposed with the Centre for Metabolomics 
and Bioanalysis (CEMBIO) at the Universidad San Pablo in Madrid, Spain.  A six 
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month exchange project was undertaken with the aim of developing a lipidomic 
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Chapter 4:  
Comprehensive Lipidomics Method 
Development 
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4.1 – Introduction 
Due to the vast variations in the chemical properties of analytes, current 
methodology can only identify subsets of the metabolic content of biological 
samples.  Most comprehensive approaches use a combination of technologies, for 
example LC-MS, NMR and GC-MS.  For example, recent work by the previously 
mentioned HMDB project utilised these approaches to comprehensively profile 
human serum metabolites (<1500Da) resulting in the confirmation of 4600 
individual components [231-233]. 
Although this multi-pronged approach can provide a wealth of data, analysis time 
and cost are greatly increased.  However, perhaps of more importance in current 
biomarker research is the limitation of available biofluids, with valuable fluids at a 
premium.  Therefore, for the research field to progress efforts must be made to 
increase metabolite coverage within each analytical technique. 
LC-MS (along with NMR) is currently one of the main techniques used to profile 
metabolites from biological samples.  The technique can boast the benefit of on 
column separation of molecules prior to mass spectral analysis, ensuring it is able 
to provide a broad metabolic picture of the sample [271].  However issues still arise, 
for example components that are not fully resolved can undergo ion effects such as 
suppression or enhancement in the mass spectrometer source, meaning non-
separated components compete with one another for ionisation and therefore 
detection, which can lead to a reduction in selectivity and accuracy.  Further to 
this, matrix components, for example endogenous phospholipids, are a significant 
source of imprecision in analyses conducted by LC-MS/MS.  Present at relatively 
high concentrations, they are heavily associated with influencing ion suppression 
and enhancement effects, thus introducing analytical variation [272].  This is of 
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particular importance when considering the results reported in Chapter 3, which 
putatively identified a number of phospholipid classes as varying between AD, MCI 
and control groups, suggesting an improvement in extraction and separation 
would be valuable.  Therefore, an improved small molecule profile will provide 
valuable data on phospholipids and their interactions and roles in Alzheimer’s 
disease. 
Traditional LC-MS approaches to non-targeted metabolic fingerprinting typically 
tend to employ a simple protein precipitation extraction designed to remove 
protein, avoiding column degradation and blockage.  Following this, extracts are 
injected onto an LC system and analysed by a reversed-phase gradient [119, 273, 274].  
However, when utilising this general approach, the extremes of the metabolite 
spectrum are overlooked and potentially important biomarker candidates are lost.  
For example, highly polar compounds wash off in the solvent front of the 
chromatogram as they undergo little to no retention, whilst highly non-polar 
species can be insoluble in the extraction solvents used in metabolite studies, 
(methanol and acetonitrile are common), and are either not efficiently extracted or 
remain on column, unable to undergo elution. 
Increasing the metabolite coverage by optimisation of sample pre-treatment has 
been investigated previously.  For example, one recent publication by Yanes et al 
[275] examined a range of seven extraction protocols, combined with a range of 
modified chromatographic and MS detection methods.  The paper concluded that 
to extend the best range of extraction coverage an improved single-phase “all-in-
one” extraction was developed whereby the coverage of analysed molecules from 
E. Coli samples was increased.  The approach employed an extraction protocol 
using ethanol mixed with ammonium acetate, and found this combination of 
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extraction solvents to be most successful when extracting a mixture of polar and 
non-polar compounds.   
Conversely, a second approach in expanding the coverage of metabolite extractions 
can employ a combination of dual extractions, one designed for polar molecules, 
the other for non-polar has previously been reported [276].  In this investigation, a 
number of methods underwent comparison that either extracted polar metabolites 
prior to non-polar extraction, or used a two phase extraction using two solvents 
which are non-miscible and therefore separate (dichloromethane and methanol).  
Analysis was then completed via UPLC-MS with the findings suggesting that the 
optimal protocol for profiling both polar and non-polar metabolites utilised an 
aqueous extraction with water/methanol prior to an organic extraction with 
dichloromethane/methanol [276]. 
It is becoming more common in the literature for publications to focus on specific 
subsets of the metabolome, rather than attempting to cover it all in one extraction.  
For example, a major research area currently is termed lipidomics.  Lipidomics 
represents a subset of metabolomics, focused of the lipid fraction of tissues, and is 
becoming particularly prevalent in biomarker studies as a large number of disease 
states are associated with irregularities in lipid metabolism.  These include 
neurological diseases such as AD [142], schizophrenia [277] and Parkinson’s disease 
[278]; cardiac disease such as atherosclerosis [279]; viral infection [280] and bacterial 
infection [281]; as well as obesity [282] and type 1 [283] and type 2 [284] diabetes.  
Furthermore, it is well known that lipids play vital roles in cellular functions, 
including membrane regulation [285], source of reserve energy within vacuoles [286] 
and cell signalling transduction processes [287].   
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In addition to the challenges faced when considering approaches to take with 
sample extraction method development, it is also of critical importance that when 
extracting metabolites for fingerprinting, no “false” metabolites are introduced to 
the sample via the pre-treatment process.  A common known fact, which highlights 
this, is that unsaturated fatty acids and unsaturated lipid species can undergo 
oxidation when exposed to atmospheric conditions including UV light exposure 
combined with atmospheric oxygen [288].  Therefore care must be taken when 
drying or transferring any extracts, to avoid these modifications.  Again, other 
systematic errors introduced by extraction protocols such as loses when 
transferring sample between vials and tubes during extraction.  It stands to reason 
that, because of this, the more stages of transfer within a procedure, the more 
chances there are of introducing these errors. 
The results in Chapter 3 highlighted a number of non-polar lipid classes of 
particular interest from the models.  This information, combined with the ever 
increasing need of developing methods that expand the metabolite coverage of 
extraction approaches, lead to the development of a novel two phase metabolic 
fingerprinting method.  The method developed here produces both a lipophilic 
non-polar extract, combined with a hydrophilic polar extract from 20µL of plasma.   
The complete extraction and analysis was designed to be completed within the 
same LC-MS vial, therefore reducing extraction steps and analytical variation.  Each 
phase was individually analysed using LC- MS, using an optimised gradient for the 
metabolites present in each layer.  The method was designed to increase the 
component coverage from a small sample aliquot and to improve the 
reproducibility of the overall process.  Further to this, metabolites remain 
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constantly suspended in solution; therefore reducing the risk of modification due 
to external influences such as drying loses. 
The method was named “in-vial dual extraction” (IVDE), a direct injection 
metabolic fingerprinting method which both increases metabolite coverage whilst 
decreasing the analytical variability, making it ideal for comprehensive metabolic 
profiling and biomarker discovery.  In addition, particular relevance was placed 
upon the upper phase of the extraction, as it specialises in non-polar lipid 
components, making it an ideal tool to analysis an extended AD sample set, 
reducing the limitations encountered in Chapter 3. 
The developed method presented here in Chapter 4 consists of two major 
components.  The first stage of progression focused on the method development 
and employed human plasma from healthy volunteers.  The in-vial approach was 
designed to improved reproducibility and therefore underwent comparison with a 
traditional style approach involving vial transfers, evaporation to dryness, and re-
suspension in mobile phase. 
Once the method development was completed, it underwent a validation 
procedure.  When developing a novel biomarker method it is useful to demonstrate 
its successful implementation in a sample set of known major metabolic 
irregularities.  If the method can not determine known differences, it is unlikely 
that it will be of use in an unknown sample set.  Therefore a sample set of animal 
models for diabetes was employed as it is widely accepted that metabolic 
differences, particularly in lipid metabolism, are widely apparent, and therefore, 
should be a suitable test set in order to validate the method.  An overview of the 
investigation can be observed in Figure 4.1.  
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Figure 4.1: Overview of Chapter 4 Progression 
The above figure presents the progression of the IVDE method development, and the tests 




•Selection of extraction solvents
•Methyl-tert-butyl-ether was selected over chloroform due to its density








fused core particle column selection for the upper non-polar phase 
enabled the reduction of both run time and column temperature
Validation 
Comparison 1
•Comparison of the novel IVDE method against traditonal evaporation of 
extraction solvent  and re-suspension in mobile phase
•Observation of improved extraction reproducibility using IVDE method
Validation 
Comparison 2
•Comparison of novel IVDE method against a previously published and 
accepted  non-targeted LC-MS precipitate and inject method
•Observation of improved metabolite coverage using IVDE method
Validation 
Comparison 3
•Comparison of novel IVDE method against precipitate and inject 
method in a biomarker study
•Observation of an increased number of biomarker candidates 
putatively identified in database matching
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4.2 – Materials and Methods 
4.2.1 – Materials 
Ultrapure water, used to prepare all the aqueous solutions was obtained from an in 
house Milli-Q+ 185 filtration system (Millipore, Billerica, MA, USA).  LC-MS grade 
methanol, acetonitrile and analytical grade formic acid were purchased from Fluka 
Analytical (Sigma-Aldrich Chemie GmbH, Steinheim, Germany).  Analytical grade 
ammonium hydroxide was acquired from Panreac Quimica SA (Barcelona, Spain) 
and analytical grade methyl-tert-butyl-ether (MTBE) was from Sigma-Aldrich 
Chemie GmbH (Steinheim, Germany).  A C15 triacylglycerol (tripentadecanoin) 
with m/z 764.6894 (C48O6H92) purchased from Larodan Fine Chemicals AB 
(Malmö, Sweden) was used as an internal standard.  Chromacol 03-FIV HPLC vials 
with fixed 0.3mL glass inserts (Chromacol - Welwyn Garden City, UK) were chosen. 
4.2.2 – Instrumentation 
The analysis was completed using an HPLC system (1200 series, Agilent 
Technologies, Waldbronn, Germany) coupled to an Agilent MS (6520 series, 
Agilent Technologies, Waldbronn, Germany) equipped with an electrospray 
ionisation source.  The HPLC system consisted of a degasser, two binary pumps, 
temperature controlled autosampler and column oven.  During all analysis two 
reference m/z were used: m/z 121.0509 (C5H4N4) and m/z 922.0098 
(C18H18O6N3P3F24) for positive ionisation mode and m/z 112.9856 (C2O2F3(NH4)) 
and m/z 1033.9881 (C18H18O6N3P3F24) for negative mode.  These m/z are 
continuously infused to the system to allow constant mass correction.   
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4.2.3 – Samples 
The extraction method and analytical conditions for analysis were developed using 
human plasma from a healthy volunteer.   
The study designed to test the biomarker discovery capabilities of the obtained 
method was performed using rat plasma from streptozotocin (STZ) diabetic and 
control (age and sex matched).   
Sprague-Dawley male rats, 12 ± 2 weeks of age, from the animal quarters of 
University San Pablo-CEU, were used.  Throughout the experiments the animals 
were kept in collective cages (less than 7 animals per cage) and controlled 
conditions (22 ± 2 ºC and 55 ± 10% relative humidity).  Animals had free access to 
tap water and diet (Harlan Global Diet 2014, Harlan Interfauna Ibérica, Madrid, 
Spain). 
Samples were obtained from rats that came from two experimental groups: 
Animals that received an intraperitoneal dose (50 mg/kg, dissolved in 50mM 
citrate, pH=4.5) of streptozotocin and showed blood glucose levels over 200mg/dL 
4 days after treatment (diabetics, D; n=9) were sacrificed at 14 days after the STZ 
administration.  Sex and age-matched rats that did not receive STZ were studied in 
parallel (controls, C; n=7). 
The experiments were approved by the Ethical Committee of the University San 
Pablo-CEU and they are in agreement with Amsterdam Treaty and Spanish 
legislation (RD 223/1988). 
More information can be found and the same animal models used as in the 
publication [289]. 
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4.2.4 – Sample Extraction Methods 
The novel IVDE method underwent a comparison with two further traditional 
extraction approaches, to investigate if an in-vial approach improved 
reproducibility across an analytical run. 
4.2.4.1 – Sample Extraction Method 1: In Vial Dual Extraction Followed by 
Direct Injection to Liquid Chromatography-Mass Spectrometry 
The IVDE method uses MTBE as an organic phase solvent, originally presented as 
an alternative to the commonly used chloroform by Matyash et al. [217].  During this 
procedure the whole plasma extraction and separation of the two phases (ether 
and water) was performed within a HPLC vial (Figure 4.2).  The volumes of the 
method were adapted to suit the size of the vial inserts.  20µL of plasma was mixed 
with 10µL of MilliQ water.  Proteins were precipitated with 40µL of methanol and 
vortex-mixed for 2 min.  Then 200µL of MTBE containing 10µg/mL of internal 
standard (TGC15) were added, prior to mixing of the whole mixture via vortex at 
room temperature for one hour.  After adding 50µL of MilliQ water, the sample was 
mixed and centrifuged at 3,000g for 10 min.  The upper MTBE and lower 
methanol-water phases were then injected onto the LC-MS system directly from 
the vial by adjustment of the instruments needle height in two separate runs, at 5 
or 15 mm from the bottom (positions -5 and +5 in the autosampler settings), with 
the same drawing and ejecting speed (200 µL/min). 
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Figure 4.2: In Vial Extraction Overview 
A schematic diagram of the in vial extraction.  20µL of plasma is added to the vial, followed 
by water, methanol and ether.  After centrifugation the final result can be seen in the 
above three layers. 
1) Upper phase consisting of ether containing the non-polar compounds, 
particularly lipids 
2) Lower phase consisting of water containing the polar compounds 
3) A solid pellet consisting of precipitated protein 
Layers 1 and 2 can then progress to LC-MS analyses specialised for each phase.  Injection 
onto the LC-MS is achieved by adjusting the needle height of the autosampler, and 
therefore removes any requirement for the extraction to undergo any transfer or drying 
stages. 
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4.2.4.2 – Sample Extraction Method 2: Ether Extraction, Evaporation and Re-
Suspension in Traditional Liquid Chromatography Compatible Solvents 
Traditional extraction methods often involve the transfer of sample between 
extraction and LC-MS vials, as well as the evaporation of extraction solvent, 
followed by the re-suspension in a typical LC-MS compatible solvent.  Therefore a 
study was designed in order to compare this traditional approach with the 
developed IVDE method, to see if removal of transfer, evaporation and re-
suspension stages of the extraction improved overall reproducibility. 
The use of MTBE as an extraction solvent was previously presented as a solvent 
suitable for lipid extraction by Matyash et al [217], however, described here is the 
method was adapted for use within an LC-MS sample vial.  To summarise, 20µL of 
plasma was added to glass tubes along with, 10µL of MS-grade water and 40µL of 
MS-grade methanol prior to a vortex-mix for 2min.  Following this 200µL of MTBE 
(containing 5µg/mL internal standard) was added.  The capped tube was vortex-
mixed for 1hour, 50µL MS-grade water was added and vortex-mixed for 2min.  
Tubes were centrifuged at 3000g for 10min.  From the upper phase 50µL of MTBE 
was removed and transferred to new glass tubes.  Samples were evaporated to 
dryness at 35°C in a vacuum evaporator (Thermo Fisher Scientific, Waltham, MA, 
USA) and finally re-suspended (vortex for 2min) in 50µL of isopropanol (IPA), 
before being transferred to a HPLC vial and injected onto the LC-MS system. 
4.2.4.3 – Sample Extraction Method 3: Precipitate and Inject  
Precipitation of protein using an organic solvent such as methanol or acetonitrile is 
a widely accepted and used approach in non-targeted metabolite profiling.  
Therefore, a previously published precipitate and inject method was applied to the 
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same plasma pool as a comparative control to observe if the IVDE method 
increased metabolite coverage. 
The extraction method has been previously described and employed for the 
purpose of plasma metabolic fingerprinting, and therefore is an ideal comparison 
tool [274, 289].  This method consisted of protein precipitation with 3 volumes of cold 
(maintained on ice) methanol:ethanol mixture (1:1) to 1 volume of plasma.  
Samples were vortex-mixed and then incubated on ice for 5 min, and centrifuged at 
3000g at 4°C for 20min.  Collected supernatant was filtered through a 0.22µm 
nylon, syringe filter and passed to a HPLC vial for the analysis.   
4.2.5 – Instrumental Conditions 
Two sets of instrumental conditions were used for the comparisons.  The first was 
specifically designed for the non-polar upper ether phase.  It was used to compare 
the IVDE method 1, described in Section 4.2.4.1, with the evaporation and re-
suspension method 2, described in Section 4.2.4.2. 
The second set of conditions has previously been published [274, 289] alongside the 
precipitate and inject extraction.  The method consists of a typical reversed-phase 
gradient employed to cover a wide range of polarities.  In the comparison study 
reported here, the analytical set up was employed to analyse the extracts from the 
precipitate and inject method as a comparative control.  The method was also used 
to analyse the lower water phase from the IVDE extraction method as a tool to 
expand overall metabolite coverage.   
4.2.5.1 – Instrumental Condition Set 1 – Non-Polar Upper Ether Based Phase  
Analysis was completed at 60°C using an Agilent Poroshell 120 EC-C8 column (150 
x 2.1mm, 2.7µm).  A gradient was employed consisting of mobile phase A (10mM 
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ammonium formate in MilliQ water) and mobile phase B (10mM ammonium 
formate in methanol) pumped at 0.5mL/min.  Initial conditions were 75%B, 
increasing 96%B in 23min.  This was then held until 45min.  The gradient then 
increased to 100%B by 46min and held until 50min.  Starting conditions were 
returned by 51min and a 9min re-equilibration time was included taking the total 
run time to 60min.  Chromatographic conditions were previously optimised as 
described below. 
Mass spectromic detection was performed in both positive and negative ESI mode 
in full scan from 50 to 1200 m/z.  The mass spectrometer source conditions 
consisted of a capillary voltage of 3500V (positive mode) or 4500V (negative 
mode), whilst both ionisation modes used a scan rate of 0.2 seconds per scan, a 
nebulizer gas flow rate of 10.0L/min, a source temperature of 350°C and a source 
pressure of 40psig.  The same instrumental conditions were applied when 
comparing the evaporation method described above 
4.2.5.2 – Instrumental Condition Set 2: Polar Lower Water Based Phase and 
Traditional Precipitate and Inject  
Conditions were as previously described [274, 289]: 10µL of extracted sample was 
injected onto a reversed-phase C18 column (Discovery HS C18 150 x 2.1mm, 3µm; 
Supelco) with a guard column (Discovery HS C18 20 x 2.1mm, 3µm; Supelco).  
Separation was performed in 40°C at the flow rate 0.6mL with solvent A composed 
of water with 0.1% of formic acid, and solvent B consisted of acetonitrile with 0.1% 
of formic acid.  Metabolites were eluted using general gradient started from 25% B 
to 95% B in 35 min, and returned to initial conditions in 1 min, with 9 min re-
equilibration time.   
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Mass spectromic detection was completed in both positive and negative ESI mode 
in full scan from 50 to 1000 m/z for positive mode and from 50 to 1000 m/z for 
negative mode.  The capillary voltage was accordingly 3kV for positive polarity and 
4kV for negative ionisation.  Scan rate of 0.2 seconds per scan, and nebulizer gas 
flow rate 10.5L/min, temperature 325°C, pressure 52psig were the same for both 
ionisation modes. 
4.2.6 – Data Treatment 
Data from all analytical runs were processed and treated in the same manner, to 
ensure comparison between methods was consistent. 
The raw data collected by the analytical instrumentation were cleaned of 
background noise, and unrelated ions by the Molecular Feature Extraction tool in 
the MassHunter Qualitative Analysis Software (B.04.00, Agilent Technologies).  The 
MFE algorithm uses the accuracy of the m/z measurements to group ions related 
by charge-state envelope, isotopic distribution, and/or the presence of adducts and 
dimmers.  The MFE then creates a listing of all possible components as represented 
by the full MS data.  Each compound is described as a feature and contains m/z, 
retention time and abundance. 
For data extraction the pre-set “small molecules (chromatographic)” algorithm 
was applied, with 200 counts as a limit for the background noise.  In addition, the 
algorithm was set to find co-eluting adducts of the same feature.  For this, adduct 
settings were applied for the lower aqueous phase (+H, +Na, +K, neutral loss of 
water) in positive ionisation and (-H, +HCOO) for negative ionisation.  Due to the 
ammonium formate in the mobile phase, for the upper lipid phase the adduct 
settings (+H, +Na, +K, neutral loss of water, +NH4) for positive ionisation applied 
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and (-H, +CH3COO) for negative ionisation were applied.  For the upper phase the 
option for “salt dominated ion” was also applied. 
Due to subtle retention time shifts, samples need alignment to ensure the same 
metabolite is listed as the same feature within each sample analysis.  Therefore 
samples were aligned using MassProfiler Professional (B.02.01, Agilent).  
Alignment applied retention time correction as well as correction of the m/z.   
To filter the data matrix from background signals and data Agilent’s filter by 
frequency algorithm was applied.  The process works by filtering only those 
features present in all samples per group.  For example in a disease classifier study, 
the feature must be present in all controls or all disease samples to be included for 
further analysis.  The theory behind this approach is that sporadic features which 
are only in one or two samples have increased likelihood that they are background 
or an exogenous compound present in a test tissue. 
In the “Comparison 3” study between control and diabetic rats, univariate data 
analysis was completed to identify those features that vary significantly between 
groups.  After logarithmic transformation student´s t-test (p ≤ 0.05) was competed. 
4.2.7 – Databases for identification 
Metabolites were identified by searching by m/z against the online available 
databases such as the METLIN [234], HMDB[231-233], and the Mass Translator into 
Pathways (MassTRIX) database [290].  For the database search the error mass used 
for was adjusted to 7 ppm.  
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4.3 – Results 
4.3.1 – Comparison One 
4.3.1.1 – In Vial Dual Extraction Compared with Evaporation and Re-
Suspension 
Initially a comparison was completed between the novel IVDE approach and a 
more typical approach which involves removal of the extraction solvent via 
evaporation and replacing it with a conventional LC-MS compatible solvent such as 
methanol, acetonitrile or isopropanol.  More on this selection of solvent is 
examined in the discussion (Section 4.4.1 (Page 183)). 
The results from the comparison are presented in Table 4.1 and can be visualised 
in Figure 4.3.  It can clearly be seen from the table that the IVDE method is more 
reproducible.  Initially it can be seen that the total number of features in all 
samples (n=3) is increased in the IVDE method (2280 compared with 603).  
Further to this the number of features exhibiting a lower %RSD between extracts 
is also increased, for example the number of features with a %RSD <5 were 821 for 
IVDE, but only 86 for evaporation and re-suspension.  In addition, an increase in 
both total signal and total useable signal can also be observed. 
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 Parameter IVDE Evaporation  
 Number of features present in all 
samples 2280 603 
 
 RSD<30% 1912 338  
 RSD<20% 1738 280  
 RSD<10% 1358 182  
 RDS<5% 821 86  
 RSD<30% [%] 83.86 56.05  
 RSD<20% [%] 76.23 46.43  
 RSD<10% [%] 59.56 30.18  
 RDS<5% [%] 36.01 14.26  
 TS 2.95E+09 2.24E+09  
 TUS 2.88E+09 1.95E+08  
Table 4.1: Comparison 1: In Vial Dual Extraction and Evaporation/Re-Suspension 
The above table displays the results from the comparison between the IVDE method (upper 
ether phase only) and the traditional evaporation and re-suspension method when used to 
extract the same pool of human plasma (n=3).  The apparent compatibility of the MTBE and 
LC-MS allowed the direct injection of the extraction solvent for analysis.  The data are for 
positive ionisation detection only. 
The improvement in reproducibility can clearly be seen, with both more features in all 
samples and more features present at a lower %RSD in the direct injection method.  Further 
to this an increase in both total signal and total useable signal can also be observed. 
TS (total signal): sum of signals for all features detected in all replicates.   
TUS (total useful signal): sum of signals only for features common for all three samples.   
[%]: percent of features with expected RSD among number of features present in all samples. 
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Figure 4.3: Comparison of In Vial Dual Extraction and Evaporation/Re-Suspension 
The above figure highlights the comparison between the IVDE extraction (upper ether 
phase only) and the traditional evaporation and re-suspension method when used to 
extract the same pool of human plasma (n=3). 
A) Extracted compound chromatograms (ECC) for IVDE (blue) and for the evaporation 
approach (grey).  The increase in overall signal can be seen for the blue IVDE method. 
B) LC-MS feature map of data collected using the IVDE method.  An LC-MS feature map is 
a visual plot of m/z (y-axis) and retention time (x-axis).  Each feature is coloured by 
frequency of detection in each of the three plasma replicates.  (Red = 1, Orange = 2, 
Yellow = 3). 
C) LC-MS feature map of data collected using the evaporation and re-suspension 
approach. 
From this figure, reproducibility for IVDE can be seen, with greater signal intensities in (A) 
and more yellow features on the feature map of IVDE (B), suggesting improved extraction 
reproducibility. 
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4.3.2 – Comparison Two 
4.3.2.1 – In Vial Dual Extraction Compared with Precipitate and Inject 
To further test the capabilities of the IVDE method, it underwent comparison 
alongside a previously published precipitate and inject method [274, 289].  Particular 
interest in this instance was on the total number of features extracted from each 
method. 
The IVDE approach consisted of two phases, and underwent MS analysis in 
positive and negative ionisation.  The precipitate and inject approach only 
consisted of the single phase, but was also analysed using positive and negative 
ionisation. 
The improvement in the metabolite coverage when using the IVDE extraction can 
be observed in Table 4.2.   
In positive ionisation detection, 3636 reproducible features were observed in the 
upper and lower positive ionisation phase of the IVDE, with only 1020 features 
observed in the precipitate and inject method. 
More features are also observed in the IVDE combined approach in negative 
ionisation, with 826 features, compared with 636 in the precipitate and inject 
method. 
The two extraction methods were also compared by the number of features that 
returned database hits following a search.  Again it can be seen that an increase is 
apparent in the IVDE approach, with 1425 (positive) and 314 (negative) features 
observed, compared with 493 (positive) and 283 (negative) in the precipitate and 
inject method.  
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Parameter 
IVDE (Both Phases) Precipitate and Inject  
 Positive Negative Positive Negative  
 Features present 
in all samples 
3636 826 1020 636  
 RSD<30% 3120 696 916 418  
 RSD<20% 2762 556 852 310  
 RSD<10% 1738 348 698 126  
 RDS<5% 637 210 489 38  
 RSD<30% [%] 85.81 84.26 89.80 65.72  
 RSD<20% [%] 75.96 67.31 83.53 48.74  
 RSD<10% [%] 47.80 42.13 68.43 19.81  
 RDS<5% [%] 17.52 25.42 47.94 5.97  
 Features 
identified 
1425 314 493 283 
 
Table 4.2: Comparison 2: In Vial Dual Extraction and Precipitation and Injection 
The above table displays the results from the comparison between the IVDE method and 
the previously published precipitate and inject method when used to extract the same 
pool of human plasma (n=3). 
The improvement in the metabolite coverage can be observed from the table with 3636 
reproducible features observed in the upper and lower positive ionisation phase of the 
IVDE, and only 1020 features in the precipitate and inject method. 
More features are also observed in the IVDE combined approach in negative ionisation, 
with 826 features, compared with 636 in the precipitate and inject method. 
The Features Identified row represents those features that returned a database search hit.  
Again it can be seen that an increase is apparent in the IVDE approach. 
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4.3.3 – Comparison Three 
4.3.3.1 – In Vial Dual Extraction Compared with Precipitate and Inject in a 
Non-Targeted Biomarker Discovery Study 
In order to ensure the IVDE method performed well in a realistic biomarker 
discovery scenario, it underwent a validation investigation using control rat 
plasma along with diabetic rat plasma. 
The results of which were run in parallel with the previously published precipitate 
and inject method [273, 274]. 
The analysis using the IVDE extraction method produced more reproducible 
features present in all samples, in both positive and negative ionisation detection 
modes.  Following this filtration of features present in all samples, the features 
underwent univariate analysis, via means analysis with student’s t-test.  Again the 
IVDE method produced more significant features in both positive and negative 
ionisation MS detection modes. 
Finally the significant features underwent analysis using the MassTRIX pathway 
generator [290].  The algorithm analyses the m/z and produces a model metabolic 
map.  Following this MassTRIX pathway search algorithm, once again the IVDE 
method returned a higher number of significant than the precipitate and inject 
approach.  
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Parameter 
IVDE (Both Phases) Precipitate and Inject  
 Positive Negative Positive Negative  
 
Features present 
in all samples 




536 165 140 79  
 Identified features 293 102 99 72  




13 16 11 5  
Table 4.3: Comparison 3: In Vial Dual Extraction and Precipitation and Injection  
The above table displays the results form a comparison between the novel IVDE method 
and the precipitate and inject method when applied to a biomarker discovery scenario.  
Plasma from control (n=6) and diabetic (n=6) rats underwent analysis by both methods.  
Features were filtered and had to be present in all samples.  An increase in the number of 
features was observed when using the IVDE method. 
Following univariate data analysis the number of significant (Welch’s t-test) features that 
differentiated between control and disease groups also increased using the IVDE method. 
Features also underwent analysis using the MassTRIX pathway translator [290]; again more 
pathways of interest were observed using the IVDE method. 
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Figure 4.4: Overview of Finalised Chromatography 
The above figure presents chromatograms from each of the IVDE extraction phases.  Both 
positive and negative ionisation chromatograms are presented. 
The schematic displays the IVDE method with two different specialised chromatographic 
conditions and two polarity modes.  Extracted compound chromatograms (ECC) are 
displayed for  
A) Upper phase analysed in positive mode  
B) Upper phase analysed in negative mode.   
C) Lower phase analysed in positive mode 
D) Lower phase analysed in negative mode.   
Chromatograms in grey are representative for controls whilst those in blue are for diabetic 
rat model plasma.   
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4.4 – Discussion 
IVDE extraction consists of adding two non-miscible solvents to 20µL of plasma in 
a 300µL vial insert.  The procedure leads to a separation of analytes that disperse 
into either phase, meaning successive re-extractions with solvents of different 
polarities will not be necessary to improve the detection of less polar compounds.  
Two different chromatographic methods optimised for each type of metabolites 
were employed with the aim of decreasing matrix effects, increasing resolution 
and improving compound identification.   
4.4.1 – Selection of Solvents for In Vial Dual Extraction 
The IVDE method selected MTBE as extraction solvent over a number of published 
alternatives, especially the more commonly accepted Folch method [291], due to its 
density and polarity.   
The Folch method is a widely accepted gold standard of lipid extraction that 
employs chloroform as an organic solvent.  Figure 4.5 demonstrates the advantage 
of using the MTBE based extraction employed in the IVDE approach compared 
with the Folch chloroform extraction.  Importantly, the MTBE method produces 
two layers of solvent above the protein precipitate, which forms a solid pellet of 
protein in the base of the vial.  This is in contrast to the traditional Folch lipid 
extraction, which results in the lipid phase sitting below the floating protein 
precipitate.  Traditional analysis of this dense phase requires careful collection, 
following the removal of both the upper aqueous and protein layers.  When 
working with small volumes, such as the IVDE method described here (20µL of 
plasma is required) this is a delicate operation increasing the risk of analytical 
errors and the introduction of variation. 
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As previously described above, the IVDE method results in a protein pellet at the 
base of the vial.  This enables the easy injection of the two phases, whilst removing 
the risk of column blockages caused by the precipitate.   
 
Figure 4.5: Solvent Dispersion in Extraction Using Ether or Chloroform 
The above schematic view demonstrates the resulting phase dispersion after the 
completion of the novel IVDE and the classical Folch procedure.  The IVDE method 
employs methyl-tert-butyl-ether (MTBE), whilst the Folch procedure utilises the more 
dense chloroform to extract lipid components. 
On the left IVDE example, the lipid containing MTBE layer is the top most phase, enabling 
easy analysis.  A further important aspect of the procedure is the fact that the protein 
forms a solid pellet at the bottom of the extraction vial.  This enables the direct injection 
onto LC-MS analytical systems, as the risk of protein injection and therefore blockages 
within the LC-MS system is removed. 
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The ether extraction method was first described by Matyash et al [217] and has been 
extensively tested against the Folch method resulting in comparable if not 
favourable extraction recoveries.   
A further advantage of the completion of the extraction using the method 
described here was that MTBE was found to be suitable for direct injection onto 
the LC-MS gradient.  Traditionally, the injection of 100% organic solvent is not 
advised when completing LC separation due to the adverse effect it can have on 
early eluting peaks.  However, as the separation described here is completed over 
the course of an hour long gradient, the direct injection of MTBE was found to have 
no effect on the reproducibility and separation achieved.  This observation 
included the early eluting peaks.  Therefore in using MTBE as an extraction solvent, 
not only is the extraction method and collection procedure simpler, but it removes 
a drying and re-suspension stage from the protocol, reducing the risk of drying 
losses, analytical variation, and potentially oxidative conditions to dried 
unsaturated lipid species, such as UV light and atmospheric oxygen exposure. 
Arguably the greatest benefit to using the described IVDE extraction is the ability 
to complete the extraction and analysis in one simple in-vial procedure.  It was 
found that by adding the plasma and extraction solvents to a capped LC vial the 
extraction could be completed prior to direct injection.  The ability to manually 
adjust the injector needle enabled both the upper and the lower phase could be 
directly injected onto column in separate runs.   
4.4.2 – Development of Liquid Chromatography – Mass Spectrometry 
Specific LC-MS methods and parameters were developed for each extraction phase 
of the IVDE method.  These are discussed in detail below: 
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4.4.2.1 – Upper Phase of the In Vial Dual Extraction 
A selection of different columns, gradients and temperatures were tested to 
optimise the chromatographic separation for the upper phase.  Starting conditions 
were adapted from Sandra et al [292].  Chromatographic methods were compared by 
injecting the same extract onto the LC-MS analytical set up.  Resulting 
chromatograms from the method development process were compared in terms 
of: 
• Visual inspection of chromatograms looking at the intensity of the signal, 
number and aspect of the peaks;  
• The total number of features obtained following feature extraction and 
alignment 
• The number of features extracted, aligned and observed in every sample of 
a triplicate series of injections; 
• The relative standard deviation (%RSD) of those features present in each 
sample of a triplicate injection to check method repeatability;  
• The quality of the separation for two phospholipids: PE(36:2) and PC(34:1) 
that differ in m/z by 0.0364 Da to inspect chromatographic resolution.  This 
approach was previously employed in the previous publication by Sandra et 
al [292];  
• The number of features identified in a database search to test the biological 
usefulness of the method; 
Figure 4.6 summarises initial and final conditions as well as the extracted 
compound chromatograms (ECC) (Figure 4.6, panels A, C and E) and extracted ion 
chromatograms (EIC) showing PE(36:2) and PC(34:1) traces (Figure 4.6, panels B 
and D).   
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A number of modifications were made from the original conditions.  The most 
significant of which was the change in column stationary phase particles from 
totally porous to fused core with a porous outer layer. 
The use of superficially porous stationary phases can provide a number of 
advantages.  These are highlighted in Figure 4.7.  As can be seen in the figure, fused 
core stationary phases reduce the dispersion distance of analytes, therefore 
helping to reduce band broadening and to improve peak shape and resolution. 
A second advantage of the phase is due to the design of the solid core.  This enables 
a more uniform peak shape, and therefore improves its packing within the column, 
helping to remove dead volumes and voids.  Again, this can lead to improved peak 
shape, and an increase in resolution.  
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Figure 4.6: Chromatographic Development Overview 
Figure on previous page. 
Initial and optimised chromatographic conditions for the IVDE upper phase extract of 
human plasma.   
A) Extracted Compound Chromatograms (ECC) for initial conditions in positive 
ionisation mode.  The conditions employed a Supelco Ascentis® Express column 
with a C18 stationary phase.  The overall runtime was 85min. 
B) Extracted Ion Chromatogram (EIC) for PE(36:2) and PC(P-34:1) when using the 
starting conditions in (A)  
C) ECC for the final optimised conditions in positive ionisation mode.  The final 
conditions employed an Agilent Poroshell® column with a C8 stationary phase.  
The overall runtime was reduced from the original conditions to 60min.   
D) EIC for PE(36:2) and PC(34:1) when using the optimised conditions in (C)  
E) ECC for optimised conditions in negative ionisation mode.  The same 
chromatographic conditions were used for both ionisation polarities, and again an 
Agilent Poroshell® column with a C8 stationary phase was used for the separation. 
F) Enlarged C  
G) Enlarged E 
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Figure 4.7: Schematic Comparison of Fused Core Stationary Phases 
The above figure demonstrates the key differences between traditional porous LC 
stationary phase particles and those stationary phases that consist of superficially porous 
particles. 
The superficially porous particles are manufactured by applying typical stationary phase 
to a solid inner particle.  The advantage of this is a reduction in the distance that analytes 
have to disperse through the stationary phase.  This can lead to a reduction in band 
broadening, and lead to improved peak shape and resolution  
A further advantage of the fused core approach is a more uniform particle size, which 
enables better stationary phase packing, and reduction of void volumes, again improving 
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A further modification to stationary phase selection was made via a switch to a C8 
phase.  These changes combined enabled the reduction of column temperature 
from 75ºC to 60ºC, whilst still providing an efficient separation of lipid features, 
protecting the column lifetime.  Further to this, the optimised gradient developed 
on the C8 phase enabled a reduction in the overall runtime from 85 to 60min. 
For the LC-MS analysis of the IVDE lower phase analysis, a gradient with reversed-
phase chromatography previously optimised for total plasma [273, 274] was 
employed under the hypothesis that after eliminating non-polar compounds, ion 
suppression would decrease and a higher number of compounds could be 
identified with an appropriate sensitivity and reproducibility.  Furthermore, the 
method has performed well when analysing the polar compounds of urine [289].   
4.4.3 – Comparison One  
4.4.3.1 – In Vial Dual Extraction Compared with Evaporation and Re-
Suspension 
Once the chromatographic conditions were optimised, a separate experiment 
compared a direct injection of the IVDE upper phase with a traditional transfer, 
evaporation and re-suspension approach common in many profiling methods [292]. 
Reproducibility of both methods was examined by comparing the RSD% values for 
features detected in all three replicate extractions of the same plasma pool.  Table 
4.1 clearly demonstrates a higher number (378% increase) of molecules extracted 
using the IVDE method with an acceptable RSD% value compared with the 
evaporation approach. 
Other comparison parameters which were used to examine the methods were: 
Total Signal (TS), which is the sum of signals for all features detected in all three 
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replicates, and Total Useful Signal (TUS), being the sum of signals only for those 
common features which are found in all three sample replicates.   
The TS obtained with both type of sample treatments is relatively similar, with 
little difference between the two, whilst the TUS differs significantly (Figure 4.3).  
The difference between TS and TUS is very small for the IVDE approach, but for the 
evaporation method the difference is comparatively large, further confirming the 
superior reproducibility of sample treatment when performing IVDE direct 
injection. 
Due to the observations in the results, the benefit of completing the IVDE method 
as opposed to a typical evaporation and re-suspension is thought to be a result of 
the reduction of sample preparation steps, and therefore reducing the number of 
instances that variation can be introduced to samples.  The approach also avoids 
drying and transfer losses, however the exact reason of this loss of metabolites is 
difficult to identify. 
4.4.4 – Comparison Two  
4.4.4.1 – In-Vial Dual Extraction Compared with Precipitation and Injection 
Further testing and validation of the IVDE method was demonstrated by the 
completion of an evaluation study designed to compare the novel IVDE approach 
to that of a currently accepted method [273, 274] employing a single phase precipitate 
and inject to LC-MS approach. 
As can be seen in Table 4.2, splitting the sample extraction into two phases using 
the IVDE approach gave a 256% increase in reproducible features (positive 
ionisation) and 30% (negative ionisation) compared with the precipitate and inject 
method, meaning a total increase of reproducible features of 269%. 
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The results presented suggest that the implementation of the IVDE method has 
successfully increased the metabolite coverage when compared with tradition 
precipitate and inject methods.  The use of two injection phases, from the same 
20µL plasma extract also provides the advantage of expanding the coverage whilst 
preserving valuable sample. 
4.4.5 – Comparison Three 
4.4.5.1 – In Vial Dual Extraction Compared with Precipitation and Injection in 
a Biomarker Discovery Model 
As the IVDE method was developed with the aim for use in future biomarker 
identification studies, it had to undergo validation for its capabilities for 
completing this role.  In order to achieve this, a non-targeted biomarker study was 
developed comparing control rats with those treated to show signs of diabetes.  
This model is a preliminary test for a method such as one like the IVDE, as it is 
commonly accepted that lipid abnormalities are apparent in both forms (type 1 
and type 2) of the disease [283, 284]. 
Plasma samples were obtained from rats in two groups; rats that received STZ (D 
group), and their corresponding sex and age-matched controls (C group).  It is 
known that STZ selectively destroys the beta cells of the Langerhans islets from 
pancreas, and therefore insulin cannot be further synthesised, mimicking the 
complications of type 1 diabetes [293].  Additionally, STZ treated rats are of interest 
as they have previously been used as a model for AD.  This is due to the 
development of an insulin resistant brain state which is thought to possibly 
proceed Aβ pathology in the brain [294, 295]. 
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Table 4.3 shows the results for a comparison of coverage between the two groups 
of samples.  Again the samples were prepared via both IVDE and the precipitate 
and inject method.  In the IVDE method, results from upper and lower phase were 
combined to provide a comprehensive overview. 
To evaluate the two analytical approaches the total number of features present in 
all samples for each group was compared, with results showing an increase in the 
number of statistically significant and identified features in the IVDE method 
compared with the precipitate and inject method.  The IVDE method increased the 
number of reproducible features by 162% in positive MS and 103% for negative 
MS compared with traditional precipitate and inject.   
Following multivariate modelling the total number of statistically significant 
features found to be responsible for the separation between samples from control 
and diabetic animals also increased in the IVDE method compared with precipitate 
and inject, by 283% in positive MS and 109% for negative MS.   
These statistically significant molecules then underwent putative database 
identification, with the IVDE method again providing an increase with 196% and 
42% more features identified in positive MS and negative MS respectively 
compared with the precipitate and injection method. 
In addition to this, the MassTRIX [290] metabolic pathway translator was employed 
to analyse both approaches, with the two phase method providing information on 
approximately twice the number of pathways, than the traditional single method. 
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4.5 – Conclusions 
Over the course of the study presented here in Chapter 4, an IVDE followed by LC-
MS analytical method has been developed that was designed to decrease analytical 
variation and expand the global coverage of metabolite identification.  The end 
result was a method capable of the analysis of >4500 reproducible features from a 
20μL plasma extract.   
This was achieved by the development of an in-vial two phase extraction, taking 
advantage of the non-miscible properties of the interaction between MTBE and 
water.  The extraction solvent was then able to undergo direct analysis via LC-MS.  
The method was robustly tested and provided data that demonstrated an increase 
in the overall number of features and a decrease in the variability observed 
between injections when compared with two typically previously accepted 
methods.   
Finally the IVDE method was applied to an animal model of diabetes – a model well 
accepted as having plasma metabolic differences.  Following univariate data 
mining, data suggested that the IVDE held an advantage for fingerprinting over 
traditional precipitate and inject approaches. 
The results complemented the aims set from Chapter 3, by improving metabolite 
coverage, particularly chromatographic separation in the lipid component of the 
extraction.  The method was then progressed to a biomarker study with regard to 
plasma from control, MCI and AD patient groups, expanding on the findings 
reported in the initial LC-MS screen in Chapter 3. 
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Chapter 5:  
Comprehensive LC-MS Lipidomics 
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5.1 – Introduction 
From the results discussed in Chapter 3, it was apparent that non-polar lipid 
species were of high influence to the multivariate models and subsequent data 
analysis.  The methodology in Chapter 3 employed a rapid LC-MS screen type 
approach, and putatively identified a number of lipid based features.  Three 
features significantly reduced from control to AD patient groups.  However, a high 
amount of co-elution was observed, therefore introducing potential ion 
suppression effects, which may have affected this result.   
Further to the findings in Chapter 3, there is a plethora of previously published 
studies (either targeted or non-targeted) that identified abnormal concentrations 
of lipids or lipid groups in AD, with much of this evidence suggesting a role for HDL 
and related proteins in plasma [106, 193, 196, 296, 297].  Other studies pointing towards 
metabolic markers of AD include, in particular, the genetic studies confirming 
ApoE as a susceptibility factor [19] and both genome wide studies and plasma 
proteomics identifying apolipoprotein J (clusterin) in association with AD [106].  
Clusterin is found as a component of HDL and is thought to be a chaperone of 
amyloid protein, heavily involved in the pathology of AD [106, 107]. 
In addition, two recent plasma fingerprinting studies discovered AD-linked 
alterations in lipid metabolism. The first study found an increase in ceramide (CER 
C16) levels and a decrease in sphingolipid (SP16) levels in the plasma of AD 
patients [193]. A second investigation identified a phosphatidylcholine (PC 
16:0/16:0) as one of a cluster of three metabolites, thought to be predictive 
markers of AD development in people with MCI [196].   
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Therefore with these literature examples in mind, along with the initial result from 
Chapter 3, a novel comprehensive lipidomic method was developed, focused on the 
non-targeted biomarker discovery of lipid species in plasma (Chapter 4). 
To briefly summarise, the developed method consisted of a lipid specific extraction 
using ether within an LC vial.  This was followed by a direct injection from the vial 
onto the LC-MS system.  The idea behind this was to minimise the transfer steps of 
the process, thereby improving reproducibility. 
Four separate phases and LC-MS methods were employed to make it a fully 
comprehensive approach, as both the non-polar ether phase and the polar aqueous 
phase were developed and analysed in both positive and negative ionisation.   
However due to the high number of samples presented here in Chapter 5 (n=141 + 
20QC) combined with the extended run time of the improved method, it was not 
feasible with financial and time resources available to complete all analyses for the 
sample set size.  Therefore, in an attempt to produce the highest chance of 
biomarker discovery, a decision was made to analyse only in positive mode which, 
based on, the results in Chapter 3, produced better analytical results.  In addition 
the three features of significance were identified in the positive ionisation 
conditions.   
The database search returned hits for PC compounds, suggesting a non-polar lipid 
extraction would be best suited.  Therefore, with these considerations in mind the 
sample set was subjected to ether based lipid extraction followed by the positive 
lipidomic analysis described in Section 4.2. 
  
Chapter 5 199 
 
5.2 – Materials and Methods 
The method used is the upper phase positive ionisation analysis described in detail 
in Chapter 4 (Section 4.2).  As previously discussed, the method described in 
Chapter 4 was developed with an Agilent 1200 LC in combination with an Agilent 
6520 QTOF mass spectrometer.  Upon return to King’s College London the method 
was transferred to the equivalent Waters Acquity® LC connected to a Waters 
Xevo® QTOF mass spectrometer, therefore the methods are summarised below. 
5.2.1 – Materials 
LC-MS grade methanol was purchased from VWR (Leicestershire, UK) and high 
purity water deionised water was obtained from an in house Millipore filtration 
system (Millipore, MA, USA). Analytical grade ammonium formate was purchased 
from Sigma UK (Gillingham, Dorset, UK).  Analytical grade MTBE was purchased 
from Fisher Scientific (Loughborough, UK).   The internal standard, 
(triacylglyceride C15:0/C15:0/C15:0 [TG15:0]), was purchased from Larodan fine 
chemicals (Sweden). 
5.2.2 – Instrumentation 
LC-MS analysis was completed using a Waters Acquity UPLC®  (Waters, Milford, 
USA) coupled to a Waters Xevo® G1 QTOF (Waters, Milford, USA).  Analysis was 
completed in positive ionisation mode.  
Chromatographic separation was achieved using an Agilent Poroshell 120 EC-C8 
column (150mm × 2.1mm, 2.7μ m), maintained at 60°C.  A gradient was employed 
consisting of 10mM ammonium formate (A) and 10mM ammonium formate in 
methanol (B).  The solvent was delivered at a flow rate of 0.5mL/min.  The 
gradient consisted of 0min (75%B), 23min (96%B), 45min (96%B), 46min 
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(100%), 50min (100%).  The column was re-equilibrated at 75%B for 9min prior 
to each injection.   
The Waters Xevo® QTOF MS was operated in the positive ion mode with a 
capillary voltage of 3.2kV and a cone voltage of 60V. The desolvation gas flow was 
800L/hour and the source temperature was 120°C. All analyses were acquired 
using the reference solution spray to ensure accuracy and reproducibility; leucine 
encephalin were used as lock mass (m/z 556.2771 and 278.1141) at a 
concentration of 500ng/mL and a flow rate of 10μL/min. Data were collected in 
the centroid mode over the m/z range 100–1000Da with an acquisition time of 0.1 
seconds a scan. 
5.2.3 – Waters MSe Data Collection 
As discussed in Chapter 3 (Section 3.2.3), the Waters Xevo QTOF MS employs a 
technique referred to MSe, enabling the application of a high collision energy to 
ions, resulting in their fragmentation.  This is of particular use, as fragment data 
can assist with identification of unknown species.  As with the screen phase 
discussed in Chapter 3, level one data was acquired using a low collision energy of 
5V, whereas level two acquired the data at a high collision energy of 50V. 
5.2.4 – Samples Used for Analysis  
Samples were collected and obtained from the two cohorts (AddNeuroMed and 
DCR) that make up the Institute of Psychiatry sample bank.  These have been 
discussed previously in great detail in Section 2.2.3.3. 
N=141 age and gender matched samples underwent analysis by the method 
described above. A summary of the samples can be viewed in Table 5.1. 
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A pool of plasma was used as a quality control sample.  This was extracted 
alongside patient plasma, and underwent LC-MS analysis at regular time points 
across the run (n=20).  Patient samples were analysed in a randomised order. 
Due to the large number of samples, and therefore the extended analytical run 
time, samples were analysed in four evenly distributed separate batches (n=40).  
In addition, before each analytical run a pool of plasma was extracted and injected 
onto the column n=5 times.  This ensured maximum column equilibration 
recommended when analysing biofluids in a metabolomic or lipidomic approach 
[298].  This resulted in approximately a total run time of 45hr per batch. 
      
  Control MCI AD  
 Total Samples 49 50 42  
 Age (years) Mean 78.27 78.91 78.27  
 Age Std Dev 6.57 5.48 7.78  
 MMSE Mean 28.88 26.60 21.33  
 MMSE Std. Dev 1.17 2.16 5.06  
 Male/Female 24/25 24/26 22/20  
 % Male/Female 49/51 48/52 52/48  
Table 5.1: Summary of Plasma Samples Used in Comprehensive Lipidomics 
Table presenting the age and gender matched samples used for lipidomics analysis.  
Compared with the screen study discussed in Chapter 3, sample numbers were increased 
to n=141. 
5.2.5 – Data Processing  
Data was analysed in two ways.  Firstly multivariate data analysis was completed 
by aligning the data set using the MarkerLynx package within MassLynx 4.1 
(Waters, Milford, USA).  Data was normalised according to internal standard 
(TGC15:0) to adjust for inter batch runs.   
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Following this a pareto scaled PCA model was created using SIMCA-P+ (Umetrics, 
Sweden) to ensure QC samples grouped, providing evidence for the reproducibility 
of the study.  As with the PCA models in Chapter 3, grouping within <15% of both 
t[1] and t[2] of the total model was used as an arbitrary cut off value.  The 
clustering of QCs was particularly important when considering the analysis was 
completed over four separate batches.  
PC molecule m/z were extracted from the raw LC-MS data from all samples 
(n=141) using Waters QuanLynx software, a package within MassLynx 4.1 (Waters 
Corporation, Milford, USA).  Following this each feature was normalised via peak 
area ratio to peak area of internal standard TG15:0.  This was completed in 
Microsoft Excel 2010 (Microsoft, Reading, UK).   
Univariate analysis for each PC ratio was then completed using SPSS statistical 
software (IBM, Portsmouth, UK) via “Students” t-test mean analysis. 
This approach of raw data alignment in MarkerLynx, followed by multivariate data 
analysis in SIMCA-P+  univariate data analysis  identification using database 
matching and fragmentation patterns has successfully been employed in a 
previous metabolomics publication [268]. 
Finally a predicative receiver operating characteristic (ROC) analysis was 
completed.  Logistic regression was used to investigate the association of each of 
the three features with disease status after adjusting for the number of ApoE ε4 
alleles.  The three features were log transformed prior logistic regression analysis.  
Different models using different predictor combinations were tested and the best 
predictor combination was selected by step-wise regression using the Akaike's 
information criterion.  ROC curves, were completed, with the area under the curve 
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(AUC) values reported for each model.  Analyses were performed in STATA 10 
(StataCorp. 2007. Stata Statistical Software: Release 10. College Station, TX: 
StataCorp LP.).  The ROC analyses were completed in collaboration with Petroula 
Proitsi, a bioinformatician based at the Institute of Psychiatry with the required 
STATA 10 licensed software. 
5.2.6 – Structural Elucidation and Feature Identification 
Initially, putative identification was achieved using databases.  Accurate m/z 
extracted from the raw data underwent database searching using the HMDB [232] 
and METLIN [234]. 
To enable the confirmation of features from the database matching, MS fragment 
patterns were analysed.  Fragment patterns for each molecule were collected using 
Waters MSe technology within the MS collection parameters.  The technology 
allows a rapidly alternating mode of data collection grouped in levels (Section 5.2.3 
(Page 200)).  This approach has been employed in a previous publication by 
Rainville et al. [230]. 
5.3 – Results 
5.3.1 – PCA to Demonstrate Reproducibility 
Data from the n=141 test and n=20 QC samples underwent feature alignment using 
Waters MarkerLynx.  A pareto scaled PCA analysis was completed using SIMPCA-
P+ to demonstrate intra and inter batch overall reproducibility (Figure 5.1.A). 
Although the QCs generally grouped in the centre of the PCA, the distribution was 
slightly skewed.  This observation was due to a slight batch effect (Figure 5.1.B) 
between samples run on different days.  However, as with the PCA analyses in 
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Chapter 3, a cut off value of <15% of the total model (both t[1] and t[2]) was 
required.  QCs clustered within this cut off. 
As with the screen phase of the thesis discussed in Chapter 3, the three disease 
classes demonstrated no grouping in the PCA (Figure 5.1.C).  This is as expected in 
a randomised extraction and analytical run and suggests no analytical trends 
between the groups, and therefore differences identified are more likely to be 
biologically related.  




= Quality Control = Batch 1 = Batch 2= Batch 3 =Batch 4  
 (C)  
 
 = Control  = Mild Cognitive Impairment  = Alzheimer’s Disease 
Figure 5.1: Principle Component Analysis of Comprehensive Lipidomics 
Analysis of all samples (n=141 + n=20 QC) analysed as part of the human plasma lipidomic 
study.   
(A) Displays quality controls (QC) clustering in the centre of the model.  There is a 
minor batch effect as samples had to be split into four batches, however 
clustering (<15% of total model) can still be seen to be centralised in the 
model and has an acceptable grouping. 
(B) A summary PCA of the batch effect observed in QC sample clustering displayed 
in (A).  Each day has been designated a separate colour, and it can be seen that 
days two and four in particular show batch grouping. 
(C) A demonstration of all samples coloured by disease class.  The PCA shows no 
obvious grouping, as would be expected from a randomised extraction and 
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5.3.2 – Univariate Feature Confirmation 
Peak area values for features highlighted in the positive ionisation screen 
experiment previously discussed in Chapter 3 were extracted from the raw 
chromatographic data.  Of these, three features that were previously identified as 
undergoing significant change between groups in the screen study, these were 
found to be significantly reduced in intensity in AD samples (Table 5.2 and Figure 
5.2).  Example extracted ion chromatograms for the features can be found in Figure 
5.3. 
      
 m/z (M+H)  
[Da] 
Mean PAR  
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Table 5.2: Peak Area Ratio Values for Features of Significance from Lipidomic Data 
Mean peak area ratios of features demonstrated to significantly change between disease 
classes in the comprehensive lipidomic analysis.  Peak areas for each m/z were extracted 
from the raw data using Waters QuanLynx, and were then normalised using an internal 
standard (Triacylglyceride C15:0/15:0/C15:0) resulting in a peak area ratio.   
Significance was calculated by performing a “student’s” t-test on the mean peak area ratio 
values. (a) p=<0.05, (b) p=<0.005, (c) p=<0.001.   
In column “m/z” the m/z of the PC molecule is also shown, alongside that of the m/z 
detected by the LC-MS (in brackets).  In the remaining columns the standard deviation 
(SD) is provided. 
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Figure 5.2: Box Plot Analysis of Features of Significance from Lipidomic Data 
Box plot analysis for the three significant molecules highlighted in the comprehensive 
lipidomic analysis.  Disease group data was tested for statistical significance by analysing 
the mean values using “Students” t-test.  Interestingly, the overall trend was a reduction 
from Control  MCI  AD 
* p<0.05, ** p<0.01, *** p<0.001. 
 
  








Figure 5.3: Example Extracted Ion Chromatograms 
(a) Feature with m/z 780.5578 at 15.65 minutes 
(b) Feature with m/z 806.5746 at 16.47 minutes 
(c) Feature with m/z 834.6026 at 18.13 minutes 
  
Time















Chapter 5 209 
 
5.3.3 – Structural Identification of Features 
Once the three features had been shown to demonstrate significant reductions in 
AD, structural identification and elucidation was required.   
As described in section 5.2.6 above, level two data was analysed from the MSe 
technology on the Waters Xevo instrument.  Fragments were analysed enabling the 
structures to be identified. 
Initial observations demonstrated a fragment ion in each m/z at 184.0773Da, 
which is indicative of the choline head unit common in both phosphatidylcholine 
PC and SPH species.  However when observing the results from the vast databases 
in both HMDB and METLIN, no sphingomyelin species were associated with the 
relevant m/z, providing a strong indication that the species of interest are PC 
molecules.  
PC molecules consist of a choline head unit bound to two FA side chains.  These 
side chains were elucidated by observing fragments lost, for example a loss of 
302.2246 indicates a structure consisting of C20H30O2 suggesting a chain loss of 
C20 with 5 unsaturated double bonds, otherwise known as eicosapentaenoic acid.  
This approach using fragmentation patterns has been used previously for 
phosphatidylcholine elucidation [236], and also in particular with Waters MSe 
technology [230]. 
Final identification resulted in three phosphatidylcholine species PC16:0/20:5, 
PC16:0/22:6 and PC18:0/22:6.  Figure 5.4, Figure 5.5 and Figure 5.6 present the 
structural elucidation of each molecule, and Table 5.3 displays each fragment, its 
exact m/z and the m/z observed in the MS data. 
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Figure 5.4: MSe Fragmentation Pattern for Parent Ion m/z 780.5538Da 
MSe spectrum for feature m/z 780.5538Da.  The identification of phosphatidylcholine (PC) 
molecular class was confirmed by the presence a fragment m/z at 184.0773Da, indicative 
of PC species.  As the MS was completed in positive mode and therefore requires the PC 
head group for ionisation, the identification focused on side chains lost.  For example, m/z 
478.3292Da is the combination of the PC head unit and side chain C16:0.  The m/z that is 
lost compared to the parent ion is 302.2264Da, indicating a loss of side chain 20:5.  Two 
fragments that differ by 18Da indicated a fragmentation that has occurred on either side of 
an oxygen bond, further assisting with the structural confirmation.  
  
Chapter 5 211 
 
 
Figure 5.5: MSe Fragmentation Pattern for Parent Ion m/z 806.5694Da 
MSe spectrum for feature m/z 806.5694Da.  The identification of phosphatidylcholine (PC) 
molecular class was confirmed by the presence a fragment m/z at 184.0773Da, indicative 
of PC species.  As the MS was completed in positive mode and therefore requires the PC 
head group for ionisation, the identification focused on side chains lost.  For example, m/z 
478.3292Da is the combination of the PC head unit and side chain C16:0.  The m/z that is 
lost compared to the parent ion is 302.2264Da, indicating a loss of side chain 20:5.  Two 
fragments that differ by 18Da indicated a fragmentation that has occurred on either side of 
an oxygen bond, further assisting with the structural confirmation. 
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Figure 5.6: MSe Fragmentation Pattern for Parent Ion m/z 834.6007Da  
MSe spectrum for feature m/z 780.5538Da.  The identification of phosphatidylcholine (PC) 
molecular class was confirmed by the presence a fragment m/z at 184.0773Da, indicative 
of PC species.  As the MS was completed in positive mode and therefore requires the PC 
head group for ionisation, the identification focused on side chains lost.  For example, m/z 
506.3605Da is the combination of the PC head unit and side chain C18:0.  The m/z that is 
lost compared to the parent ion is 328.2402Da, indicating a loss of side chain 22:6.  As 
before, two fragments that differ by 18Da indicated a fragmentation that has occurred on 
either side of an oxygen bond, further assisting with the structural confirmation. 
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5.3.4 – Support of Findings – Screen Identification 
To further provide evidence and support for the findings that three PC species 
significantly decrease in AD, the matching three features in the screen study also 
underwent structural fragmentation elucidation.  
The three features were also found to be PC16:0/20:5, PC16:0/22:6 and 
PC18:0/22:6.  The results of the fragmentation can be observed in Table 5.3. 
This provides confidence in the findings, as now the three molecules have been 
shown to significantly reduce in AD in two separate methods, using two different 
sample sets of different numbers and also completed at different time points 
during the PhD project.  
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Table 5.3: Fragmentation Data for Phosphatidylcholine Molecules 
The above table presents MSe data of the three PC molecules which demonstrated a significant decrease in AD 
compared with controls.  The table presents both parent and fragment data for all masses that were used to 
confirm the structure of the molecule.  Identification was completed in both the larger lipidomic study 
discussed in Chapter 5, as well as plasma samples from Chapter 3.  The three PC species exhibited a significant 
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Table 5.3: Fragmentation Data for Phosphatidylcholine Molecules (Continued from Previous Page) 
The above table presents MSe data of the three PC molecules which demonstrated a significant decrease in AD 
compared with controls.  The table presents both parent and fragment data for all masses that were used to 
confirm the structure of the molecule.  Identification was completed in both the larger lipidomic study 
discussed in Chapter 5, as well as plasma samples from Chapter 3.  The three PC species exhibited a significant 














































































































































































































































































































































































































































































































































































































Chapter 5 216 
 
 
Table 5.3: Fragmentation Data for Phosphatidylcholine Molecules (Continued from Previous Page) 
The above table presents MSe data of the three PC molecules which demonstrated a significant decrease in AD 
compared with controls.  The table presents both parent and fragment data for all masses that were used to 
confirm the structure of the molecule.  Identification was completed in both the larger lipidomic study 
discussed in Chapter 5, as well as plasma samples from Chapter 3.  The three PC species exhibited a significant 
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Table 5.3: Fragmentation Data for Phosphatidylcholine Molecules (Continued from Previous Page) 
The above table presents MSe data of the three PC molecules which demonstrated a significant decrease in AD 
compared with controls.  The table presents both parent and fragment data for all masses that were used to 
confirm the structure of the molecule.  Identification was completed in both the larger lipidomic study 
discussed in Chapter 5, as well as plasma samples from Chapter 3.  The three PC species exhibited a significant 
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5.3.5 – Further Investigation into Phosphatidylcholine Molecules 
Due to the findings reported above, further PC molecules that were both present in 
the MS raw data and also shared similar side chain arrangements also underwent 
extraction from the raw data.  Again peak area ratios were calculated, and the 
means underwent “student’s” t-test analysis for significance, however these 
molecules did not show significance (Table 5.4).  
       











































Table 5.4: Further Phosphatidylcholine Molecule Analysis 
The above table presents peak area ratio figures for three further phosphatidylcholine 
(PC) species.  Their selection was based upon availability from the in the raw mass 
spectrometry data and also sharing similar side chains to the three significant features 
discussed previously.  PC species were confirmed by accurate m/z matching to databases 
as well as side chain elucidation using fragmentation patterns.  No significant variations 
were observed between the disease classes. 
5.3.6 – Receiver Operating Characteristic Analysis 
To test the sensitivity and specificity of the three phosphatidylcholine species as a 
biomarker predictor for the disease, a ROC was completed.  Peak area ratio data for 
each of the three PC species was analysed both individually (Figure 5.7) as well as 
when combined with patient ApoE gene data (Figure 5.8), a well established risk 
factor for predicting the disease [244].   
For the n=141 sample set, ApoE data on its own gave an initial reference AUC of 
0.667.  Individually, both PC16:0/20:5 and 16:0/22:6 provide increased AUC 
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scores of 0.722 and 0.680 respectively.  PC16:0/22:6 returned an AUC of 0.662, 
slightly below that of the ApoE benchmark for the sample set. 
The combination of each of the individual PC peak area ratios along with patient 
ApoE data improves the AUC score for the analysis.  PC16:0/20:5 + ApoE returns 
an AUC of 0.782 + ApoE, PC16:0/22:6 returned 0.746 and finally PC18:0/22:6 + 
ApoE returned an AUC of 0.756.  Combined peak area ratios for all three PC 
molecules, used in combination with ApoE patient data for the analysis returned 
the most promising result, with an AUC of 0.8279 (Figure 5.7 and Figure 5.8). 
ROC analyses were also completed in order to observe the predictive properties of 
Control vs. MCI and MCI vs. AD.  These were less promising, yet still provided an 
increase compared with using ApoE patient data alone.  For example combining 
the PAR data along with ApoE data as opposed to ApoE data alone, increased the 
AUC from 0.570 to 0.672 (Control vs. MCI) and from 0.593 to 0.651 (MCI vs. AD) 
respectively.  A full AUC summary of the ROC analyses can be found in Table 5.5. 
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  Control vs. AD Control vs. MCI MCI vs. AD  
 ApoE Only Data 0.667 0.570 0.593  
 PC16:0/20:5 0.722 0.625 0.576  
 PC16:0/22:6 0.622 0.569 0.588  
 PC18:0/22:6 0.680 0.592 0.594  
 All Three PC  0.786 0.640 0.588  
 PC16:0/20:5 + ApoE  0.776 0.665 0.638  
 PC16:0/22:6 + ApoE  0.739 0.624 0.629  
 PC18:0/22:6 + ApoE  0.754 0.637 0.631  
 All Three PC + ApoE  0.827 0.672 0.651  
Table 5.5: Area Under the Curve from Receiver Operated Characteristic 
The above table presents the area under the curve (AUC) values which were observed 
following a receiver operated characteristic (ROC) analysis.  ROC analyses were completed 
comparing all disease groups (including Control vs. AD, Control vs. MCI).  This enables the 
observation of the predictive properties of each phosphatidylcholine (PC) molecule and 
for each disease state.  The most promising approach involved combining data from all 
three PC peak area ratios with ApoE gene data.  The end result of which was an AUC of 
0.827 when comparing Control and AD patients.   
Example ROC analyses can be observed in Figure 5.7 and Figure 5.8. 
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Figure 5.7: Receiver Operating Characteristic Analysis 
Peak area ratios (PAR) for each phosphatidylcholine molecule (PC) were used to produces 
this receiver operated characteristic (ROC) analysis.   
ApoE data was initially used on its own as a start comparison point and provided an area 
under the curve (AUC) of 0.667.   
Each PC PAR was then used individually in order to observe its predictive properties.  
Both PC 16:0/20:5 (m/z 780) and PC 18:0/22:6 (m/z 834) returned AUC scores of greater 
than ApoE on its own (0.722 and 0.680 respectively).  PC 16:0/22:6 (m/z 806) returned 
an AUC of 0.662, slightly below that of ApoE. 
When combining the PAR data of all three PC species, the AUC was 0.786. 
A combination of all three PC molecules and ApoE data returned the most promising result 
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Figure 5.8: Receiver Operating Characteristic Analysis with ApoE Data 
Peak area ratios for each phosphatidylcholine molecule (PC) were combined with patient 
ApoE gene data to produce this receiver operated characteristic (ROC) analysis.   
ApoE data was initially used on its own as a start comparison point and provided an area 
under the curve (AUC) of 0.667.  Each PC molecule combined with ApoE improved this 
AUC with PC16:0/20:5 (m/z 780) returning 0.782, PC16:0/22:6 (m/z 806) returning 
0.746 and PC18:0/22:6 (m/z 834) returning and AUC of 0.756.   
A combination of all three PC molecules and ApoE data returned the most promising result 
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5.4 – Discussion 
Lipidomic analysis was completed on an n=141 sample set, to provide clarification 
and confidence on those results reported in the screen phase of the Ph.D. project 
discussed in Chapter 3.  From the screen, three features were of most interest as 
they were identified at significantly reduced values in the disease samples after 
univariate data treatment; 780.5578 (p=<0.001), 806.5746 (p=<0.01) and 
834.6026 (p=<0.01). 
Following the promising results from the LC-MS screen, an extended LC-MS 
method underwent development with the aim of reducing co-elution and 
expanding the number of features analysed.  This is discussed in great detail in 
Chapter 4.  The extended LC-MS method was then applied to an increased sample 
set (n=141).  Due to cost constraints the focus was upon lipid species that ionise in 
the positive mode.  This decision was based upon a number of factors. 
• Better multivariate model results in the LC-MS Screen from Chapter 3. 
• The three significant features from the LC-MS Screen were all identified in 
univariate analysis of the positive screen. 
• Greater sensitivity and overall number of features available in positive 
ionisation phase, as reported in Chapter 4. 
5.4.1 – Quality Control and Batch Analysis 
Due to concerns about instrument mass accuracy over a long term analytical run, 
samples were divided into four batches to enable regular instrument calibrations.  
Therefore it was of importance to ensure QC repeatability across the four batches.  
Normalisation using internal standard intensities was completed in the alignment 
process using MarkerLynx. 
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Figure 5.1.A presents the breakdown of PCA that were created using the data.  As 
can be seen, QC samples clustered in the middle of the model.  Figure 5.1.B 
presents the n=5 QC samples from each batch as a different colour.  A minor batch 
effect can be observed, however as there were no QC outliers from any batch, the 
data were progressed to further multivariate analysis.  Minor inter-batch variation 
is common in LC-MS metabolomics, however pooled QC analysis, and the inclusion 
of an internal standard, is a commonly used and accepted approach in overcoming 
these problems [299]. 
5.4.2 – Significant Lipids and their Identification 
Findings in the extended LC-MS method reported here, confirmed that the three 
features of interest from the LC-MS screen in Chapter 3, are also reflected in a 
larger sample set and using an improved method.  To ensure the m/z related to the 
same molecules, and not just features that share the same molecular m/z, they too 
underwent identification using fragmentation patterns analysis.  The process was 
described in great detail above in the results section, and follows that of similar 
publications [230, 236].  Three PC species (PC16:0/20:5, PC16:0/22:6 and 
PC18:0/22:6) were therefore identified and observed to significantly decrease in 
AD compared with controls. 
Confidence in the reporting of the three PC species is therefore increased.  This 
confidence is obtained from the fact that they were identified at significantly 
reduced levels in AD in:   
• Two completely different LC-MS methods and approaches – the LC-MS 
screen discussed in Chapter 3 and the extended LC-MS analysis discussed here in 
Chapter 5.  In order to prevent confusion in this discussion piece, the findings in 
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Chapter 3 will be referred to as screen.  The new results presented here in Chapter 
5 are referred to as validation LC-MS. 
• Two sets of different samples were employed for both the screen and the 
validation LC-MS, with no overlap of samples. 
PC16:0/20:5, PC16:0/22:6 and PC18:0/22:6 were all found to be diminished in AD 
samples from two LC-MS analytical sample sets, with respective p values of <0.001, 
0.011 and 0.004 in the extended LC-MS results discussed here. In the results also 
the overall trend - i.e. control>MCI>AD - suggested a general decline linked to 
cognition.   
5.4.3 – Phosphatidylcholine species decrease in AD plasma 
As previously discussed in Chapter 3, PCs are a class of diacylglycerophospholipids 
that are an essential component of cell membranes, and make up ~ 95% of the 
total choline compound pool in most tissues [238, 239].  Figure 5.9 demonstrates their 
structure, with a choline head group and FA side chains.  The length of these side 
chains can influence PC function and help define their structural roles, since chain 
length differences can affect cell membrane fluidity, as per reference [240]. 
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Figure 5.9: Phosphatidylcholine Structure 
The above figure highlights the general phosphatidylcholine (PC) structure, with the key 
components highlighted.  In red is the choline head unit common in all PC structures.  This 
is then connected to two fatty acid (FA) side chains.  The attached table highlights the side 
chains of specific interest, which were shown to significantly decrease in AD disease 
compared with control patients. 
Image provided by a collaborator Dr Arundhuti Sen with permission to reproduce 
Along with their structural roles, they are also found as components of 
lipoproteins, in particular of HDL. PCs interact with ApoE as part of the HDL group, 
and are implicated in cholesterol transport [241].  This is of interest as ApoE is 
linked with AD [242, 243], and the ε4 allele of the ApoE gene is a well-established 
predictor (indeed, considered one of the most significant risk indicators) of AD 
[244]. 
A previous publication also expands further knowledge on the genetic background 
to PC species.  A genome-wide association study (GWAS) incorporated the results 
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from a metabolomic analysis of human serum.  The study reported a number of 
loci associated with the concentration ratios of a number of PCs, for example 
PLEKHH1, a gene of presently unknown function, and PC36:5 were found to be 
linked [300].  This finding provides evidence that PC metabolism is genetically 
linked, and therefore it is possible that irregular PC metabolism may be linked to 
genetic causes of AD. 
Figure 5.10 presents the major metabolic transformations which regulate PC and 
choline homeostasis. Within the figure there is particular emphasis on those that 
are thought to be relevant to various neurodegenerative pathologies. 
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Figure 5.10: Phosphatidylcholine metabolism and Alzheimer's disease 
This overview illustrates the major routes to phosphatidylcholine (PC) biosynthesis, with 
an emphasis on steps involving choline-containing compounds and those that have been 
previously associated with the pathology of Alzheimer's disease.  Phosphatidate 
(phosphatidic acid (PA)) is synthesised endogenously from glycerol-3-phosphate in most 
tissues, and is a key signalling molecule and a precursor for other 1,2-
diacylglycerophospholipids. PA is converted to 1,2-diacylglycerol (DAG) and then enters 
the CDP-choline Kennedy pathway to form PC (PC can also be formed in the liver from 
phosphatidylethanolamine (PE) in a multi-step pathway catalysed by PE-methyl 
transferase). PC is subject to the action of a variety of phospholipases, two main families of 
which are the phospholipase D (PLD) and phospholipase A2 (PLA2): PLD enzymes 
hydrolyse PC to yield free choline (Ch) and PA, while PLA2 enzymes cleave acyl groups 
from the sn-2 position of PC to yield LysoPC. 
Image created by Dr Arundhuti Sen with permission to reproduce. 
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The most significant pathways involving PC metabolism is the Kennedy pathway, 
which consists of the enzymes (CK, CCT, CPT in Figure 5.10) and phosphatidic acid 
phosphatase (PAP).  The pathway is involved in the biosynthesis of PC  molecules 
from choline and phosphatic acid (PA), and are associated primarily with cell 
growth, proliferation and signal transduction cascades [301].  
It is this enzyme pathway that catalyses and regulates the general breakdown of 
PC, to phosphatidate, via use of the phospholipase D (PLD) and to 
glycerophosphocholine and free fatty acids using the phospholipase A2 enzymes 
(PLA2).  PLA2 enzymes are of particular interest as they have previously been 
directly associated with AD [301-303].  
The PLA2 family of enzymes is further linked to AD as it has been observed that 
they undergo increased activation within neurons by Aβ, in turn releasing 
secondary lipid messengers such as AA [202]. 
The release of AA has downstream effects that include the stimulation of the 
sphingomyelinase-ceramide pathway responsible for the metabolism of 
sphingomyelin (of which PC is a precursor) to phosphocholine and ceramide.  This 
pathway has been previously investigated with regard to AD, with results 
reporting increases in sphingomyelinase and acid ceramidase activity in the AD 
brain [255, 256].  
Several previous publications [304-308] have reported that PLA2 activity and 
expression in the AD brain and CNS.  Activity and expression appears to be 
correlated with the progression of AD, with results reporting reduced activity in 
the early stages and the up-regulation in the later stages of the disease. These 
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findings, therefore suggest further support to the importance of lipid and 
glycerophospholipid pathways in AD pathology [297]. 
The findings from the extended study here in Chapter 5 reported three PC 
molecules, PC16:0/20:5, PC16:0/22:6 and PC18:0/22:6, which are diminished in 
AD plasma.  This finding complements numerous previous data on AD-associated 
differences in phosphoglycerolipid metabolism, some of which have been reviewed 
elsewhere [141].  In previously published studies sphingomyelins, ceramides and 
diacylglycerols have been found to be elevated in brain tissue and, more recently, 
in plasma, serum and CSF of AD patients [160, 193, 309-311].  Since PC is a precursor for 
sphingomyelin (via the sphingomyelin synthases), our results are in agreement 
with the observed increase in these molecules. Furthermore, Gaudin et al found 
that two PCs (32:0 and 34:1) were decreased in senile plaques extracted from the 
post-mortem AD brain.  In the publications the PC species were reported with 
values representing combined side chains, and were not fully elucidated, for 
example PC32:0 could relate to PC16:0/16:0 or 18:0/14:0. The group concluded 
that PC regulation was affected in AD and that it could be linked to the roles of 
PLA2 and PLD1 in Aß activation [245].  
Interestingly, the results of Chapter 5 identify side chain 22:6 in two PCs, 
PC16:0/22:6 and PC18:0/22:6, and is therefore linked to the FA DHA.  To the best 
of our knowledge, these two PC species have not been reported previously as being 
different in AD patient plasma when compared with control samples.  DHA with 
regard to AD was discussed in great detail in Chapter 2.   
To investigate the possibility that changes in PLA2 activity may be causing the 
observed decrease in PCs, the findings reported here were linked to those reported 
in Chapter 2.  Results reported in the earlier Chapter suggested that the 
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concentration of DHATOTAL and EPATOTAL in circulating plasma provided 
significance values of p=0.107 and 0.023 respectively (controlAD). This suggests 
that plasma DHATOTAL is consistent between groups, and that therefore a possible 
imbalance exists in the distribution and metabolism of DHA to phospholipid 
species.  In contrast, plasma EPATOTAL shows a moderate decrease from Control  
AD.  This concentration of EPATOTAL could therefore be linked to the depletion of PC 
20:5, but interpreting these results in a more quantitative fashion is beyond the 
scope of this study and would require further work.   
While our results are in keeping with the general trend observed in previous 
studies (i.e. disruptions in glycerophospholipid pathways appear to be correlated 
with the prevalence of AD), Figure 5.10 all too clearly illustrates the complexity of 
choline and phospholipid biochemistry. Thus it is difficult to hypothesise about the 
exact metabolic reasons for the reductions of the three PCs in AD plasma, without 
more precise knowledge about the links of particular side chains to enzymatic 
steps and their involvement in the overall pathway.  
5.4.4 – Phosphatidylcholine C16:0/20:5 
Of the three molecules identified as potential candidates, PC16:0/20:5 was of the 
greatest significance from the resulting data. The PC16:0/20:5 has previously been 
discussed with regards to AD, again the result was generated by a non-targeted 
metabolite analysis.  However, the PC was not deemed to significantly alter on its 
own merits, but was reported in a cluster-style analysis.  The study employed a 
combination of molecules which it termed “clusters”.  These consisted of three or 
four individual markers, the resulting variations of which were combined, 
resulting in a model of prediction for the conversion of MCI to AD [196]. In the 
example of the cluster which included PC16:0/20:5 as one of its features, no 
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significant prediction properties (p=0.27) for the three-molecule cluster as a group 
were apparent. 
Conversely, in the results reported here within the thesis, PC16:0/20:5 showed a 
highly significant decrease between controls and AD, with p=0.001 and <0.001 for 
the screen results reported in Chapter 3 and the extended validation LC-MS phase 
reported in Chapter 5.  
When comparing MCI and AD, a significant decrease was also observed in the 
screen results in Chapter 3 (p=0.038), however in the analysis described here in 
Chapter 5 a non-significant decrease was observed (p=0.102).  This data suggests a 
potential role for PC16:0/20:5 as a predictor for AD when compared with controls, 
however not as a converter marker from MCI and is therefore in agreement with 
the cluster analysis discussed previously [196].  
The cluster-style analysis did however find three major molecules which showed 
promise as predictors of progression from MCI to AD. Interestingly these included 
a PC (PC16:0/16:0), alongside 2,4-dihydroxybutanoic acid and an unidentified 
molecule [196].  Of particular relevance and interest was the fact that the identified 
PC contained two 16:0 side chains, therefore suggesting a potential link with two 
of the three molecules identified throughout the thesis, which also contained 16:0 
side chains (16:0/20:5 and 16:0/22:6).   
This result takes on further relevance when considered in conjunction with the 
consideration that LysoPC16:0 is a precursor of platelet activating factor (PAF).  
LysoPC16:0 is a metabolite of PC species with a 16:0 side chain and is generated by 
the previously discussed PLA2.  PAF has a role in mammalian physiology as a 
mediator in inflammation-related processes.  Perhaps more interestingly, the 
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C16:0 PAF has been shown to be toxic to neurons [312] and therefore it is plausible 
that neurone death in AD could, in some part be a result of abnormal PC 
metabolism in the disease.  
Further to this, a metabolomics study by Han et al. reported SPH and CER with 
chains C22:0, C23:0 and C16:0 to significantly vary between AD and controls, with 
high correlation with AD progression [193]. Of particular relevance is the reported 
ratio of CER/SPH molecules, which contains the C16:0 side chain, as this provided 
the highest correlation with AD, providing further evidence to the importance of 
this particular chain length. 
As discussed earlier, abnormalities in the phospholipase pathways have been 
implicated in the pathology of AD.  As illustrated in Figure 5.10, such altered PL 
activity for selected PCs could very well lead to an over-metabolism of these 
molecules, and therefore a subsequent diminishment in plasma levels.   
Further to this, the link between membrane breakdown, amyloid deposits and 
neuronal dysfunction has been supported by publications from Dyrke et al.[313] and 
Pettigrew et al. [314].  These previously published results all support the abnormal 
PC levels found in AD disease patients in this study, and suggest a relationship with 
the amyloid deposits associated with the brain pathology of the disease.  This 
would suggest that PCs may have a crucial role in AD biomarker discovery. 
5.4.5 – Choline Metabolism and Links to Phosphatidylcholines 
In the previous sections above the focus of the discussion was structured around 
the metabolism of side chains, however the metabolism of the choline component 
of PCs may also be a cause of the results observed presented throughout the thesis. 
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Kantarci et al have published findings which correlated the amounts of choline-
containing compounds to AD pathology in specific regions of the brain. Using MRS, 
they measured an increase in choline to creatine ratios in AD patients [315]. They 
argued that an increase in the membrane turnover of choline during neuronal 
degeneration led to increased free choline in the brain. 
Further discussions have hypothesised an alternative model, which would suggest 
that Aβ binding to membrane lipids is directly responsible for the disruption of 
membrane structures [316], and it is this which leads to an increase in free choline 
throughout the human brain. 
5.4.6 – Phosphatidylcholines as Clinical Biomarker Candidates for AD 
Perhaps the most clinically relevant aspect of the study and therefore the thesis 
project on the whole is the overall predictive properties of the three PC molecules 
of interest.  Therefore to test these predictive properties, a number of ROC 
analyses were completed.   
A ROC analysis is essentially a statistical technique which enables the visualisation 
of classifier values, such as those for the PC molecules.  The ROC graph is a two 
dimensional graph which is the result of plotting a predicative value that 
incorporates both the sensitivity (the prediction rate of true positives) and 
specificity (the prediction rate of false positives). 
The false positive rate is calculated by dividing the negatives incorrectly classified 
by total negatives, whilst the true positive rate is the positives correctly classified 
value divided by the total positives.   
In some classifier cases, the model is designed to produce only one class decision 
for example a Yes or No, and therefore produces a single ROC point.  However in 
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the case of the ROC model employed here, a ROC curve is plotted by the 
implementation of an arbitrary threshold value. The threshold value changes 
throughout the plot, for example if it was set at 1, any value >1 would be classed as 
a positive result and <1 visa versa.  As the threshold increases, the risk of a false 
positive may decrease, but as does the chance of obtaining an actual positive.  
Therefore the curve model implements a range of arbitrary threshold values, and 
plots the specificity and sensitivity associated with each, thereby forming a curve 
shape on the plot area.  The area under this curve is often referred to, and 
represents the probability that a positive patient will rank higher than a randomly 
chosen negative one.  Therefore the higher the value, the better the predictive 
properties of the marker set.  A full review of ROC analyses can be read at the 
following review by Fawcett [317]. 
Currently, one of the major genetic markers of AD is the presence of one of the two 
ApoE gene alleles (ε2 or ε4) [15].  In the case of the extended LC-MS samples set 
presented here (n=141) using ApoE data alone gave an AUC of 0.667. When 
combined with the three lipid peak area ratio findings, the AUC rose to 0.828, 
suggesting a predictive potential of >80%.  80% is an important benchmark as it is 
currently regarded as a minimum requirement for AD biomarker candidate 
molecules [318, 319]. 
AUC scores for other combinations of PC and ApoE data, were not able to match 
the 0.828 value.  Similarly combinations of the data sets in comparisons between 
MCI and AD and Control and MCI were not as promising, with the highest AUC 
scores at 0.651 and 0.672 respectively.  However, this figure could potentially be 
improved with a longitudinal study design, where those MCI patients which 
progress to AD over a number of visits are recorded.  This would enable the 
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differentiation of MCI but stable and MCI that convert to AD.  This further study 
could provide interesting data regarding the progression of the disease. 
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5.5– Conclusions 
The work presented here in Chapter 5, elucidated the structures of three PC 
species that were identified in the screen phase of the project presented in Chapter 
3.  The three PC species – 16:0/20:5, 16:0/22:6 and 18:0/22:6, were further tested 
in a larger dataset of n=141, with an improved profiling methodology, and were 
shown to significantly reduces following a pattern of Control  MCI  AD.   
A series of ROC analyses were employed in order to visualise the predictive 
classifier properties of the PC molecules, where the most promising approach was 
to combine peak area ratio data with ApoE data for each patient, which produced 
an AUC of 0.827 when comparing control and AD.  This suggests early promise for 
the PC species as biomarkers of AD.  Further work is required in order to confirm 
and refine the finding, particularly as ROC results between AD and MCI were less 
promising, suggesting that MCI markers need to be more specific with progression 
into AD accounted for.  A comparison between various disease states, including 
other forms of dementia such as Lewy body dementia and vascular dementia 
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Chapter 6:  
Conclusions and Further Work 
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AD is rapidly becoming a major global burden.  Aging populations and an increased 
efficacy at treating infectious and acute disease, is resulting in the sharp rise of 
diagnosed cases.  This is having a major impact on both the economic cost of care, 
and the personal stresses and strains that occur within affected families. 
Currently one of the significant challenges facing the management of AD is in the 
actual diagnosis, with current approaches relying on cognition testing combined 
with physical assessment and expert opinion.  Whilst the process can be effective, 
inconsistencies occur, particularly when diagnosing between the numerous types 
of dementia.  In addition, AD progression and response to treatment is difficult to 
track and record, with certain patients capable of performing well in cognition 
testing even if suffering from moderate to severe dementia.  Therefore, a 
requirement exists for molecular markers that are capable of either (or both) the 
diagnosis of the disease and the accurate tracking of disease progression and 
cognitive decline. 
A further challenge in the current procedure is that for a diagnosis to be given it is 
essential for symptoms to be apparent in the patient.  However, there is a 
consensus that the mechanism behind AD pathology potentially begins in the 
patient 20 years or earlier, prior to the initial observation of symptoms [29, 30].  With 
this in mind it has been mooted that future pharmaceutical treatments will be 
designed to be disease modifying, altering the course of the disease from an early 
time point, before the patient has progressed to signs of cognitive impairment.  
Again, suggesting a need for a biomarker, especially one that can predict disease 
state from in pre-symptomatic patients. 
Despite numerous candidate markers in the literature, both protein and genetic, 
current lead candidate biomarkers have proved inconsistent, especially when 
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diagnosing between AD and alternative dementias.  Therefore, in order to expand 
the field on AD biomarkers and to present an alternative approach work was 
completed on small molecule biomarker research, in an attempt to identify novel 
candidate markers in the disease. 
6.1 – Fatty Acid TOTAL in Alzheimer’s Disease 
6.1.1 – Study MB2 
The initial study design utilised bio-tissue from both animal mouse model (brain) 
and human plasma, with a target study designed to investigate the possibility of 
the use of FATOTAL as a biomarker for the disease.  Despite frequent discussions in 
the literature regarding FA in AD, to date, the use of FATOTAL has not previously 
been reported for AD in a biomarker capacity.   
When comparing FATOTAL concentrations between AD model mouse and wild-type, 
differences were observed, however, statistical validation was not possible due to 
a restriction on available sample numbers.  In order to provide a statistical 
interpretation of the findings, future work would be required that would 
incorporate brain regions from a greater number of animals.  An interesting 
additional aspect which could be included in the study design would be to analyse 
concentrations in FATOTAL in the brain regions, along with corresponding plasma or 
serum.  This would enable the observation of metabolite variations across the 
blood brain barrier, further increasing the understanding of FATOTAL in AD.   
Additionally, if careful consideration was taken in the study design and sample 
volumes were managed effectively, a battery of analytical procedures could be 
completed on the different tissues, for example NMR, LC-MS targeted and LC-MS 
untargeted methods.  This would provide a wealth of data, both in the biomarker 
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discovery phase, as well as metabolite ratios between the brain and the peripheral 
system.  Animal models would be ideal subjects for this, as they exist in an 
extremely controlled environment.  Despite the advantage of this controlled 
environment, results from a study designed with animal models as sources of 
tissue and biofluid, should clearly be considered as preliminary in a biomarker 
discovery workflow, due to the significant differences between animal models and 
actual human AD pathology.  Therefore, any significant biomarker discovery would 
need to undergo further validation in a human population. 
6.1.2 – Study HP30 
It was a requirement for clinical relevance which drove much of the project 
planning presented within the thesis, hence the focus upon human plasma.  The 
initial investigation into plasma concentrations of three major FATOTAL returned 
interesting results.  Most promisingly, EPATOTAL was reported to significantly 
decrease when comparing control patient with AD patient plasma (p=0.023).  In 
addition, the ratio of AATOTAL/EPATOTAL was demonstrated to significantly increase 
when comparing control patient with AD patient plasma (p=0.05).   
Again, expansion of this study could provide further interesting results.  Initially 
the increase of sample numbers would validate the statistical significance over a 
larger population.  In addition, the LC-MS targeted approach could be adapted for a 
number of further FATOTAL species for example C16:0 and C18:0, which were 
associated with the three PC compounds of interest that were discussed in the 
later chapters.   
Additionally, LC-MS targeted work could be completed on the individual fractions 
of individual FA molecules for example, FATOTAL, FAFREE and FABOUND to various 
lipids and subclasses.  This would enable the observation of the distribution ratios 
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within the disease classes.  Despite the fact that other research groups have 
previously published results reporting the concentration of FA in both FAFREE and 
FABOUND forms [208, 209]; as yet no one has published findings reporting the 
percentage distribution of individual fatty acids in an AD-control comparison. 
6.2 – Lipidomics in Alzheimer’s Disease 
Following the early FATOTAL result, a decision was taken to continue with the use of 
human patient plasma.  Plasma was selected based upon not only sample 
availability, but perhaps more importantly, potential clinical relevance and 
application.  As discussed previously, the selection of biofluid is an important 
consideration, as for a biomarker to be successfully applied in a clinical scenario; 
ideally it needs to be obtainable from a non-invasive and easy to obtain biofluid. 
A non-targeted screening study was developed, aimed at the investigation of small 
molecules using LC-MS combined with metabolomic data treatment.  Results of 
this were promising, and following multivariate data modelling a number of 
features of interest were isolated for further investigation.  Of particular 
significance was the observation of three features, later identified as PC molecules, 
which were demonstrated to be significantly reduced when analysed using 
univariate statistics in AD plasma, when compared with control patients. 
Following this, a comprehensive lipid profiling method underwent development.  
Once the method had undergone a number of validation procedures, designed to 
examine extraction reproducibility and metabolite coverage, a study was 
completed which analysed an expanded AD/MCI/control human plasma sample 
cohort (n=141).  The results of this investigation identified confirmed that three 
previously unreported PC species (PC16:0/20:5, PC16:0/22:6 and 18:0/22:6) 
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significantly decreased in AD compared with controls.  Results demonstrated that 
the same three molecules were significantly decreased both in the screen and the 
comprehensive studies, further providing confidence to the finding.  When 
combining the patient PC data with ApoE allele data, a ROC analysis returned an 
area under the curve of 0.827.   
This reported result opens up numerous avenues of progression, and a number of 
additional studies can be completed to expand the investigation. 
One of the major findings in the thesis was the significant decrease of three FA 
when comparing control plasma with AD plasma.  An initial continuation 
experiment of this of particular interest would be the development and 
implementation of a fully validated LC-MS targeted study that is designed 
specifically to quantify the three PC molecules.   
Future study design would ideally incorporate a larger cohort, in order to 
investigate if the observed trends are reflected in increased sample numbers.  
However, a number of challenges would be presented, the most significant of 
which would be the completion of the chromatographic separation of the three 
compounds, using a short as possible analytical run time.  The speed of such an 
analysis would be an important consideration and method development should be 
focused on achieving a rapid extraction and analysis procedure.  This would be an 
advantage when increasing sample numbers, as the use of an hour gradient 
employed in the comprehensive non-targeted analysis discussed here, would be 
unfeasible.  A rapid separation would enable the analysis of a large as possible 
number of samples for a provided budget.  The greater the number of samples 
which can be afforded would provide a greater weight of significance in any 
resultant findings. 
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However, the design of such a study should undergo meticulous planning.  The 
reason for this is that study design in biomarker discovery is increasingly coming 
under scrutiny.  Predominantly in the literature, studies are completed such as 
those described here in the thesis, in a traditional case (AD)-control design, and 
are often termed “cross sectional”.  However, recent alternative approaches have 
started to appear in the literature regarding identification of biomarkers that aim 
to reflect disease state [105].  This evolution is especially important in a disease such 
as AD which is the result of a long preclinical phase, and there is a growing 
consensus that controls are likely to have early signs of AD pathology even in the 
absence of clinical symptoms, making biomarker discovery challenging [105].  
Alternative approaches include longitudinal designs, where patients are monitored 
at the first visit (termed baseline) and then at fixed time points as the disease 
progresses.  This enables a picture to be painted of potential markers, with their 
effect observed over time along with increasing disease severity. 
One such example of where this approach would be especially useful is in the case 
of MCI and AD progression.  In the results presented within the thesis, the only PC 
molecule which reported a significant change between control and MCI was 
PC16:0/20:5.  In addition no PC was found to significantly alter between MCI and 
AD despite the observation of a trend control>MCI>AD.  With this in mind, the 
development of a specific method to quantify the three PC markers could therefore 
be employed to investigate this further, however, in a longitudinal manner that 
analyses plasma from control and MCI patients at baseline visit one and from 
follow up visits.  This would enable the tracking of PC concentrations in those 
patients who convert to AD from MCI and controls and those who are stable over 
time (effectively two distinct “groups” of MCI).  The application of this longitudinal 
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design would enable the investigation of PCs as a predictor for AD in MCI cases, 
and may help to identify those patients at most risk in the MCI stage. 
However, often this longitudinal study design still employs classic case-control 
disease classes.  Opinions are starting to shift, with recent publications beginning 
to explore avenues outside of this traditional approach.  Examples of such include, 
correlating potential markers to known disease progression over time, such as 
brain atrophy and Aβ concentrations in the brain [109, 110].  Opinions in the 
literature have recently been published to this effect, and there is a consensus that 
it this more flexible approach, rather than the rigid case(AD)-control subgroups 
may reveal AD biomarkers that are both sensitive to AD severity and progression 
[105].  Therefore, an option for further work would be to complete a study in parallel 
with brain imaging data, to observe if the PC compounds alter with brain atrophy.  
In addition, it would be interesting to correlate the PC concentrations with Aβ 
brain levels, which can be achieved using positron emission tomography scans, 
and therefore it would be interesting to complete a study that ran plasma PC 
quantification alongside the real time Aβ aggregation values. 
The results of this thesis focused upon the biomarker sensitivity and specificity 
when comparing between disease classes, with a ROC area under to curve of 0.827 
when comparing AD with controls.  However another important factor when 
considering the merits of a biomarker is the ability to classify between related 
dementia cases.  There are many examples where biomarkers have appeared 
promising in case-control experiments, however when compared with a range of 
further conditions, the specificity of the biomarker has been found to be less 
effective.  Examples of this include levels of Aβ42 in CSF which have previously 
been reported to decrease in AD, providing sensitivity and specificity values of up 
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to 85% when compared with controls [83-85].  However, its use in a diagnostic 
environment has been bought into question due to the fact that a reduction in Aβ42 
concentrations have also been observed to decrease in other variants of dementia, 
for example Lewy body dementia [86], vascular dementia [87] and frontotemporal 
dementia [84]. 
Therefore, an interesting further work pathway would be to compare plasma PC 
concentrations from AD cases with a range of alternative types of dementia, 
cognitive impairment and neurological disorders, for example; vascular, 
frontotemporal and Lewy body dementia, as well as cases of brain tumour and 
stroke.  The results from a study of this design would be important when 
evaluating the full merits of the three PC molecules as biomarkers of AD.  To be 
useful in a clinical environment, the markers would ideally be unique markers of 
AD, and able to differentiate not only between controls, but also between dementia 
types.  Therefore, it would be of significant interest to investigate how PC 
concentrations would perform when compared with a range of conditions. 
An additional aspect of further interest would be to investigate whether the PC 
decrease observed in AD is a primary or secondary response to the disease.  This is 
important as links to lipoprotein abnormalities have been widely reported in the 
disease, for example ApoE and clusterin [15, 106, 107], therefore, it could be feasible 
that the differences in PC could be linked to protein abnormalities as opposed to be 
a direct response to the disease.  To investigate, it would be interesting to complete 
a study design that incorporated both proteomic and targeted PC analysis on 
parallel sample cohorts.  From the resultant data it would be interesting to see if 
there are any correlations between the PC species and the major lipoproteins 
linked to AD in the literature. 
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6.3 – Alternative Avenues in Future Work 
The above discussed further work focuses on the use of the three PC species as a 
marker for the disease.  However, an alternative future work direction would be to 
investigate the actual biochemical pathways and imbalances behind the 
concentration variations of the PC molecules.  An approach such as this could 
identify novel pathway targets in AD and help improve understanding of the 
disease, and lead to novel therapeutic treatments.   
A starting point for such a study could be the enzyme PLA2, responsible for the 
cleavage of FA side chains from PC molecules, with evidence in the literature 
suggesting a possible role in AD [202].  In order to investigate the role of PLA2, FA 
side chains, the products of the enzymatic cleavage reaction, could be investigated 
with regard to PC species.  A preliminary discussion of this was considered in 
Chapter 5, with the FATOTAL data of Chapter 2 being combined with the PC data, 
where it was highlighted that two of the side chains and in circulating plasma 
provided significance values of p=0.107 and 0.023 respectively (controlAD).  
This suggested that the concentration of EPATOTAL could therefore be linked to the 
depletion of PC 20:5, but interpreting these results in a more quantitative fashion 
was beyond the scope of the study and needs require further work.   
One such approach that would improve the understanding of FA distribution in AD 
compared with controls was previously discussed above, with individual analyses 
of FATOTAL, FAFREE and FABOUND to individual lipid species, in order to elucidate the 
metabolic balance within plasma.  This could be expanded to include the side 
chains 16:0 and 18:0 which were not part of the original investigation in Chapter 2, 
however, were components of the three PC molecules of interest. 
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A further, more complex investigation in PC metabolism would be to introduce 
radiolabelled [methyl-3H]choline into cell and organ cultures.  As choline is a 
precursor to PC species, over time the [methyl-3H]choline becomes incorporated 
into the PC metabolism pathway.  Individual PC species can then be observed using 
a combination of LC-MS, detection by fluorescent tagging, as well as the use of 
liquid scintillation detection.  This method at monitoring the metabolism of 
individual PC has previously been applied to rat trachea and lung parenchyma 
tissue [320].  The paper investigated the composition, the synthesis and release of PC 
compounds and reported observations that the trachea contained and synthesised 
more PC16:0/18:1, PC16:0/18:2, PC16:0/20:4 and PC16:0/16:0 than rat 
parenchyma.  This approach could be adapted to investigate PC metabolism in AD 
brain tissue and a pilot study of this design could initially employ a neuronal cell 
line in vitro model.  The radioisotope compounds could be introduced to the cell 
line, and monitored for effect following the introduction of insoluble Aβ 
aggregates.   
To briefly summarise the project identified a number of biomarker candidates, of 
particular interest, including EPATOTAL, AATOTAL/EPATOTAL ratio and three 
previously unreported PC compounds (PC16:0/20:5, PC16:0/22:6 and 18:0/22:6).  
The results presented herein also open up future directions in both AD biomarker 
validation, as well as providing leads for future research on the pathways of the 
disease which could lead to an improvement in the understanding of the 
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